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Résumé 
Le régulateur transcriptionnel BAP1 est une déubiquitinase nucléaire (DUB) dont le 
substrat est l’histone H2A modifiée par monoubiquitination au niveau des residus lysines 
118 et 119 (K118/K119). Depuis les dernières années, BAP1 emerge comme un gene 
suppresseur de tumeur majeur. En effet, BAP1 est inactivé dans un plethore de maladies 
humaines héréditaires et sporadiques. Cependant, malgré l’accumulation significative des 
connaissances concernant l’occurrence, la pénétrance et l’impact des défauts de BAP1 sur 
le développement de cancers, ses mécanismes d’action et de régulation restent très peu 
compris. Cette étude est dédiée à la caractérisation moléculaire et fonctionnelle du 
complexe multi-protéique de BAP1 et se présente parmi les premiers travaux décrivant sa 
régulation par des modifications post-traductionnelles.  
 D’abord, nous avons défini la composition du corps du complexe BAP1 ainsi que 
ses principaux partenaires d’interaction. Ensuite, nous nous sommes spécifiquement 
intéressés a investiguer d’avantage deux principaux aspects de la régulation de BAP1. Nous  
avons d’abord décrit l’inter-régulation entre deux composantes majeures du complexe 
BAP1, soit HCF-1 et OGT. D’une manière très intéressante, nous avons trouvé que le 
cofacteur HCF-1 est un important régulateur des niveaux protéiques d’OGT. En retour, 
OGT est requise pour la maturation protéolytique de HCF-1 en promouvant sa protéolyse  
par O-GlcNAcylation, un processus de régulation très important pour le bon 
fonctionnement de HCF-1. D’autre part, nous avons découvert un mécanisme unique de 
régulation de BAP1 médiée par l’ubiquitine ligase atypique UBE2O. en effet, UBE2O se 
caractérise par le fait qu’il s’agit aussi bien d’une ubiquitine conjuratrice et d’une 
ubiquitine ligase. UBE2O, multi-monoubiquitine BAP1 au niveau de son domaine NLS et 
promeut son exclusion du noyau, le séquestrant ainsi dans le cytoplasme. De façon 
importante, nos travaux ont permis de mettre de l’emphase sur le rôle de l’activité auto-
catalytique de chacune de ces enzymes, soit l’activité d’auto-déubiquitination de BAP1 qui 
est requise pour  la maintenance de sa localisation nucléaire ainsi que l’activité d’auto-
ubiquitination d’UBE2O impliquée dans son transport nucléo-cytoplasmique. De manière 
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significative, nous avons trouvé que des défauts au niveau de l’auto-déubiquitination de 
BAP1 due à des mutations associées à certains cancers indiquent l’importance d’une propre 
regulation de cette déubiquitinase pour les processus associés à la suppression de tumeurs.  
 
Mots clés: Chromatine, marque épigénctique, OGT, HCF-1, BAP1, UBE2O, O-
GlcNAcylation, régulation protéolytique, ubiquitination, déubiquitinase, ubiquitine ligase 
atypique, activité auto-catalytique, cancer 
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Abstract 
BAP1 is a nuclear deubiquitinating enzyme (DUB) that acts as a transcription 
regulator and a DUB of nucleosomal histone H2AK119. In the recent years, it has become 
clear that BAP1 is a major tumor suppressor, inactivated in a plethora of hereditary and 
sporadic human malignancies. Although, we now accumulated a significant body of 
knowledge in respect to the occurrence, penetrance and impact of BAP1 disruption in 
cancer, its mechanism of action and regulation remained poorly defined. This work is 
dedicated to the biochemical and functional characterization of the BAP1 multiprotein 
complex and presents one of the first cases regarding its regulation by post-translational 
modifications.  
First, we defined the initial composition of the BAP1 complex and its main 
interacting components. Second, we specifically focused on two aspects of BAP1 
regulation. We described the cross regulation between the two major components of the 
complex namely HCF-1 and OGT. We found that HCF-1 is important for the maintenance 
of the cellular levels of OGT. OGT, in turn, is required for the proper maturation of HCF-1 
by promoting O-GlcNAcylation-mediated limited proteolysis of its precursor. Third, we 
discovered an intricate regulatory mechanism of BAP1 mediated by the atypical ubiquitin 
ligase UBE2O. UBE2O multi-monoubiquitinates BAP1 on its NLS and promotes its 
exclusion from the nucleus. Importantly, our work emphasises the role of the autocatalytic 
activity of both enzymes namely the auto-deubiquitination activity of BAP1, required for 
the maintenance of nuclear BAP1 and the auto-ubiquitination of UBE2O implicated in its 
nucleocytoplasmic transport. Significantly, we found that auto-deubiquitination of BAP1 is 
disrupted by cancer-associated mutations, indicating the involvement of this process in 
tumor suppression.  
Keywords: Chromatin, epigenetic mark, OGT, HCF-1, BAP1, UBE2O, O-GlcNAcylation, 
proteolytic processing, ubiquitination, deubiquitinase, atypical ubiquitin ligase, 
autocatalytic activity, cancer 
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 Introduction 
 
Chromatin structure and transcription regulation 
 
One of the pillars of life is the ability to acquire information from external stimuli 
and, depending on its nature, build the proper response to sustain homeostasis (Koshland, 
2002). This intrinsic “rationalism” of every living organism is dictated by its genetic 
information which can be differentially expressed depending on the stimuli or the type of 
cell that receives it. One of the first examples of regulated gene expression was elucidated 
through the work done by François Jacob and Jacques Monod (Jacob and Monod, 1961) 
who used the E. coli lactose operon (lac) as a model of a mechanism of gene repression in 
response to the availability of a preferable energy source. Although the lac operon 
represents one of the simplest modes of gene expression regulation, the same underlying 
principle is found within most prokaryotic and eukaryotic genetic regulatory circuits (Lelli 
et al., 2012).  
According to the classical view of gene expression regulation, DNA is considered 
as a linear genetic element free of obstacles and higher order structures. Genes are thus 
being differentially transcribed as a function of the RNA polymerase and transcription 
factors recruitment to promoters. This view persisted for decades in the field of molecular 
genetics and helped to establish numerous principles of gene expression regulation at the 
level of transcription factor recruitment, binding and transcription initiation (Lelli et al., 
2012). On the other hand, this model did not take into account the numerous biophysical 
and biochemical constraints that influence gene expression in vivo especially in eukaryotic 
organisms. 
Although the circular genetic material (nucleoid) of prokaryotic cell is almost 
devoid of intergenic elements and introns and is openly located in the cytoplasm, recent 
studies were able to map regions within the nucleoid with different densities, nuclease 
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sensitivity and transcriptional activity, suggesting that its expression is regulated by higher 
order chromatin structures (Dillon and Dorman, 2010; Postow et al., 2004). In contrast to 
prokaryotes, eukaryotes acquired vast amounts of noncoding/structural/regulatory DNA 
that comprise up to 98% of all the genetic material (Lelli et al., 2012). This dramatic 
increase of genome size and constitution required the concurrent establishment of elaborate 
mechanisms that coordinate its compaction and packaging within the confined space of the 
nucleus (Kornberg, 1974).  
In 1881, the German biologist Walther Flemming coined the term chromatin. 
Flemming made an observation that the nuclear material of the cell was specifically stained 
by the basophilic aniline dyes (such as haematoxylin) (Flemming 1882). In years that 
followed, several discoveries pushed the boundaries of chromatin research: the discovery of 
histones (Zacharias, 1894), nuclein and “transforming principle” (Avery et al., 1944; 
Griffith, 1928), followed by the discovery of the structure of DNA (Watson and Crick, 
1953). All these, and many more findings, advanced our understanding of the mechanisms 
of life including chromatin biology and epigenetics (Olins and Olins, 2003). 
Chromatin, at its most simplest level, is the stoichiometric deoxyribonucleoprotein 
complex that contains the DNA molecule wrapped around the histone protein core and is 
termed the nucleosome (Khorasanizadeh, 2004; Kornberg, 1974; Luger et al., 1997; Olins 
and Olins, 1974; Senior et al., 1975). 
The first electron micrographs of chromatin at its most basic level were acquired by 
Oudet et al. in 1975 and resembled beads on a string later renamed the 10 nm fiber (Oudet 
et al., 1975). At that time, it was already known that eukaryotic DNA formed a tight 
complex with a defined number of histone proteins. The early images of chromatin shed 
light on how DNA might be compacted inside an interphase nucleus. The early studies on 
chromatin structure defined that the histones and DNA form repetitive structures of DNA 
and nucleosome cores, namely the 10 nm fiber.  This structure can be further compacted 
into an even higher order chromatin structures named the 30 nm fibers (Dorigo et al., 2004; 
Kruithof et al., 2009; Luger et al., 2012; Schalch et al., 2005). Zigzag and solenoid models 
are the two main models explaining the higher order chromatin structure, although some 
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studies question the very existence of such structures in vivo (Fussner et al., 2011; Nishino 
et al., 2012). Interestingly, the debate around the exact organisation of chromatin at its 
higher levels remains open (Luger et al., 2012; Luger and Hansen, 2005). Nonetheless, the 
30 nm fiber can be further compacted to form higher order structures, and the degree of 
compaction of chromatin at this level is highly dependent on the chromosome region, the 
cell cycle phase and external stimuli (Koundrioukoff et al., 2004; Luger et al., 2012). 
Typical nucleosomes include a core histone octamer composed of four pairs of 
histones, namely H2A/H2B and H3/H4, which act as a spool for the DNA to wrap around. 
The DNA is wound into a 1.67 left handed supercoil turn around the histone core and 
encompasses 147 nucleotide base pairs (Luger et al., 1997). The nucleosomes are linked by 
short DNA sequences, namely linker DNA, which may also be bound by the histone H1, 
that promotes further chromatin compaction (Caterino and Hayes, 2011; Kornberg, 1974; 
Oudet et al., 1975). 
Histones are highly conserved among most of eukaryotic species (Pontarotti, 2009). 
The only phyla of the eukaryotic organism devoid of histones are the Dinoflagellates. This 
group of small free-living flagellate protists seems to have abandoned the classical 
chromatin architecture and evolved its own unique mode of chromatin packaging. 
Dinoflagellates genomes protein to DNA ratio is very low (around 1:10). Nonetheless, 
recent studies found that their genome is compacted by basic proteins that have only distant 
relation to histones and composed by a family of viral DNA binding proteins (Gornik et al., 
2012). On the other hand, other sources predict homology with the DNA binding proteins 
of Bacteria (Wong et al., 2003). 
In eukaryotes, the histone molecule is comprised of α-helical histone fold, and the 
unstructured histone tail (N-terminal for H3/H4 and C-terminal for H2A/H2B). The histone 
fold is capable of forming tight heterodimers of H2A/H2B and H3/H4, which can further 
complex to form tetramers and the core histone particle (Luger et al., 1997). Being highly 
alkaline in its amino acid composition, the histone octamer forms high affinity complex 
with DNA. On the contrary, the histone tails remain free of interaction and protrude 
between the DNA supercoils like antennae. These “antennae” act as major determinants of 
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chromatin function since they may be marked with numerous signaling and epigenetic post-
translational modifications (PTMs) so as to regulate gene expression, DNA replication, 
DNA repair and epigenetic memory (Campos and Reinberg, 2009; Lelli et al., 2012; 
Ruthenburg et al., 2007; Shilatifard, 2006). The histone tails do not usually directly act as 
structural nucleosome elements, but rather play the role of chromatin signalling elements. 
Numerous PTMs were identified in the histone tail regions. These include the classical 
PTMs such as serine/threonine phosphorylation, lysine acetylation and ubiquitination, 
lysine/arginine methylation (Chi et al., 2010; Strahl and Allis, 2000), as well as less studied 
PTMs such as serine/threonine O-GlcNAcylation and lysine crotonylation (Fujiki et al., 
2011; Sakabe et al., 2010; Tan et al., 2011).  
 
 
 
 
 
 
 
 
 
 
 
Depending on the region within the genome, chromatin may be highly condensed, such as 
centromeric or telomeric regions or less condensed such as in active transcription regions. 
Traditionally, chromatin was thought to exist in two main states: heterochromatin, which is 
represented by highly compacted nucleosomes and euchromatin, characterised by 
“loosened” condensation of the nucleosomes (Avramova, 2002; Gaspar-Maia et al., 2011; 
1881# 1975##
Luger,#1997##
2000#
Walther#Flemming,#1878# Kornberg,#1974## Strahl#and#Allis#2000##270}#
1997##
The#term#chroma.n##
Structure#and#composi.on#
#of#chroma.n#
#Structure#of#the#nucleosome## Histone#code#
Figure 1 The timeline of chromatin biology. (Flemming, 1882; Luger et al., 
1997; Olins and Olins, 2003), Abcam website.  
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Weiler and Wakimoto, 1995). Heterochromatic regions of the nucleus often localize to the 
nuclear periphery forming the so-called chromocenters/foci. This view of the nuclear 
architecture persisted for a number of decades and was helpful in understanding how the 
chromatin architecture would influence gene expression. In recent years, this simplistic 
view of nuclear organisation dramatically changed, giving rise to a more complex model of 
chromatin architecture (Oberdoerffer and Sinclair, 2007). The advances in this area of 
research can be attributed to the development of high fidelity chromatin 
immunoprecipitation coupled to next generation sequencing analysis ((CHIP-chip/CHIP-
seq (Chromatin immunoprecipitation linked to microarray analysis or high throughput 
sequencing) (Ren et al., 2000; Sealfon and Chu, 2011), chromosome conformation capture 
(from Chromosome Conformation Capture (3C) to Carbon-Copy Chromosome 
Conformation Capture (5C) and Genome conformation capture (GCC and Hi-C)(Dekker et 
al., 2002; Dostie et al., 2006; Lieberman-Aiden et al., 2009; Zhao et al., 2006) along with 
gene expression profiling ((DNA microarray/seq (RNA expression profiling using 
microarray analysis or high throughput sequencing )) (Sealfon and Chu, 2011). 
Systematic use of these techniques brought about the subdivision of the historical 
dichotomy between euchromatin/heterochromatin to new and functionally diverse 
chromatin domains. For example, one study in Drosophila cells applied the DamID (DNA 
adenine methyltransferase identification) and CHIP/seq techniques to study the distribution 
of 53 well-characterized chromatin regulators so as to create the integral map of their 
genomic distribution (Filion et al., 2010). This approach is based on the view that a subset 
of chromatin regulatory elements along with different epigenetic histone marks and DNA 
modifications can be subdivided into several physically derived chromatin segments. The 
study divided the chromatin into several distinct but overlapping types. Three types of 
“repressed” chromatin (schematically indicated as green, blue and black) and two types of 
“euchromatin” (yellow and red) were distinguished. The green chromatin represents the 
classical heterochromatin that is marked by its typical epigenetic mark trimethylated H3K9, 
its reader HP1 and writer the Su(var) 3-9 methyltransferase as well as histone H1. The other 
repressive type of chromatin schematized as blue most closely resembles the chromatin 
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established by the polycomb group (PcG) proteins: it recruits the PcG group proteins PCL, 
PSC, E(z) and is enriched in trimethylated H3K27 histone mark. Most surprisingly, the 
most abundant type of chromatin that covers roughly half the genome, the black chromatin, 
is much less diverse in the chromatin bound components, it is devoid of most of the earlier 
mentioned chromatin elements and consists of large genomic domains of more than 100 kb 
in length. This type of chromatin recruits the histone H1, lamin (Lam) the regulator of the 
late polytene chromosomes Suppressor of Underreplication (SUUR) and others and is 
highly repressive, since the transgenes in this region display low level of expression. The 
yellow and red euchromatin regions share many similar features and are bound by 
numerous positive and negative transcriptional regulators as well as the activation 
transcription marks such as dimethylated H3K4 and trimethylated H3K79. Nonetheless, 
these two types of euchromatin display different modes of transcription regulation. For 
example, the yellow chromatin is enriched in trimethylated H3K36 histone mark. The 
distribution of genes is also different in both types of euchromatin with the red chromatin 
being enriched in genes important for general cell physiology and involved in DNA repair 
and nucleic acid metabolism, whereas the yellow chromatin bears more specialized and 
tissue specific genes involved in signal transduction, extracellular matrix remodelling and 
transcription factor activity (Filion et al., 2010). 
The sequencing of the human genome announced the beginning of a new “post 
genomic era” in molecular biology (Venter et al., 2001). The result of the human genome 
project revealed an unexpected outcome: the human genome, expected to be comprised of 
50-100 thousand genes contained only ≈ 20 thousand protein coding genes. This number of 
genes, highly comparable to the mouse genome was only double the number of genes of the 
Drosophila melanogaster and the amebae Dictyostelium (12 thousand protein coding 
genes) (Adams et al., 2000) and half the amount of genes compared to some plants (Goff et 
al., 2002; Tuskan et al., 2006). This result indicated that the complexity of the human body, 
its self-awareness, intellect and its ability to construct organized societies are derived from 
the way genes are regulated, rather than the sheer number. Indeed, the vertebrate genomes 
encompass tremendous amounts of noncoding/structural DNA along with a whole army of 
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noncoding RNAs that play an important role in gene expression regulation and in shaping 
the epigenetic landscape of the cell (Wells, 2011). 
The structure of chromatin is subject to an active regulation, this includes the direct 
chromatin remodeling by the DNA/histone directed ATPases (Ahel et al., 2009; Chan et al., 
2005; Chen et al., 2011; Morrison and Shen, 2009; Narlikar et al., 2013; Wu et al., 2007), 
the chromatin modifying enzymes that target DNA, for example DNA methyltransferases 
(Goll and Bestor, 2005) and 5-methylcytosine dioxygenases (TET family) (Branco et al., 
2012), the histone modifying enzymes such as histone acetyltransferases and deacetylases 
(Shahbazian and Grunstein, 2007) as well as the histone methyltransferases and 
demethylases (Klose and Zhang, 2007). Functionally, these proteins may be divided into 
several groups such as writers, readers and erasers (Patel and Wang, 2013). In order to 
combine different biochemical properties of these chromatin regulators, these functional 
groups of proteins often form stable complexes, resulting in the formation of 
multifunctional epigenetic machineries (Chen et al., 2011; Ho and Crabtree, 2010; Wu et 
al., 2007; Yokoyama et al., 2004). Several of such protein complexes most relevant to this 
work are described below in more detail. 
 
Polycomb and Trithorax group protein complexes: regulation of 
Hox genes and beyond 
 
Hox genes 
 
The coordination of developmental processes in multicellular organisms requires 
elaborate gene expression regulatory mechanisms. These mechanisms are coordinated by 
the superfamily of homeotic transcription factors that contain specific DNA binding 
modules named homeodomains, that bind a specific DNA sequence named the homeobox 
(Bridges, 1921; McGinnis et al., 1984a; McGinnis et al., 1984b; Scott and Weiner, 1984; 
  
 
14
Shah and Sukumar, 2010). Historically, Hox genes were regarded as master regulators of 
morphogenesis and body patterning. The differential expression of Hox genes dictates the 
development of specific body parts (Dolle et al., 1993; Wellik, 2009). This notion arose 
from the studies in Drosophila where Hox gene mutants display a specific anterio-posterior 
homeotic transformation. In this process, the anterior segments of the body acquire the 
morphology of the more posterior body segments (Bridges, 1921; Lewis, 1978; Scott et al., 
1983). 
From an evolutionary perspective, the increasing complexity of the animal body 
plan usually correlates with the increasing number of Hox genes, their paralogs and the 
patterns of their expression (Pearson et al., 2005; Pendleton et al., 1993). For example, one 
of the simplest body plans in the Metazoa is that of the cnidarian Hydra has only two Hox 
genes Cnox-3 and Cnox-2 and one ParaHox gene Cnox-1. These genes define the anterior 
part of the body with the tentacles and the mouth opening as well as the posterior part of the 
body responsible for the binding to the substrate. Further, the expression patterns of Cnox-3 
and Cnox-2 show that Cnox-3, a homologue of the Drosophila Hox gene labial (lab), plays 
a role in oral anterior patterning. On the contrary, the Cnox-2, the homologue of the 
Drosophila Deformed (Gsx) that belongs to the ParaHox cluster represses the anterior 
patterning in the body column (Schummer et al., 1992; Shenk et al., 1993).  
The more complex body plan in arthropods such as Drosophila is accompanied by 
the expansion of the Hox gene cluster (Carroll, 1995; Pendleton et al., 1993). The 
Drosophila genome encodes eight Hox genes divided into two clusters called Antennopedia 
and Bithorax. The Drosophila developmental model is highly suitable for the study of body 
patterning since arthropod segmentation is easily detectable throughout their development. 
The pattern of the Hox gene expression correlates with the position of the gene in its 
corresponding cluster, for example the most anterior segments of the mouth apparatus 
express the Antennapedia member gene lab and the most posterior segments of the 
abdomen express the Bithorax family member Abdominal-B (Abd-B) (Pearson et al., 2005). 
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The mammalian genome contains 39 Hox genes divided into four clusters (A, B, C 
and D) (Pendleton et al., 1993). Each cluster contains the Hox genes orthologous to the 
Drosophila Antennapedia and Bithorax (with some orthologs lost or duplicated depending 
on the clusters). The considerable increase in the number of the Hox genes can be explained 
by the global duplication of the ancestral chordate genome (Lynch and Wagner, 2009). The 
complex and often redundant expression pattern of the Hox genes in mammals dictates 
development of their body plan through complex, and sometimes highly convoluted 
mechanisms. Pattering of the mammalian body can be visualized by following the Hox 
gene expression along the vertebral column and somites of the mammalian embryo 
(Cardoso, 1995; Pendleton et al., 1993; Perez-Cabrera et al., 2002). 
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Figure 2. Structure and composition of the PcG and TrxG protein complexes. 
The simplified models of the complexes are shown.  
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The polycomb group (PcG) and trithorax group (TrxG) regulatory 
complexes 
 
Two crucial groups of regulatory genes, the polycomb group (PcG) and the trithorax 
group (TrxG), dictate the patterns of Hox gene expression and are required for the normal 
body plan development.  The study of these complexes was initiated using genetic 
experiments in Drosophila based on the homeotic transformation phenotypes. The 
biochemical analysis of the PcG and Trx proteins subsequently revealed that they often 
constitute large multisubunit chromatin modifying complexes responsible for gene 
repression and activation respectively (Cao et al., 2002; Kuzmichev et al., 2002; Levine et 
al., 2002; Wang et al., 2004).  
The TrxG proteins come together to form complexes containing the SET (Su(var)3-
9, Enhancer-of-zeste and Trithorax) domain containing methyltransferase responsible for 
histone H3K4 methylation, the epigenetic mark usually associated with transcriptionally 
active regions in all eukaryotes (Bernstein et al., 2002; Ng et al., 2003). Set1 was first 
found as a part of the macromolecular complex COMPASS (complex of proteins associated 
with Set 1) and is the only member of this class of methyltransferases in Saccharomyces 
cerevisiae. COMPASS is responsible for the introduction of all mono-, di-, and 
trimethylations of H3K4 in yeast (Breen and Harte, 1991; Ingham, 1985; Krogan et al., 
2002).  
The Drosophila genome encodes several SET domain-containing proteins. These 
include the founding member of the Trithorax (Trx) family, Trithorax-related (Trr) and 
dSet1. All the members of this methyltransferase family form complexes related to the 
Saccharomyces cerevisiae COMPASS and catalyze the methylation of H3K4 (Eissenberg 
and Shilatifard, 2010; Hallson et al., 2012; Sedkov et al., 2003). 
Trx was first identified as a gene whose mutation leads to “posterior to anterior” 
transformation phenotype. In contrast, mutations in PcG genes lead to the inverse 
phenotype (Breen and Harte, 1991). Notably the activation and repressive role of Trx and 
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PcG genes respectively were studied in genetic complementation studies and showed that 
the PcG homeotic transformation phenotypes can be suppressed by the mutations in Trx 
(Shilatifard, 2008). 
Mammalian COMPASS-related proteins are represented by at least seven different 
complexes namely the SETD1A, SETD1B, MLL1 (Mixed lineage leukemia, also known as 
MLL), MLL2, MLL3, MLL4 and MLL5. SETD1A and SETD1B are the orthologs of the 
Drosophila dSet, the MLL1 and MLL2 related to the Drosophila Trx; MLL3 to MLL5 are 
orthologs of the Trr (Hallson et al., 2012; Mohan et al., 2010; Schuettengruber et al., 2007; 
Sedkov et al., 2003). The members of the COMPASS-like complexes in mammalian cells 
are responsible for the establishment of the active chromatin state and the removal of the 
repressive epigenetic marks, for example by the H3K27 demethylase UTX (Lee et al., 
2007).  
 
Overview of the PcG complexes 
 
Biochemically, the PcG proteins form two major complexes, PRC1 and PRC2 (Cao 
et al., 2002; Schuettengruber et al., 2007; Wang et al., 2004). The subsequent studies of 
PcG proteins resulted in discovery of multiple variants and subdivisions of PRC1 and 
PRC2 complexes. This is most evident in respect to the mammalian orthologs of the 
Drosophila PRC1 complex, which are often represented by multiple subunit isoforms. The 
combination of different PcG subunits along with facultative components may results in the 
formation of tens if not hundreds of complex combinations. In addition to classical PRC1 
and PRC2 PcG complexes, several other complexes can be defined such as the Pho 
repressive complex (Pho-RC) (Klymenko et al., 2006), Drosophila Ring-associated factors 
(dRAF) (Lagarou et al., 2008), and the recently discovered Pc-repressive deubiquitinase 
complex (PR-DUB), also known as BAP1 complex in mammals (Abdel-Wahab and Dey, 
2013; Carbone et al., 2013; Dey et al., 2012; Scheuermann et al., 2010; Yu et al., 2010). 
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Polycomb repressive complex 2 (PRC2) 
 
The main catalytic product of the PRC2 complex is the repressive di- and 
trimethylated H3K27 epigenetic mark that is catalyzed by the SET domain containing 
histone methyltransferase Enhancer-of-zeste (E (z)) (the EZH1 and EZH2 in mammals). 
The other components of the complex are represented by the Suppressor Of Zeste 12 
(SUZ12), the Polycomb like (PCL) (PLC1, 2 and 3 in mammals), Extra sex combs (ESC) 
(mammalian EED) and the chromatin remodeling factor Nurf 55 (RbAp46/48 in mammals) 
(Margueron and Reinberg, 2011). The mammalian complexes also contain the Jumonji- and 
AT-rich interaction domain (ARID)-domain-containing protein JARID2 that encodes for 
catalytic inactive methyltransferase, necessary for the proper recruitment of PRC2 to 
chromatin (Landeira et al., 2010; Pasini et al., 2010). The PRC2 complexes may also 
interact with a plethora of other transcriptional regulators such as chromatin remodelers, 
erasers of epigenetic marks (such as the HDACs and KDMs)(Shen et al., 2009; Tong et al., 
2012) and most notably the numerous members of the non-coding RNAs (ncRNAs), to 
facilitate PRC2 recruitment and transcriptional repression (Gupta et al., 2010; Kaneko et 
al., 2010; Rinn et al., 2007).  
The methyltransferase subunits of the PRC2 complex EZH1 and 2, despite being 
highly similar in their amino acid sequence, play different roles in the maintenance and 
establishment of the repressive chromatin state and are differentially expressed depending 
on the proliferative potential of the cell. EZH1 is expressed in both proliferating and 
quiescent cells. In contrast, EZH2 expression is only detected in proliferating cells. The two 
EZH subunits also have different contributions to the global level of H3K27 methylation 
(Margueron et al., 2008; Shen et al., 2008). The EZH1 knockout cells display little changes 
in their H3K27 methylation levels, whereas the EZH2 knockout cells cannot maintain their 
H3K27 methylation. Interestingly, EZH1 seems to act mostly in a catalytic activity 
independent manner, and is able to promote chromatin condensation whereas the 
EZH2/PRC2 complexes lack this ability. Therefore, the roles of the EZH1 and EZH2 may 
differ in respect to regulating H3K27 methylation levels. EZH2 appears to be required for 
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establishing the global H3K27 methylation levels whereas EZH1 might be required for the 
replenishment of H3K27 methylation following site-specific demethylation (Margueron et 
al., 2008).  
The role of two PRC2 complexes in mammalian cells was extensively studied in the 
model of myogenic differentiation. The PRC2 complex is essential for maintaining the 
repressive state of the muscle specific genes (Stojic et al., 2011).  
Indeed, during myogenic differentiation, the decrease of EZH2 expression is 
concomitant with the decrease of the H3K27 methylation; while the levels of EZH1 
increase during this process (Caretti et al., 2004; Juan et al., 2009). Moreover, EZH1 is 
required for the recruitment of the myogenic transcription factor MyoD and Pol II to the 
early myogenic differentiation gene MyoG (myogenin). In line with these findings, the 
knockdown of EZH1 inhibits muscle differentiation (Stojic et al., 2011).  These findings 
suggest that EZH1 might have a role in transcriptional activation.  Indeed, the study of the 
global occupancy of EZH1 showed that it co-localizes with transcriptionally active 
chromatin: H3K4 trimethylation, Poll II occupancy and mRNA production (Mousavi et al., 
2012). Of note, the catalytic activity of the EZH1 was shown to be required for normal 
myogenesis. These findings suggest that EZH1 and EZH2 may play distinct but 
overlapping roles in transcriptional regulation and maintenance of gene repression 
(Margueron et al., 2008). 
The EED subunit of the PRC2 complex plays a role in the integration of the 
components of the complex and is required for the recruitment of PRC2 to chromatin. It 
also seems to play a role in the allosteric activation of the histone methyltransferase activity 
of EZH2 and the H3K27 methylation mark propagation (Margueron et al., 2009). The 
knockout of EED leads to the destabilisation of the other components of the complex 
(Chamberlain et al., 2008). EED also plays a role in the trans-generational propagation of 
the H3K27 di- and trimethylation marks during the S phase of the cell cycle. The EED 
recruits the PRC2 complex to the replication fork and promote DNA synthesis-assisted 
methylation of the newly-incorporated nucleosomes. This is achieved by the PRC2 subunits 
EZH2 and EED’s ability to recognise its own H3K27 methylation epigenetic mark. In 
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respect to EED, it was shown that the WD40 repeats of the EED form an aromatic cage 
around the H3K27 methylated mark and is required for the propagation of the repressive 
chromatin state (Hansen et al., 2008; Margueron et al., 2009). A recent study has shown an 
intriguing role for EED as an integral subunit of both the PRC2 and the PRC1 complexes. 
EED was shown to be required for the H3K27 trimethylation as well as for the ubiquitin 
ligase activity of the PRC1 (Cao et al., 2014).  
Although the histone H3K27 trimethylation is considered the main product of 
PRC2, some non-histone substrates where also described. For example, EZH2 was shown 
to methylate the cardiac specific transcription factor GATA4 on lysine 299 and attenuate its 
transcriptional activity by reducing its ability to recruit the p300 acetyltransferase (He et al., 
2012). Although in this case, EZH2 activity also promoted gene repression independent of 
its H3K27 methyltransferase activity. Another study suggests that EZH2 function, at least 
following its deregulation in disease, may not always be connected with the PRC2 complex 
(Xu et al., 2012). Moreover, the PRC2 and H3K27 trimethylation-independent function of 
EZH2 correlates with gene activation. EZH2 interacts with the androgen receptor (AR) and 
promotes its agonist-independent transcriptional activity in castration-resistant prostate 
cancer (CRPC) (Xu et al., 2012). Notably the AR/EZH2 interaction is dependent on 
phosphorylation of EZH2 on Ser 21 by Akt, and links the oncogenic PI3K-Akt signaling 
pathway to the regulation of gene expression by AR (Xu et al., 2012). These findings 
suggest that EZH2, in different contexts, may also target substrates other than the H3K27 
and be involved in gene activation.  
The unconventional role of the PRC2 complex may also include DNA double-
strand break (DSB) repair. EZH2 was identified in a screen designed to identify novel DSB 
response molecules, and is enriched at the sites of IRIF (Ionizing Radiation Induced Foci) 
along with its catalytic product trimethylated H3K27 (Chou et al., 2010). The exact role of 
PRC2 in this process is unclear since chromatin at IRIF is considered to be in a more 
relaxed state as a consequence of DSB repair factors recruitment (Qin and Parthun, 2002; 
Yu et al., 2005). 
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Polycomb repressive complex 1 (PRC1) 
 
Drosophila PRC1 complex usually contains the following components in more or 
less stoichiometric amounts: the founding member of the PcG proteins Polycomb (Pc), Sex 
Comb Extra (Sce or RING), Posterior Sex Combs (PSC), Polyhomeotic (Ph) and Sex Comb 
on Midleg (Scm) (Kennison, 1995). 
In mammalian species, each of these proteins has multiple homologs. There are 
three homologs of the Drosophila Ph in humans: PH1, PH2, and PH3 and two homologs of 
Drosophila Sce: Ring1B and Ring1A. The six mammalian homologs of PSC are termed the 
PcG RING fingers (PcGFs). These include Bmi-1, the most characterised cofactor, as well 
as its paralogs MBLR (Mel18 and Bmi1-like RING finger protein), MEL18 and NSPC1 
(nervous system Pc1). The Drosophila Pc homologs in mammals are represented by the 
multiple homologs of the Chromobox proteins (Cbx) proteins that usually recognise the 
PRC2 catalyzed epigenetic mark di- or trimethylated H3K27. Pc/Cbx proteins seem to have 
specific functions such as maintenance of stem cell pluripotency or coordinating lineage 
commitment (Lanzuolo and Orlando, 2012).  
The main catalytic function of the PRC1 complexes is the ubiquitin E3 ligase 
activity towards the C-terminal histone H2A tail at the position K119 (K118 in 
Drosophila). This activity usually attributed to the core PRC1 subunits Ring1B and Bmi-1 
or its paralogs. The crucial N-terminal RING domain engages the ubiquitin charged E2 
conjugating enzyme UbcH5c and promotes H2A ubiquitination (Bentley et al., 2011). 
Ring1B is able to directly ubiquitinate H2A in vitro, although its activity is dramatically 
enhanced by Bmi-1, which is also required for optimal Ring1B activity in vivo. The Bmi-1 
subunit of the PRC1 also contains a RING domain but is devoid of catalytic activity. 
Similarly to other double RING ligase complexes, Bmi-1 and Ring1B form a heterodimer 
complex through their cognate RING domains. The unique basic patch on the Ring1B/Bmi-
1 heterodimer promotes direct recognition of the nucleosomal DNA (Bentley et al., 2011). 
Moreover, a single basic residue (K93) in the RING finger of Ring1B is also required for 
DNA recognition and ligase activity of the Ring1B/Bmi-1 complex (Mattiroli et al., 2012). 
  
 
22
The ubiquitin ligase activity of the PRC1 complex is crucial for the execution of its 
repressive function and mutation of the RING domain of the Ring1B results in gene 
derepression despite persistent promoter H3K27 trimethylation (Endoh et al., 2012; 
Scheuermann et al., 2010; Trojer et al., 2011). The exact mechanism of ubiquitin H2A-
mediated repression is unclear, as direct physical changes in the chromatin structure were 
also observed in PRC1 E3 activity-independent manner (Eskeland et al., 2010; Grau et al., 
2011). Nonetheless, the ubiquitinated H2A mark acts as inhibitory signal towards Pol II-
mediated transcription initiation by competing with MLL complex mediated di- and tri-
methylation of H3 K4 (Nakagawa et al., 2008). 
The ubiquitinated H2A appears to be also required for the maintenance of the 
bivalent chromatin domains (containing the repressive and activation histone marks) in 
embryonic stem cell. This mechanism appears to stabilize the poised state of the initiated 
(Ser5 phosphorylated) Pol II. Indeed, Ring1B knockout ES cells display a significant loss 
of the H2A ubiquitination on such loci, along with the Pol II release and elongation, which 
result in derepression of the bivalent genes (Stock et al., 2007). The PRC1 complex also 
participates in the maintenance of the inactivated X chromosome (Xi) (Fang et al., 2004). A 
high signal of H2A ubiquitination is detectible on the Barr body, and moreover the double 
Ring1B/Ring1A knockout cells display a loss of H2A ubiquitination on the Xi. Of note, 
both the PRC1 and PRC2 stably associate with Xi in Xist (X chromosome specific 
ncRNA)-dependent manner. Nonetheless, the Xi initiation does not seem to require any 
PcGs (de Napoles et al., 2004; Mak et al., 2002; Silva et al., 2003). Thus, the question 
about the function of PcGs at the Xi requires further investigations. 
The role of H2A ubiquitination as a true epigenetic mark remains unclear. Although 
being very abundant (5-15% of total H2A), it seems to be erased with each cell division. 
Indeed the cells that enter the early stages of mitosis almost completely lose chromosomal 
H2A ubiquitination. This process seems to be inversely correlated with H3S10 
phosphorylation, the well-known mitotic histone mark (Bradbury, 1992; Joo et al., 2007; 
Mueller et al., 1985). The H2A ubiquitination levels are restored immediately after nuclear 
envelop reestablishment. In Drosophila cells, the PSC (PcGFs in human) subunit of the 
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PRC1 complex remains chromatin-bound throughout DNA replication in vitro, indicating 
that it may be involved in the restoration of the ubiquitin H2A at their proper genomic loci 
(Francis et al., 2009). 
The removal of ubiquitin from H2A also requires a specific and well-controlled 
deubiquitination reaction. The ever-growing army of DUBs for H2A suggests that this 
process may be ensured by several enzymes depending on the physiological context, 
although some overlapping roles might exist (Hammond-Martel et al., 2012).  
The primary signals for PRC1 recruitment and H2A ubiquitination remain to be 
fully defined, and may be ensured by multiple non-overlapping factors. For instance, a role 
in PRC1 recruitment was attributed to the product of the catalytic activity of the PRC2 
complex: the repressive epigenetic mark trimethylated H3K27. Indeed the CBX (Pc) PRC1 
subunits display the ability to bind trimethyl-H3K27. It was suggested that the PRC1 
recruitment and activity is guided and dependent on the PRC2 H3K27 trimethylation as a 
priming epigenetic mark (Boyer et al., 2006; Cao et al., 2002; Wang et al., 2004). However, 
this role of the PRC2 in respect to the PRC1 was put to question by several recent studies. 
Indeed, the EED (the nonanalytic subunit of the PRC2) knockout cells still maintain a 
significant level of H2A ubiquitination despite the complete loss of trimethylated H3K27. 
The recruitment of the PRC1 as well as H2A ubiquitination levels at the Xi was 
independent of the PRC2 (Schoeftner et al., 2006). PRC2-independent H2A ubiquitination 
was also attributed to the RYBP and YAF2 subtype of the PRC1 complexes. These PRC1 
complexes are devoid of the CBX subunit and promote the RYBP/YAF2-dependent, but 
the trimethyl-H3K27-independent, recruitment of the Ring1B to chromatin and subsequent 
H2A ubiquitination (Tavares et al., 2012; Wilkinson et al., 2010). Another study describes 
the atypical PRC1 complex (dRAF in Drosophila also part of the BCOR complex) 
containing the H3K36me2 demethylase Fbxl10/Kdm2b that appears to be also required for 
the maintenance of global H2A ubiquitination. The Fbxl10/Kdm2b recruits the 
Ring1B/NSPC1 ligase complex to CpG islands containing promoters with subsequent H2A 
ubiquitination (Wu et al., 2013). These results indicate that the non-constitutive 
components of the complex may contribute significantly to PRC1-mediated repression.  
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It is noteworthy to point that PRC1 also displays H2A ubiquitination-independent 
effect on chromatin. In vitro, the purified PRC1 complexes promote condensation of the 
nucleosomal arrays independently of their histone tails and ubiquitination. Furthermore, a 
study using Ring1B knockout fibroblasts showed that the Ring1B RING domain mutant, 
unable to interact with E2-conjugating enzyme, was able to restore chromatin condensation 
and Hox gene repression without an increase in H2A ubiquitination (Eskeland et al., 2010; 
Grau et al., 2011). These results indicate that PRC1 may execute its function through 
multiple mechanisms that also include a direct effect on chromatin structure. It would be 
interesting to define the exact mechanism underlying such H2A ubiquitination-independent 
effect of PRC1. 
The catalytic core of the PRC1 can be found in other repressive complexes such as 
PRC1L4, dRAF, BCOR and E2F6 com. (Gearhart et al., 2006; Lagarou et al., 2008; Ogawa 
et al., 2002; Trojer et al., 2011). The selective assembly of the different sub-complexes 
around the Ring1B/PcGF core result in distinct and overlapping roles in gene repression. 
The dRAF and BCOR seem to share common subunits including the H3K36me2 
demethylase Fbxl10/KDM2B and Ring1B/NSPC1 and establish the crosstalk between the 
H3K36me2 demethylation and histone ubiquitination. The BCOR complex was also shown 
to be important for BCL6-mediated gene repression (Gearhart et al., 2006; Lagarou et al., 
2008).  
The complex formed by the cell cycle regulator and transcription factor E2F6, in 
addition to the core Ring1B/PcGF contains the Myc oncogene regulatory factors such as 
Max and MGA as well as heterochromatin factors including HP1ϒ and the 
methyltransferases G9a and GLP. The methyltransferase activity of the G9a/GLP targets 
H3K9 for di-methylation and promotes the repression of the Myc-responsive genes in G0 
cells (Ogawa et al., 2002). 
While being a major transcription regulation complex, the PRC1 also appears to 
function in other chromatin-associated processes, and was suggested to be important for 
DNA double strand break repair (DSB). Indeed, the components of the PRC1 complex can 
be recruited to the sites of the DSB and promote the ubiquitination of the histones H2A and 
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its variant H2AX. This activity of PRC1 is also required for efficient DSB repair and cell 
survival following genotoxic stress (Gieni et al., 2011; Ismail et al., 2010). The exact 
function of the H2A/H2AX ubiquitination in DSB repair remains unclear, especially with 
respect to the ubiquitin ligase activity of the major DSB response E3 ligases RNF8 and 
RNF168, which catalyze the ubiquitination of H2A on K13/K15 sites (Mattiroli et al., 
2012). It would be interesting to define the role and the crosstalk between the two 
modifications in DSB signaling and repair. 
 
Chromatin recruitment of PcGs 
 
The PRC1 and PRC2 are usually considered not to possess sequence-specific DNA 
binding activities. This raises the question of how these complexes being targeted to 
genomic loci to execute their gene repressive roles? Previous studies in Drosophila 
revealed a subset of specific DNA elements called the PcG responsive elements (PRE) 
(Lanzuolo and Orlando, 2012). The deletion of the PRE elements from the Hox locus 
causes homeotic transformation. Moreover, the insertion of these elements in other 
unrelated genomic regions promotes PcG recruitment and gene repression. The non-
catalytic components of the PcG complexes were also suggested to play a role in their 
recruitment to chromatin. For example, the ESC-Nurf55 module of the PRC2 complex is 
the minimal histone-binding element required for histone binding and the HMT activity of 
the PRC2 (Nekrasov et al., 2007; Yao et al., 2008). 
Nonetheless, other studies have shown that the PRE itself is nucleosome-depleted 
and that the nucleosomes are dynamically evicted and replaced from these regions 
suggesting that the nucleosomal context is not sufficient/required for the recruitment of 
PcG complexes (Muller and Kassis, 2006). The Pho protein (Yin Yang1 (YY1) in 
mammals) is the only PcG member with distinct DNA sequence specificity towards the 
PRE (Lanzuolo and Orlando, 2012; Shi et al., 1997). Indeed, Pho was found to co-occupy 
most of the PRE regions with the PRC1 and PRC2 complexes and was shown to interact 
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with these elements in vitro (Xi et al., 2007). On the other hand, other studies suggested 
that Pho and PhoRC (Pho repressive complex) were not sufficient to promote the 
recruitment of PcG and were often recruited to chromatin sites that were distinct from those 
occupied by PRC1 and PRC2 (Dejardin et al., 2005). 
The PRE elements in mammals are even less studied. The few elements identified 
so far are represented by the PRE-kr sequence that can repress the MafB-Kreisler locus by 
recruiting the PRC1 and PRC2 complexes (Sing et al., 2009). The other PRE-like sequence 
was identified in the HOXD cluster between the HOXD11 and the HOXD12 named the 
D11.12. It represents a 1.8 kb GC rich DNA sequence capable of inducing the heritable 
gene repression of the reporter gene. Notably, the D11.12 element incorporates the YY1 
binding sequences that were required for repression, indicating the importance of this 
transcription factor binding for the recruitment of PcG complexes (Woo et al., 2010). 
Although, the exact mechanisms of PcG recruitment in mammalian cells remain to be 
defined, the higher order chromatin structure also seems to play an important role. The PcG 
repressive chromatin is often organised in so-called polycomb bodies and represents a 
condensed areas of chromatin containing the repressive chromatin marks. Notably, the Hox 
gene cluster can be dynamically associated and displaced from such regions. Indeed, during 
murine embryogenesis, cells with the repressed Hox cluster are incorporated within the 
transcriptionally inactive PcG bodies. On the contrary, the activated Hox clusters leave the 
PcG bodies and acquire active chromatin marks (Noordermeer et al., 2011). 
The recent discovery of the new PRC complex termed the PR-DUB (BAP1 complex 
in mammals) raises more questions and possibilities for the mechanism of PcG repression. 
The PR-DUB in Drosophila consists of the deubiquitinating enzyme Calypso (BAP1 in 
mammals) and the polycomb group protein ASX (ASXL1, ASXL2, ASXL3 in mammals) 
(Scheuermann et al., 2010). On the other hand, the mammalian BAP1 complex seems to 
incorporate additional components such as HCF-1 and OGT and a subset of transcription 
factors (described below) (Carbone et al., 2013; Sowa et al., 2009; Yu et al., 2010). The 
deubiquitinase ability of the PR-DUB complex towards ubiquitinated H2A K118 (K119 in 
mammals) indicates its opposing role towards PRC1 and is thus expected to act as a 
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transcriptional activator. Nonetheless, the PR-DUB is required for proper Hox repression 
and morphogenesis (Scheuermann et al., 2010). This notion indicates that the dynamic 
ubiquitination/deubiquitination is required for the PcG induced gene repression, and that 
the repressed chromatin may be more dynamic than currently appreciated. 
 
 
Ubiquitin proteasome system  
 
 Before the discovery of the ubiquitin-proteasome system (UPS), the only known 
energy-dependent intracellular protein degradation system was the lysosome. It 
encompasses a membrane containing hydrolytic enzymes for digestion of the content of 
phagocytic and pinocytic vesicles for the purpose of generating metabolites and ensuring 
immune protection (Varshavsky, 2006; Wilkinson, 2005). Although extremely important, 
this system is highly unspecific and degrades most biopolymers that are trapped within the 
endocytic vesicles. The notion of both energy dependent and specific protein targeting 
machinery was elusive until the second half of the 20th century. It was also counterintuitive 
at that time, that the cell would spend its energy on the destruction of its own proteins.  The 
process of degradation was widely accepted to be passive and moreover, most intracellular 
proteins were considered to be long-lived (Varshavsky, 2006). It wasn’t until the late 1970s 
that the work by Aaron Ciechanover, Irwin Rose, Avram Hershko and others first described 
the ATP dependent and ubiquitous pathway of protein degradation by the UPS (Wilkinson, 
2005).  
Ubiquitination represents the attachment of a 76 AA protein modifier named 
ubiquitin to the target proteins, which results in their degradation by the cellular protein 
recycling factory: the proteasome. This classical function of ubiquitination is one of the 
best studied.  Nonetheless, numerous and highly diverse functions of ubiquitination 
including non-degradative signaling events that can regulate a plethora of cellular functions 
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were uncovered during the last decade (Geng et al., 2012; Hammond-Martel et al., 2012; 
Nakayama and Nakayama, 2006; Pickart, 2004). 
Protein conjugation, by small protein modifiers, is usual characteristic of eukaryotic 
cells and is achieved by highly hierarchical and complex biochemical cascades that result in 
protein post-translational modification. These small protein modifiers include the small 
ubiquitin like modifier (SUMO), neural precursor cell expressed, developmentally down-
regulated 8 (NEDD8), interferon-induced 15 kDa protein (ISG15), autophagy-related 
protein 8 (ATG8) and ubiquitin-related modifier 1 (URM1) (Kerscher et al., 2006; van der 
Veen and Ploegh, 2012). These protein conjugation systems regulate diverse and 
sometimes highly specialized cellular functions. For instance, ATG8 regulates the 
autophagy pathway (Boya et al., 2013) and the ISG15 regulates the antiviral immune 
response (Zhao et al., 2013). Here I will focus on protein ubiquitination, as it is most 
relevant to my work. 
Conjugation of ubiquitin to their corresponding substrates is a multistep process that 
usually requires at least three types of enzymes. The cascade begins when the ubiquitin 
activating enzyme (E1 also known as UBA1). The E1 is responsible for the first two steps 
of the process. The E1 catalyzes the activation of ubiquitin by the ATP hydrolysis-
dependent adenylation of the ubiquitin C-terminal glycine 76 (G76).  The intermediate 
ubiquitin-adenylate is quickly hydrolysed with the release of free ADP and the formation of 
ubiquitin-E1 thioester (or charged E1) on the conserved cysteine (C632) of the E1. The 
next step of the reaction requires the ubiquitin-conjugating enzyme (ubiquitin carrier) (E2). 
The charged E1 interacts with the E2 and transfers the ubiquitin moiety to the catalytic 
cysteine on the E2 molecule and this results in the formation of the E2-ubiquitin thioester 
(or charged E2) (Lee and Schindelin, 2008). The charged E2 is than recruited to the 
substrate protein with the assistance of the ubiquitin ligase (E3). Depending on the E3 type 
it may directly participate in the reaction and form an intermediate ubiquitin-E3 thioester 
(in case of HECT domain E3s) that subsequently discharges the ubiquitin to the ε-amino 
group of lysine residue of the target protein (Rotin and Kumar, 2009). Otherwise the E3 
may act as an adapter between the substrate and the charged E2 (RING and U-box domain 
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E3s) to promote the transfer of the ubiquitin to the lysine residue of the substrate (Deshaies 
and Joazeiro, 2009).  
Since ubiquitin contains seven lysine residues, it may also be targeted by 
ubiquitination, resulting in the formation of ubiquitin polymers and thus in substrate 
polyubiquitination. Depending on the type of chain, polyubiquitination might have different 
outcomes for the protein substrate. For example lysine 48 (K48)-linked chain attachment 
will typically result in proteasomal degradation of the target protein (Finley, 2009).  
Proteasome is highly conserved multisubunit and ATP-dependent protease complex 
that specifically targets the proteins marked for degradation. Proteasome is a 2.5 MDa 
complex that can be functionally and structurally divided into several sub-complexes. The 
catalytic core particle (CP or 20S subunit) is cylindrical structure that consists of four 
seven-subunit rings, with two in the middle encompassing three different proteases. The 
proteases of the CP belong to unique N-terminal nucleophile type of hydrolases and contain 
one amino-terminal threonine as a single catalytic site. Each protease catalyzes different 
types of proteolytic reactions with trypsin-like (β2), caspase-like (β1) and hydrophobic 
residue-targeting (β5) activities. The catalytic centers of the CP subunits face the internal 
space of the catalytic chamber ensuring the specificity of the reaction toward proteins that 
were actively brought into the proteasome. The CP proteases with various substrate 
preferences ensure that proteins reaching the catalytic chamber are efficiently cleaved into 
small peptides of 6-10 amino acid residues (Finley, 2009; Tomko and Hochstrasser, 2013). 
The regulatory particle (RP or 19S subunit) consists of 19 different protein subunits 
with multiple functions including the six subunits of the AAA type ATPases. One of the 
main functions of the RP is the ATP-dependent unfolding and translocation of the 
ubiquitinated protein into the CP. The other important role of the RP include the 
recognition and recruitment of polyubiquitinated substrates through the ubiquitin receptors 
and the regulation of the opening of the CP substrate channel, which can be opened only 
upon the recruitment of the RP complex. The RP also ensures ubiquitin recycling prior to 
substrate degradation (Finley, 2009). 
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The protein degradation function of the ubiquitination is essential, indeed the K48 
residue of ubiquitin is the only lysine absolutely essential for viability in yeast. Other lysine 
residues of ubiquitin do not seem to affect viability although the K63 residue is required for 
the proper response to genotoxic stress (Kolas et al., 2007; Mailand et al., 2007; Stewart et 
al., 2009; Zhao et al., 2007).  
K63-linked chains do not usually promote protein degradation by the proteasome, 
but are rather involved in signaling processes such as promoting protein translocation or 
complex assembly. The role and the mechanism of formation of other ubiquitin chains (i.e. 
K6, K11, K27, K33) or the mixed type and branched chains are much less studied although 
some regulatory roles for these chains in protein degradation and signaling have been 
proposed (Kulathu and Komander, 2012).   
Ubiquitination is one of the most complex post-translational protein modifications 
in the cell. The ubiquitination cascade is highly hierarchical, with each step of the process 
contributing to the specificity and diversity of the outcome signal. The relatively general 
activating step by E1 supplies the flow of the ubiquitin into the cascade and is represented 
by only two known enzymes UBA1 and UBA6 (Jin et al., 2007). The E2 enzymes 
represented by 39 known genes in the human genome play the role of the chain architects 
and are responsible for the processivity of the reaction and type of chain being build (van 
Wijk and Timmers, 2010). The E2s also differ in their ability to form chains, with one type 
acting as priming enzymes, e.g. UBCH5 (Wu et al., 2010) to promote monoubiquitination 
(adding the first ubiquitin on the substrate) and other type being responsible for chain 
extension via specific linkages e.g. Cdc34, UBC13/MMS2 (Parker and Ulrich, 2009; Wu et 
al., 2010). The E3 enzymes, which comprise 600-1000 genes in the human genome 
represent the vast majority of the components of the ubiquitin system (Deshaies and 
Joazeiro, 2009; Rotin and Kumar, 2009). The reason for such diversity of the E3s might be 
explained by their function in substrate recognition. The E3s are responsible for the 
specificity in the ubiquitination process and often act as intermediate elements between the 
ubiquitin signaling and other regulatory modifications such as phosphorylation (Ravid and 
Hochstrasser, 2008). The E3 family is a highly diverse group of enzymes, which differ in 
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their complexity and domain composition and range from the relatively simple monomeric 
RING domain ligases to multicomponent ubiquitin ligase machineries such as SCF and 
APC/C complexes. 
 
 
Deubiquitinating enzymes (DUBs) 
 
Ubiquitination is a reversible process and a group of specialized proteases namely 
deubiquitinases (DUBs), are responsible for the removal of the ubiquitin from target 
proteins. The human genome encodes for at least 100 DUBs. During the recent years, 
numerous regulatory roles have been defined for the DUBs in counteracting E3 ligases, 
ubiquitin chain editing, ubiquitin maturation and recycling (Komander et al., 2009). 
Notably deregulation of numerous DUBs might be involved in several human illnesses 
such as neurodegeneration diseases, inflammation and malignant neoplasias (Carbone et al., 
2013; Leonard et al., 2001; Tsou et al., 2013; Williams et al., 2011). 
The DUBs superfamily of enzymes can be subdivided into several classes 
depending on the type of their catalytic domain. The DUBs that contain a cysteine in their 
catalytic domain can be classified as ubiquitin C-terminal hydrolases (UCH), ubiquitin 
specific proteases (USP), ovarian tumour proteases (OTU) and Machado-Josephin domain 
(MJD)-containing families. Only one class of enzymes of MNP+/JAMM family represents 
the metalloprotease DUBs that contain Zn2+ in their catalytic site. 
The DUB superfamily of enzymes evolved multiple mechanisms to promote their 
specificity towards the isopeptide bond between the GG tail of the ubiquitin and the lysine 
of the target molecule. The specificity of the DUBs towards ubiquitin versus the UBLs can 
be explained by the nature of its C-terminal GG region and its neighbouring amino acid 
residues. Indeed, the unique sequence of LRLRGG in the ubiquitin is crucial for the DUB 
ability to hydrolyse the ubiquitin isopeptide bond (James et al., 2011). A recent study 
discovered that the single substitution of the leucine 73 to proline (UbL73P) generates 
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conjugation proficient ubiquitin resistant to hydrolysis by most DUBs (Bekes et al., 2013). 
 The relatively rigid structure of the ubiquitin fold makes it an ideal target for 
protein/protein interactions. For example, the hydrophobic patch around isoleucine 44 (I44) 
is crucial for the recognition by most DUBs and ubiquitin binding domains (UBDs) (Dikic 
et al., 2009; Komander et al., 2009). Nonetheless, some DUBs may display a dual 
specificity toward more than one UBL. For example, USP21 can cleave NEDD8 as well as 
the ubiquitin (Ye et al., 2011). Most of the DUBs are specific toward the isopeptide bond, 
but in some unique cases the DUB may possess the peptidase activity as well. USP1 was 
shown to promote its own autocatalytic cleavage. The USP1 is able to bind and promote the 
removal of the N-terminal UBL domain. In this case the USP catalytic domain of the DUB 
recognises the LLGG motif within the protein that mimics the C-terminus of the ubiquitin 
(Huang et al., 2006). 
DUBs display different degrees of specificity toward ubiquitin chains as linkage 
specific DUBs recognise particular polyubiquitin chain. For example, the JAMM/MNP+ 
family DUBs display high degree of specificity towards the K63 linked chains and most 
members of this family where shown to target this type of polyubiquitin. This includes the 
proteasome-associated DUB POH1, the DSB repair-associated DUB, BRCC36 and the 
endocytosis regulators, AMSH and AMSH-LP (Cooper et al., 2009; Sato et al., 2008). The 
crystal structure of AMSH-LP shed light on the mechanism of recognition and proteolysis 
of K63 chains by this DUB. The JAMM/MNP+ domain engages in interactions with the 
proximal and the distal ubiquitin molecules. Notably, the interaction also involves the 
recognition of the K63 isopeptide bond itself (Cooper et al., 2009; Sato et al., 2008). The 
K48 specific DUBs are represented by the proteasome-associated USP14 and the OTU 
family DUBs such as OTUB1 (Hu et al., 2005; Mevissen et al., 2013). Of note, there are 
several modes of recognition of the ubiquitin chains by DUBs that result in an exo- (the 
proximal or the distal ubiquitin moieties are recognised) or endo-catalytic (the enzyme 
recognises internal ubiquitin moieties) activities (Komander et al., 2009). For example, 
USP14 is considered a typical exo-catalytic DUB and can generate free ubiquitin by 
binding and deubiquitinating specifically the distal ubiquitin moiety (Hu et al., 2005). A 
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unique mode of polyubiquitin chain recognition is displayed by USP5 (IsoT) whereby the 
UBP-ZnF domain of this DUB engages in the interaction with ubiquitin in its C-terminal 
region. Thus, only unanchored ubiquitin chains can be recognised and cleaved allowing the 
cleavage of both the K48 and K63 chains (Reyes-Turcu et al., 2006). This function of 
USP5 allows the recycling of free ubiquitin, as mutations in the yeast ortholog of USP5, 
Ubp6, induce proteasomal protein degradation defects due to the depletion of the free 
ubiquitin pool (Amerik et al., 1997; Hanna et al., 2007). The endo- type catalytic activity is 
displayed by numerous DUBs (e.g., AMSH-LP, CYLD, USP8 and USP9X). The endo- and 
exo- activity modes of specific DUBs might result in the generation of monoubiquitinated 
substrates. Although much less is known about the removal of the last monoubiquitin 
moiety from substrates, it is possible that it can be further processed by additional DUBs. 
For example the UCH family DUBs (BAP1 and UCH37) are suggested to remove the 
proximal ubiquitin in monoubiquitinated substrates (Johnston et al., 1999). On the other 
hand monoubiquitinated substrates can be subjected to ubiquitin chain extension by 
ubiquitin E3 (or E4) ligases (Liu et al., 2010). The coordinated action of the DUB and the 
E3 in this process may result in ubiquitin chain type switching. For instance, a switch from 
non-degradative K63 chains to degradative K48 signal is exemplified by the action of the 
E3/DUB hybrid A20 (Wertz et al., 2004).  
In addition to deubiquitinating specific substrates, several other general functions of 
the DUBs were described. These include the maturation of the ubiquitin precursor to yield 
the functional ubiquitin, recycling of the ubiquitin upon protein degradation, counteracting 
and regulating the E2 and E3 enzyme activities as well as ubiquitin chain editing/trimming.  
The ubiquitin is translated as precursor from several genes. These include the UBC, 
UBB, UBA52 and UBA80 that are fused as a linear ubiquitin chain or to the ribosomal 
proteins (L40 and S27a). It remains to be defined which DUBs are responsible for the 
maturation of ubiquitin (Kimura and Tanaka, 2010). 
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The deubiquitinating enzyme BAP1 as a core subunit of a 
multiprotein chromatin-modifying complex 
 
BAP1 (BRCA1 associated protein 1) belongs to the superfamily of the 
deubiquitinating enzymes (DUBs) and more specifically to the ubiquitin C-terminal 
hydrolase (UCH) family of cysteine proteases. It was first identified as an interacting 
partner of BRCA1 (Breast cancer-associated 1). This pioneering study showed that it 
interacts with the RING domain of BRCA1 by the means of its C- terminal region. (Jensen 
et al., 1998). This study also showed that BAP1 was mutated in several cases of lung cancer 
and was able to enhance the tumor suppression activity of BRCA1 in the breast cancer cell 
line MCF7. Interestingly the L691P mutation introduced at the C-terminus of BAP1 
disrupted its interaction with BRCA1. Notably, BAP1 also interacts with BARD1, a major 
partner of BRCA1 partner. Interestingly, the interaction region in BAP1 is located on the 
opposite side of the protein closer to the UCH domain (AA 182-365) (Nishikawa et al., 
2009). To date the significance of BAP1 interaction with BRCA1/BARD1 remains unclear, 
although one study indicated that BAP1 interfere with BRCA1/BARD1 ubiquitin ligase 
activity in vitro by disrupting the proper heterodimer formation (Nishikawa et al., 2009).  
This effect of BAP1 was independent of its catalytic activity. Of note, this study remains 
controversial since it predicts a negative role of BAP1 in the regulation of DNA double 
strand break (DSB) repair by homologous recombination, which appears to requires 
BRCA1/BARD1 activity (Ohta et al., 2011). Studies by our group indicate the opposite; the 
inhibition of BAP1 impaired proper HR and interfered with RAD51 and BRCA1 
recruitment to DSB sites (Yu et al., 2014).  
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Recent studies showed that BAP1 is involved in transcription regulation, tumor 
suppression and development (Abdel-Wahab and Dey, 2013; Dey et al., 2012; Harbour et 
al., 2010; Je et al., 2012; Machida et al., 2009; Misaghi et al., 2009; Scheuermann et al., 
2010; Testa et al., 2011; Ventii et al., 2008; Yu et al., 2010). The first studies by our group 
and others (Machida et al., 2009; Misaghi et al., 2009; Sowa et al., 2009; Yu et al., 2010) 
showed that BAP1 nucleates multiprotein complexes with average molecular weight around 
1.6 MDa, that composed of numerous transcription and chromatin regulators (Yu et al., 
2010). Tandem affinity purification (TAP)/Mas spectrometry (MS) analysis revealed 
stoichiometric (according to gel staining and semiquantitative analysis of MS peptides) 
interaction partners of BAP1 along with substoichiometric components. Highly abundant 
components of the complex are represented by the chromatin-associated protein Host Cell 
Factor-1 (HCF-1), polycomb group proteins additional sex combs like 1 and 2 (ASXL1/2), 
histone demethylase KDM1B (LSD2), O-linked N-acetylglucosamine transferase (OGT), 
forkhead transcription factors FOXK1/FOXK2 and histone acetyl transferase 1 (HAT1) 
(Machida et al., 2009; Misaghi et al., 2009; Sowa et al., 2009; Yu et al., 2010). Less 
abundant but consistently recovered components were identified as polycomb group protein 
FIG. 8. YY1 recruits BAP1 to coactivate cox7c expression. (A) Alignment of cox7c promoter sequences from various mammalian species:
Homo sapiens (NC000005.9 [reference assembly GRCH37]), Bos taurus (NC007305.4 [reference assembly Btau_4.2]), and Mus musculus
(NC000079.5 [reference assembly C57BL/6J]). The YY1 binding sites are boxed. The transcription start site is underlined. (B) Expression of
COX7C following depletion of BAP1, HCF-1, or YY1. COX7C protein levels following transfection with BAP1 (left), HCF-1 (center), YY1
(right), or nontarget control (shControl) shRNAs in U2OS or HeLa cells are shown. Following transfection and selection with puromycin for 2
days, cells were harvested for immunoblotting. (C) Downregulation of COX7C following the expression of catalytically inactive BAP1. U2OS cells
were transduced with retroviral particles to overexpress either BAP1 or its catalytically inactive form (C91S). After 3 days, cells were harvested
for Western blotting using the indicated antibodies. (D) cox7c promoter occupancy by YY1, BAP1, and HCF-1. A YY1 shRNA was expressed in
U2OS cells by transfection and selection with puromycin for 2 days before harvesting for ChIP (left) or Western blotting (right). ChIP was
conducted by using polyclonal antibodies against BAP1, HCF-1, or YY1. An IgG was used as a control. The enrichment of factors was calculated
versus the !-globin promoter, used as a control. All exp riments w re repeated at least 3 times, an the result of a representative experiment are
shown. Data are presented as means " standard deviations. (E) Model representing the recruitment of BAP1 and HCF-1 to the cox7c promoter
by the transcription factor YY1.
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Figure 3. Model representing the recruitment of BAP1 and HCF-1 to the 
cox7c promoter by the transcription fact r YY1(Yu et al., 2010). 
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and the zinc finger transcription factor Yin Yang1 (YY1), and the atypical ubiquitin carrier 
UBE2O (Sowa et al., 2009; Yu et al., 2010). 
The overall composition of the BAP1 complex suggests its major involvement in 
the regulation of the chromatin landscape by multiple mechanisms. These include a 
potential role of the BAP1 complex as a writer of chromatin modifications by OGT and 
HAT1 (O-GlcNAcylation and acetylation of histones, respectively), a chromatin mark 
reader by ASXL1/2 (presence of PHD motifs that bind methylated lysine residues) and a 
chromatin modification eraser by BAP1 and LSD2 (deubiquitination and demethylation of 
histones) (Sowa et al., 2009; Yu et al., 2010).  
Our group showed that BAP1 is implicated in transcriptional regulation and forms a 
ternary complex with the transcription cofactor HCF-1 and the transcription factor YY1. 
BAP1 forms a tight complex with HCF-1 through its HCF-1 binding motif (HBM motif, 
see also below). Indeed, immunodepletion studies showed that all the cellular pool of BAP1 
is associated with HCF-1, although only a fraction of total HCF-1 was complexed with 
BAP1, which is not surprising taking into account that HCF-1 is a highly abundant 
chromatin-associated protein. The interaction of BAP1 with YY1 is transient, but this 
transcription factor was recoverable in the co-IP experiments. In addition, we showed that 
YY1 and HCF-1 directly interact with BAP1 through non-overlapping protein regions. 
Interestingly the loss of the HCF-1 interaction with BAP1 by the deletion of the HBM 
motif resulted in a decreased abundance of the YY1 in the complex. This result indicates 
that, although a direct interaction occurs between BAP1 and YY1, high affinity HCF-1 
binding is required to stabilize the ternary complex. Importantly, we showed that BAP1 
was able to promote transcription activation through its DUB activity, since the catalytic 
dead C91S mutant failed to do so (Yu et al., 2010). 
To define the BAP1-dependent transcriptome, we performed mRNA expression 
microarray analysis in the condition of BAP1 depletion by RNAi. Numerous genes were 
deregulated following the loss of BAP1, including genes involved in cell cycle regulation, 
DNA damage response, cell survival and apoptosis as well as cell metabolism (Yu et al., 
2010). This result suggests that the BAP1 complex is involved in the transcription 
  
 
37
regulation of numerous aspects of cell physiology. To further characterize the role of BAP1 
in transcription, we used one of the genes strongly down regulated following BAP1 
depletion. The Cox7c encodes for one subunit of the holoenzyme that mediates the terminal 
step of the mitochondrial electron transport chain. Since it was known that YY1 is involved 
in the regulation of multiple aspects of the cell metabolism (Blattler et al., 2012) including 
the expression of Cox7c, we analyzed the role of the BAP1 complex in the regulation of 
this gene. The RNAi mediated depletion of BAP1 or HCF-1 resulted in the down regulation 
of Cox7c protein level. On the other hand, the knockdown of YY1 resulted in the activation 
of Cox7c expression (Figure 3). The RNAi-mediated down regulation of YY1 also reduced 
the abundance of the BAP1 and HCF-1 on the Cox7c promoter region, indicating that YY1 
plays the role of the recruiting factor for the BAP1/HCF-1 complex to regulate transcription 
(Yu et al., 2010). 
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Figure 4. Schematic representation of BAP1 and its multiprotein complex. A) 
Comparison of human BAP1 and UCH37. B) Inventory of the components of the BAP1 
complex. Dashed arrows indicate low affinity interactions. The binding regions of 
FOXK1/2, LSD2, HAT1 and CBX factors are unknown. 
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Of note, the BAP1 complex analysis recovered several other transcription factors 
such as FOXK1/2, NRF-1, the ETS family transcription factors Elf-1, Elf-2 and Elf-3 (Yu 
et al., 2010) (and unpublished data from our laboratory). These sequence specific DNA 
binding transcription factors may play major roles in coordinating the recruitment of the 
BAP1 complex to gene promoter regions as we described for YY1. 
 
 
BAP1 as a tumor suppressor in multiple hereditary and sporadic cancers 
 
The work during the recent years has defined BAP1 as a major tumour suppressor 
mutated and inactivated in numerous sporadic and hereditary cancers (Carbone et al., 
2013).  
The first studies on BAP1 showed that it is mutated in lung cancer (Jensen et al., 
1998). The subsequent study showed a prevalence of BAP1 homozygous mutations and 
loss (84%) in the rare melanoma of the eye (involving iris, ciliary body, or choroid or 
collectively uvea). In the same study, the authors showed that siRNA-mediated knockdown 
of BAP1 in melanoma cell lines promoted morphological changes similar to metastatic 
melanomas. Notably, the mRNA expression profiling of the BAP1-depleted cells revealed 
the upregulation of genes implicated in cell invasion such as CDH1 and the proto-oncogene 
KIT, which are often associated with aggressive invasive melanomas.  On the other hand, 
the genes involved in the normal melanocyte differentiation such as neural crest migration 
gene ROBO1, and melanocyte differentiation genes CTNNB1, EDNRB and SOX10 were 
down-regulated. Therefore the loss of BAP1 may promote the acquisition of the 
characteristics of invasiveness associated with metastatic uveal melanoma (Harbour et al., 
2010).  
In a study aimed at identifying the genes that increase the risk of asbestos/erionite-
induced mesotheliomas, BAP1 was found to be mutated in this cancer (Testa et al., 2011). 
The two families described in this study were characterized by germline heterozygous 
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mutations in the BAP1 gene, which results in the production of a truncated non-functional 
protein. Notably, the individuals from both families had high incidence of mesotheliomas, 
as well as other tumours such as uveal melanomas. Importantly, the tumour samples also 
showed the loss of the second allele of BAP1 (Testa et al., 2011). Interestingly, a high 
incidence of BAP1 mutations was also observed in sporadic cases of malignant pleural 
mesotheliomas (MPM) (Bott et al., 2011). The authors performed a copy number variation 
study in a subset of 53 cases of MPM using Comparative Genomic Hybridization array 
(CGH array). The data indicated that BAP1 was inactivated in 23% of tumor samples 
analyzed. Analysis of BAP1 gene in 25 MPM cell lines also revealed that 6 of them had 
BAP1 loss or mutations. The fact that a significant proportion of BAP1 mutations/deletions 
were heterozygous indicates that BAP1 may be a haploinsufficient tumor suppressor (Bott 
et al., 2011). BAP1 germline mutations were also found in familial cases of the atypical 
melanocytic tumor syndrome (Wiesner et al., 2011). The affected individuals developed 
multiple skin neoplasms that were highly heterogeneous in morphology and histopathology 
ranging from the epithelioid nevi to atypical melanocytic proliferation that showed 
overlapping features with melanoma. Some individuals also developed uveal and cutaneous 
melanomas. As in the case of MPM, the melanoma tumours showed the loss of the second 
BAP1 allele (Carbone et al., 2012; Wiesner et al., 2011). 
BAP1 is also mutated in a subset of renal cell carcinoma (Pena-Llopis et al., 2012). 
In this study, BAP1 was also found to be a two hit tumour suppressor. The prevalence of 
BAP1 loss was 14% (24/176) (Pena-Llopis et al., 2012). 
The role of BAP1 as a tumor suppressor in myeloid malignancies was recently 
suggested by the work using the BAP1 knockout mouse. Although the BAP1 constitutive 
knockout is early embryonic lethal, the creERT2 tamoxifen conditional knockout mice at 
adult age can be generated. The animals with BAP1 deletion developed severe anemia 
accompanied by myeloproliferative/myelodysplastic syndrome within 4 weeks after 
tamoxifen injections with features close to human myelodysplastic syndrome /chronic 
myelomonocytic leukemia (MDS/CMML), which was accompanied by ineffective 
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erythropoiesis and thrombopoiesis. The authors also found that BAP1 expression is 
significantly decreased in MDS patients compared to healthy controls (Dey et al., 2012). 
The tumour-associated rearrangements in BAP1 locus range from the whole region 
deletion to point mutations. Indeed, the 3p21.1 chromosome cluster containing several 
genes is a known cancer hot spot (Ji et al., 2005). BAP1 is also subjected to mutations that 
induce frame shifts or in frame insertion/deletions and changes in splicing site.  Point 
mutations result in amino acid substitutions or acquisition of stop codons (Abdel-Rahman 
et al., 2011; Carbone et al., 2013; Harbour et al., 2010; Pena-Llopis et al., 2012; Wadt et al., 
2012; Wiesner et al., 2012; Wiesner et al., 2011; Yoshikawa et al., 2012). Point mutations 
are of particular interest for the determination of BAP1 mechanism of action and 
regulation, since they do not usually result in a drastic dysfunction of the protein, but rather 
reveal specific protein regions critical for its function. The amino acid substitutions and 
small in-frame deletions are thus of particular interest.  
The most often and well characterized point mutations occur within the catalytic 
UCH domain of BAP1. They either affect the catalytic triad itself (C91, H169 and D184) or 
amino acids within its close vicinity (i.e. F81, A95, S172), thus resulting in the disruption 
or decrease of the BAP1 catalytic activity (Abdel-Rahman et al., 2011; Carbone et al., 
2012; Carbone et al., 2013; Harbour et al., 2010; Pena-Llopis et al., 2012; Wadt et al., 
2012; Wiesner et al., 2012; Wiesner et al., 2011; Yoshikawa et al., 2012). The second most 
mutated region is the C- terminus of BAP1 (C-terminal domain (CTD) and the Nuclear 
localization signal (NLS)). This region is highly conserved and point mutations here may 
affect the ability of BAP1 to form the multiprotein complex or its subcellular localization. 
For example the small in frame deletion of the 666-669 region (Harbour et al., 2010) 
completely abrogates BAP1 catalytic activity towards the ubiquitinated histone H2A by 
disrupting the interaction with ASXL1 and ASXL2 (Salima Daou et al., submitted). 
Another interesting subset of mutations occurred in the N-terminal part of the CTD (Figure 
4) (Harbour et al., 2010). The nuclear localization was also shown to be crucial for BAP1 
tumor suppression function (Ventii et al., 2008). Indeed, cancer-associated mutations often 
result in deletions of the NLS region of BAP1, inducing its cytoplasmic localization. In this 
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regard another subset of mutations, represented by small in frame deletions/insertions 
(∆631-634 and Δ637-638InsN) induce BAP1 cytoplasmic sequestration. We found that this 
effect occurs through disrupted auto-deubiquitination activity of BAP1 towards its NLS 
region. Notably these mutations did not affect the BAP1 DUB activity towards its substrate, 
the ubiquitinated H2A. These results indicate that the loss of BAP1 tumour suppression 
function also occurs as a result of its aberrant subcellular localization (Mashtalir et al., 
2014). 
The effect of numerous mutations in BAP1 still remains to be determined, including 
multiple point mutations found in the middle (NORS) region of BAP1 (Figure 4). This 
region contains the HBM, which is important for the HCF-1 interaction with BAP1 
(Machida et al., 2009; Yu et al., 2010). Interestingly, mutations of HBM were identified in 
renal carcinoma, resulting in loss of the BAP1/HCF-1 interaction and as a result loss of its 
antiproliferative activity (Pena-Llopis et al., 2012).  
 
HCF-1 as an integrative platform for regulation of the 
chromatin landscape 
 
Initial research on BAP1 function and mechanism of action focused on its 
interaction with the most abundant component of the complex: HCF-1. HCF-1 was first 
identified as a transcriptional cofactor of the herpes simplex virus-1 (HSV-1) 
transactivation factors VP16 and the cellular factor POU2F1, important for viral immediate 
early (IE) gene expression (Herr, 1998; Mahajan and Wilson, 2000; Wilson et al., 1993; 
Wysocka and Herr, 2003). Since then, HCF-1 was implicated in multiple cellular functions 
i.e. cell cycle progression, RNA splicing metabolism and circadian rhythm regulation (Ajuh 
et al., 2002; Ruan et al., 2012; Zhang et al., 2009).  
Several functionally and structurally distinct regions can be defined in the HCF-1 
protein sequence (See the results section). The N-terminal region of HCF-1 contains five 
repeats of β-propeller-like Kelch domain.  This structure is crucial for the recruitment of 
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HCF-1 to specific transcription regulators that participate in protein/protein interactions 
with HCF-1 via the so-called HCF-1 binding motif (HBM). This short amino acid stretch 
represented by [E/D]-H-X-Y consensus comprised within numerous transcription factors 
and epigenetic regulators including HSV coactivator VP16, the transcription factors PGC-1, 
LZIP, E2F1/3/4, THAP1-4 and the deubiquitinase BAP1 (Freiman and Herr, 1997; Tyagi et 
al., 2007; Vercauteren et al., 2008; Wilson et al., 1993; Wilson et al., 1995; Yokoyama et 
al., 2004; Yu et al., 2010). Adjacent to the Kelch domain, HCF-1 contains a large basic 
domain implicated in protein/protein and intramolecular interactions and required for 
interactions with paired amphipathic helix protein SIN3A, the O-linked N-
acetylglucosamine transferase OGT (Daou et al., 2011) and the transcription factors 
GABP2 (Vogel and Kristie, 2000b) and ZBTB17 (Piluso et al., 2002).Schema 
The middle region of HCF-1 contains a unique proteolytic processing domain 
(PPD) involved in protein maturation and protein/protein interactions with transcription co-
activator/co-repressor protein four-and-a-half LIM domain-2 (FHL2) and OGT (Daou et al., 
2011; Vogel and Kristie, 2006). The C-terminal region of HCF-1 is comprised of the acidic 
region and a tandem of fibronectin type 3 domain: FN3-1 and FN3-2. The C-terminus of 
HCF-1 has been implicated in the interaction with protein phosphatase 1 (PP1) (Ajuh et al., 
2000) and PDCD2, which acts as HCF-1 negative regulator and supresses its ability to 
promote cell proliferation (Scarr and Sharp, 2002).  
HCF-1 is synthesized as a large (300kDa) precursor that is being quickly processed 
by limited proteolysis in its central PPD region (Vogel and Kristie, 2000a, 2006; Wilson et 
al., 1993; Wilson et al., 1995). The domain is composed of 8 reiterations of 20 amino acid 
residues, six of which (PPD1, 2,3, 5, 6, 8) can be proteolytically processed, yielding the N- 
and C- terminal fragments of different molecular weights (Vogel and Kristie, 2000a, 2006; 
Wilson et al., 1993; Wilson et al., 1995).  
 Following processing, the N- and C- terminal polypeptides of HCF-1 remain tightly 
associated. This interaction is attributed to the so-called self-association sequences (SAS) 
of HCF-1. The N- terminal SAS-N is adjacent to the Kelch domain and the SAS-C is 
located at the FN3-1 domain within the C-terminus of the protein. The recent crystal 
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structure of the SAS domain of HCF-1 revealed the mechanism of its self-association. The 
SAS-N sequence of the protein complements the missing beta strand structures of the 
incomplete C-terminal FN3-1 domain. This interaction is also important for proper Oct-
1/VP16/HCF-1 complex formation and transactivation (Park et al., 2012). 
HCF-1 orthologs can be found in all metazoan species. The N-and C-termini, Kelch 
domain, SAS motif and FN3 domains of HCF-1 are highly conserved. The middle region of 
the protein differs among the HCF-1 orthologs. Notably, the posttranslational proteolytic 
processing is characteristic of most HCF-1 orthologs excluding Caenorhabditis elegans 
HCF (CeHCF) (Liu et al., 1999). Intriguingly, the mechanism of the invertebrate HCF-1 
proteolysis is different from the vertebrate species. For example the Drosophila dHCF is 
missing the PPD domain, but contains the characteristic taspase-1 cleavage site required for 
its processing by this protease (Capotosti et al., 2007). This observation indicates that, 
although the mechanisms of proteolytic processing are different for invertebrates and 
vertebrates, the cleavage itself is crucial for normal HCF-1 function. Indeed, the proteolytic 
processing of the human HCF-1 was shown to be required for normal progression through 
mitosis (Julien and Herr, 2003, 2004).  
HCF-1 is a highly abundant nuclear factor found in numerous transcription 
regulatory complexes. Interestingly HCF-1 participates in both repressive as well as 
activation transcriptional regulatory complexes. For example HCF-1 can be found in 
MLL1, MLL5, SETD1A trithorax like, MOF-NSL acetyltransferase and TET 2/3 5-
metylcytosine hydroxylase transcription activation complexes as well as the repressive 
SIN3A/HDAC1/2 and THAP1/3 histone deacetylase complexes (Cai et al., 2010; Deplus et 
al., 2013; Fujiki et al., 2009; Mazars et al., 2010; Tyagi et al., 2007; Wysocka et al., 2003; 
Yokoyama et al., 2004).  
The role of the HCF-1 as an important factor for gene activation was first studied in 
the context of the HSV genome expression during the virus lytic cycle. It was suggested 
that HCF-1 promotes viral IE gene expression by recruiting chromatin modifying and 
remodeling factors to promote the active chromatin state. This includes the recruitment of 
the SETD1/MLL family methyltransferases to introduce the activating H3K4 methylation 
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marks as well as the LSD1 and JMJD2 histone lysine demethylases to remove the 
repressive histone methylation. Notably, the inhibition of LSD1 by RNAi or by a 
pharmacological inhibitor severely affected the ability of the HSV to promote its lytic 
cycle. The authors suggested that upon viral infection the intrinsic cellular response 
mechanisms promote the heterochromatinization of the integrated viral genome by the 
H3K9 methyltransferases. In order to achieve an efficient lytic cycle, this process has to be 
counteracted by the HCF-1/LSD1 and HCF-1/SETD1 in order to revert the HSV genome to 
a transcriptionally active state (Liang et al., 2009).  
HCF-1 also seems to play role in chromatin structure by recruiting the chromatin 
assembly factors, histone chaperones and the chromatin remodeling ATPases. This includes 
the recruitment of the H3/H4 histone chaperones Asf1a and Asf1b. HCF-1 interacts with 
Asf1b through it C-terminal FN3 domains and was shown to be important for the 
replication of viral DNA by tethering the chromatin assembly components to the viral 
replication machinery (Peng et al., 2010).  
HCF-1 resides in a complex with the chromatin-remodeling enzyme of the 
SWI/SNF family CHD8 (Cai et al., 2010; Smith et al., 2005). Although CHD8 is implicated 
in gene repression, it might have a potential opposite role in the transcription activation 
complexes with the HCF-1/MLL methyltransferase and the HCF-1/MOF-NSL 
acetyltransferase (Cai et al., 2010). The HCF-1/SETD1 complex was also shown to be 
engaged in the NURF chromatin-remodeling complex, suggesting its potential role in the 
establishment of heterochromatin boundaries (Li et al., 2011).  
The role of HCF-1 in gene expression activation can be exemplified by its 
interaction with acetyltransferase complexes such as the MOF-NSL and the ATAC (ADA2-
containing). HCF-1/MOF-NSL complex promotes acetylation of the histone H4K5-8-16 
and the HCF-1/ATAC or HCF-1/SAGA complexes promote acetylation of both H3 and H4 
(Cai et al., 2010; Krebs et al., 2011; Smith et al., 2005; Spedale et al., 2012).  
At the functional level, HCF-1 was identified as one of the major players in the 
control of the cell cycle. HCF-1 cooperates with E2F transcription factors, which are 
required for G1/S transition. Members of the E2F family play crucial role in the 
  
 
46
transcriptional control of their target genes required for S phase initiation and progression 
(Tyagi et al., 2007; Wysocka et al., 2003). This group of transcriptional regulators include 
activating members such as E2F1 and E2F3 as well as repressive factors, e.g., E2F4. 
During the initiation of S phase, HCF-1 appears to recruit the MLL/SETD1 complexes to 
the E2F1/3 target genes and promotes the trimethylation of histone H3K4 to activate the 
transcription of target genes. On the other hand, HCF-1 seems to be also required for the 
recruitment of repressive HDAC/SIN3A complexes by E2F4 transcription factor (Tyagi et 
al., 2007; Wysocka et al., 2003). 
Nonetheless, HCF-1 seems to function at least in part as an integral protein 
interaction platform that can involve multivalent protein/protein interactions to recruit the 
necessary regulatory components to the transcription start sequence (Dejosez et al., 2010). 
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Figure 5. HCF-1/OGT protein complex as a structural and functional 
component in a subset of chromatin modifying machineries. 
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Analysis of transcription regulatory complexes that contain HCF-1 using tandem 
affinity purification (TAP), also usually recovers significant amounts of OGT (Wysocka et 
al., 2003). This is also true for TAP purifications of OGT itself (Deplus et al., 2013) 
(Salima Daou, Nazar Mashtalir and El Bachir Affar unpublished data). In fact TAP 
purifications from multiple sources indicate that HCF-1/OGT forms a stable complex that 
can act as an integral regulatory unit of multiple if not all the HCF-1 containing chromatin 
regulatory machineries (Figure 7)(Cai et al., 2010; Dejosez et al., 2010; Fujiki et al., 2009; 
Wysocka et al., 2003; Yao et al., 2008; Yu et al., 2010). Indeed, we found a tight co-
regulation between HCF-1 and OGT. HCF-1 is required to stabilize the nuclear pool of 
OGT; and OGT is in turn required for HCF-1 proteolytic maturation (see also results and 
discussion sections)(Daou et al., 2011). 
 
OGT: one response to multiple questions 
 
The O-linked N-acetylglucosamine transferase (OGT) is an essential and ubiquitous 
eukaryotic enzyme that catalyzes the transfer of N-acetyl glucosamine sugar moiety to 
hydroxyl groups of serine and threonine amino acid residues of proteins. Until recently 
OGT was known to be the only enzyme capable of catalyzing sugar/protein O-
GlcNAcylation. It was also discovered that a secreted form termed eOGT could catalyze 
the O-GlcNAcylation of extracellular matrix proteins (Sakaidani et al., 2011). Nonetheless, 
OGT remains the sole enzyme responsible for O-GlcNAcylation of intracellular protein 
targets. Despite the fact that thousands of proteins were reported to be O-GlcNAcylated, the 
exact functions of this posttranslational modifications remain unclear (Wang et al., 2012; 
Wang et al., 2010). The widespread abundance of O-GlcNAcylation and the occurrence of 
only one enzyme responsible for this modification suggest a highly pleiotropic nature of 
OGT. Protein modification by O-GlcNAcylation was shown to have multiple outcomes on 
target proteins including changes in stability, localization, folding and activity (Hart et al., 
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2011). The dynamic changes of protein O-GlcNAcylation as a function of cell cycle phases, 
differentiation, and stress were also reported (Hart et al., 2007; Wells et al., 2001). O-
GlcNAcylation was implicated in a wide variety of cellular processes ranging from nutrient 
sensing, protein degradation, innate immune response and PI3-kinase signaling to 
regulation of gene expression, epigenetic memory and circadian rhythm modulation. 
Aberrant O-GlcNAcylation has been reported in several human conditions such as 
neurodegenerative disease, diabetes and cancer (Akimoto et al., 2000; Caldwell et al., 2010; 
Dias and Hart, 2007; Ma and Vosseller, 2013; Yang et al., 2008). 
O-GlcNAcylation is a reversible process and the hydrolysis of this modification is 
catalyzed by the sole enzyme O-linked N-acetylglucosamine hydrolase (OGA). OGA 
appears to have a dual activity, which in addition to its O-GlcNAcylhydrolase activity can 
promote protein acetylation (Comtesse et al., 2001). The apparent simplicity in the 
component composition of the O-GlcNAcylation/hydrolysis pathway and thousands of 
regulated substrates raise the questions about the specificity of O-GlcNAcylation. These 
questions can be partly addressed by the fact that OGT is a highly abundant component 
integrated within a large number of protein complexes (Cai et al., 2010; Dejosez et al., 
2010; Fujiki et al., 2009; Wysocka et al., 2003; Yao et al., 2008; Yu et al., 2010). This is 
exemplified by a subset of transcription/epigenetic regulatory complexes in which OGT is 
often found with its partner HCF-1 activating or repressing transcription. Therefore, the 
OGT interaction partners recruit it to different substrates, thus ensuring the specificity of 
GlcNAcylation. 
OGT is a highly conserved enzyme found in all metazoan organisms, although some 
similar enzymes with unknown function have been recently found in Bacteria (Martinez-
Fleites et al., 2008). The human OGT is translated as a 1028 amino acid polypeptide that 
contains 11.5 tetratricopeptide repeats (TPR) sequences at its N-terminus and a three lobed 
catalytic domain at its C-terminus. As in many other proteins, the TPR motifs of the 
enzyme participate in protein/protein interactions and substrate recognition (Clarke et al., 
2008; Iyer and Hart, 2003). The catalytic domain of OGT is closely related to the GT-B 
superfamily of glycosyltransferases but unlike most members of this group of enzymes, it 
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contains a relatively large internal domain of 120 AA between N- and C- lobes of the 
enzyme. OGT is also unique because it is the only enzyme of the GT-B superfamily 
capable of catalyzing GlcNAcylation of peptide substrates (Lairson et al., 2008). The other 
unique feature the OGT catalytic domain is its ability to act as a phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3) binding domain that is responsible for the insulin-induced 
translocation of the enzyme to the plasma membrane (Yang et al., 2008). The catalytic 
reaction involving OGT requires UDP-GlcNAc as the GlcNAc donor and the reaction 
energy is acquired from the pyrophosphate bond (Lairson et al., 2008).  
The requirement of UDP-GlcNAc for the O-GlcNAcylation reaction raised the 
interesting possibility that OGT might be a nutrient sensor. UDP-GlcNAc is a major 
product of the hexosamine biosynthetic pathway (HBP) witch is recognised as a sensor of 
nutrients in the cells (Marshall et al., 1991). Indeed, the production of UDP-GlcNAc is 
highly sensitive to nutrient availability and constitutes a limiting factor for O-
GlcNAcylation reactions. This highly sensitive interplay between UDP-GlcNAc 
concentration and target protein O-GlcNAcylation might have profound effects on the 
cellular response to nutrient availability at multiple levels ranging from modulation of 
plasma membrane-mediated signaling to regulation of gene expression (Hart et al., 2011).  
Another fascinating regulatory effect of protein O-GlcNAcylation is that it targets 
the S/T residues of proteins, which are also targeted by most protein kinases in the cell. In 
this respect, O-GlcNAcylation could directly compete with protein phosphorylation, and 
vice versa. Indeed, multiple proteomic studies found an inverse correlation between the two 
modifications (Hart et al., 2007; Hart et al., 2011; Wang et al., 2010).  
OGT is a nucleo/cytoplasmic protein, approximately equal levels of the enzyme 
being present in both compartments (Daou et al., 2011). The nuclear function of OGT is 
described in multiple studies showing its involvement in numerous repressive and 
activating protein complexes. This includes the already described HCF-1 containing 
complexes such as the H3K4 methyltransferases MLL1, MLL5, SETD1, the DNA 5-
methylcytosine hydroxylases TET1/2/3, the histone acetyltransferase MOF-NSL as well as 
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the repressive histone deacetylase complex SIN3A (Cai et al., 2010; Chen et al., 2013; 
Deplus et al., 2013; Fujiki et al., 2009; Ito et al., 2014; Yang et al., 2002). 
Recently the Drosophila polycomb group protein Super sex combs (Sxc) have been 
shown to be an ortholog of the human OGT. Sxc is recruited to the Hox gene cluster and 
promotes its transcriptional repression. Homozygous mutants of Sxc are usually early 
embryonic lethal. Moreover, some Sxc heterozygous mutants display severe homeotic 
transformation phenotype and late pupal lethality. It is currently unknown whether this 
effect will be recapitulated in mammals (Gambetta et al., 2009; Sinclair et al., 2009).  
Recent studies have also shown that OGT may directly target nucleosomal histones 
and establish O-GlcNAcylation as a novel epigenetic mark (Chen et al., 2013; Fujiki et al., 
2011; Sakabe et al., 2010).  For example the study by Hart’s group found O-GlcNAcylation 
sites on Histone H2A (T101), H2B (S36) and H4 (S47). Most histone modifications were 
found in the nucleosome histone folds, but not in histone tails where most of the epigenetic 
modifications occur (Sakabe et al., 2010). Another study showed that histone H2B is 
predominantly O-GlcNAcylated at S112. The authors generated a modification-specific 
antibody and intriguingly found that S112 O-GlcNAcylation is required for histone H2B 
monoubiquitination at position K120, a histone mark important for positive regulation of 
mRNA elongation by Pol II (Fujiki et al., 2011).  
Most recently, several studies revealed new roles of OGT in transcription 
regulation. It was shown that OGT interacts with the TET1/2/3 5-methylcytosine 
hydroxylases, enzymes responsible for the oxidation of methylated DNA and represent the 
most promising candidates for active DNA demethylation (Kohli and Zhang, 2013). 
Interestingly, several groups found that the TET family members where required for proper 
recruitment of OGT to chromatin (Chen et al., 2013; Deplus et al., 2013; Ito et al., 2014). 
One study showed that the interaction between TET2 and OGT was required for the proper 
histone H2B ubiquitination at position K120 (Chen et al., 2013). On the other hand, another 
study showed the importance of the TET2/OGT/HCF-1 interaction for proper recruitment 
of the SETD1 complex to chromatin for H3K4 trimethylation and gene activation (Deplus 
et al., 2013). 
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With respect to the BAP1 complex, the exact role of OGT and the functional link 
with deubiquitination remains to be defined. Nonetheless, one study revealed that the HCF-
1/OGT/BAP1 complex is an important regulator of gluconeogenesis. This complex appears 
to directly bind the energy balance regulatory transcription factor PGC1α and promotes its 
O-GlcNAcylation. Subsequently this modification promotes the stabilization of hepatic 
PGC1 α levels by its direct deubiquitination by BAP1 (Ruan et al., 2012). 
 
 
UBE2O: breaking the rules of the classical ubiquitin cascade 
 
One of the most unusual components of the BAP1 complex is UBE2O/E2-230k. 
UBE2O belongs to the E2 ubiquitin carrier class of enzymes, and contains the UBC domain 
proficient in the transfer of ubiquitin (Berleth and Pickart, 1996; Haldeman et al., 1995; 
Klemperer et al., 1989). UBE2O displayed many unusual biochemical features. Unlike 
most of the classical E2s, UBE2O was found to be relatively less sensitive to 
iodoacetamide, a cysteine-alkylating agent, indicating the possibility of conformational 
changes in the enzyme or the possible involvement of multiple redundant cysteines. In 
contrast, UBE2O was shown to be highly sensitive to inorganic arsenate, the alkylating 
agent that predominantly targets cysteines in close proximity and promotes their 
crosslinking. This finding prompted the authors to hypothesize that a unique mechanism of 
cysteine relay might be involved in the ubiquitin conjugation process engaging at least two 
steps of intramolecular ubiquitin transfer (Berleth and Pickart, 1996; Haldeman et al., 1995; 
Klemperer et al., 1989). The large size of UBE2O (140 kDa) was also unusual, since most 
of the E2s are small (15-25kDa) single domain enzymes (van Wijk and Timmers, 2010). 
UBE2O was also able to target artificial substrates in vitro (i.e. histone H2B) and this 
reaction did not seem to require additional E3s. These initial studies indicated that UBE2O 
might function as an atypical ubiquitin E2/E3 hybrid (Berleth and Pickart, 1996).  
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UBE2O belongs to the class IV of ubiquitin conjugating enzymes (van Wijk and 
Timmers, 2010; Yokota et al., 2001). This classification of E2s is based on the 
characteristics of the N- and C-terminal extensions relative to their “central” UBC domain. 
Class I is represented by the enzymes with no extensions and containing essentially the 
catalytic core (i.e. UbcH5c, Ubc7 and Ubc13). Class II enzymes have N-terminal 
extensions (i.e. UbcH6 and UbcH10) and class III members possess C- terminal extensions 
(i.e. CDC34). In contrast, class IV family of E2s contain both N and C- terminal extensions 
flanking their UBC domains. The extensions to the UBC domain are known to regulate 
multiple features of the E2s including their localization, E3 binding specificity and activity 
(van Wijk and Timmers, 2010). 
Only three members of the class IV enzymes represent this small and poorly 
characterized family of ubiquitin carriers. This family includes the anti-apoptotic protein 
BIRC6/Apollon/BRUCE, UBE2O and Ube2Z. The latter was shown to be specifically 
charged by UBA6 (Jin et al., 2007). Notably, BRUCE was also shown to act as an E3-
independent ubiquitin conjugating enzyme. It was shown that BRUCE uses its N-terminal 
BIR (baculoviral IAP inhibitor of apoptosis repeats) and C-terminal UBC domain to bind 
and promote ubiquitination and degradation of pro-apoptotic proteins such as SMAC and 
Caspase-9 (Bartke et al., 2004; Hao et al., 2004; Morizane et al., 2005). Recently BRUCE 
was also shown to promote the ubiquitination-dependent removal of the mid-body ring 
during the late stages of the cytokinesis (Pohl and Jentsch, 2008). Interestingly, BRUCE is 
the closest homolog of UBE2O in humans, although this homology can be found only 
within its UBC domain.  
 The function and the physiological role of UBE2O remained largely unknown. It 
was shown that UBE2O is differentially expressed in multiple tissues (Nagase et al., 2000; 
Yokota et al., 2001). The expression of UBE2O was also shown to be dramatically 
increased during erythroid differentiation (Wefes et al., 1995). In addition, UBE2O appears 
to be highly expressed in striated and heart muscle tissues as well as the brain (Nagase et 
al., 2000; Wefes et al., 1995; Yokota et al., 2001; Zhang et al., 2013a). These results 
indicate that although UBE2O seems to be a ubiquitous enzyme, its expression might also 
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be induced in response to specific stimuli (i.e. adipose, muscle and erythroid 
differentiation). 
Recent studies started to reveal some physiological roles of UBE2O. This enzyme 
seems to be involved in the regulation of TNF receptor-associated factor 6 (TRAF6)-
mediated nuclear factor NF-kappa-B (NF-κB) activation. UBE2O interacts with TRAF6 
and inhibits its ubiquitination by K63-linked polyubiquitin chains and subsequently 
promotes persistent signal transduction (Zhang et al., 2013b). This inhibition occurred 
independently of UBE2O catalytic activity and the UBC domain in general. The UBE2O 
binding to TRAF6 was shown to compete with myeloid differentiation primary response 
protein MyD88 adapter binding and inhibit its IL-1β-induced activation (Zhang et al., 
2013b). The same group also studied the role of UBE2O in the regulation of bone 
morphogenic protein (BMP)/ Mothers against decapentaplegic homolog 6 (SMAD6) 
signaling. UBE2O was found to mono-ubiquitinate SMAD6 and potentiate its activating 
role towards BMP7-induced SMAD1 phosphorylation and transcriptional responses (Zhang 
et al., 2013a). UBE2O appears to play a major role as a positive regulator of BMP signaling 
through mono-ubiquitination of SMAD6 during adipocyte differentiation. The main caveat 
of these two studies is that they used a truncated form of UBE2O (Zhang et al., 2013a). 
A crucial role of UBE2O in the regulation of retrograde vesicle trafficking and actin 
nucleation was recently discovered as a result of an E2 enzymes targeting screen (Hao et 
al., 2013). The authors studied the role of the ubiquitin ligase TRIM27 in the ubiquitination 
of the actin nucleation factor WASH. TRIM27 is responsible for the K63 ubiquitin chain 
formation on the conserved hydrophobic region of WASH and is required for actin 
nucleation and retrograde transport. In this work, UBE2O is regarded as a simple ubiquitin 
carrier that works with TRIM27, although according to our predictions of UBE2O targeting 
sequence, it is possible that UBE2O directly ubiquitinates WASH (Hao et al., 2013). 
We found that UBE2O directly interact with and ubiquitinates BAP1 nuclear 
localization signal (NLS), regulating the subcellular localization of this DUB. This 
ubiquitination can be actively counteracted by the BAP1 auto-deubiquitination (auto-DUB) 
activity, a mechanism disrupted in cancer. Moreover we identified a consensus sequence 
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for UBE2O targeting and revealed a subset of proteins with such a sequence and validated 
several of them as UBE2O substrates (Mashtalir et al., 2014) (see also the result section). 
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ABSTRACT 
 
Host Cell Factor 1 (HCF-1) plays critical roles in regulating gene expression in a 
plethora of physiological processes. HCF-1 is first synthesized as a precursor, and 
subsequently specifically proteolytically cleaved within a large middle region termed the 
proteolytic processing domain (PPD). Although the underlying mechanism remains 
enigmatic, proteolysis of HCF-1 regulates its transcriptional activity and is important for 
cell cycle progression. Here we report that HCF-1 proteolysis is a regulated process. We 
demonstrate that a large proportion of the signaling enzyme O-linked-N-
acetylglucosaminyl transferase (OGT) is complexed with HCF-1 and this interaction is 
essential for HCF-1 cleavage. Moreover, HCF-1 is, in turn, required for stabilizing OGT in 
the nucleus. We provide evidence indicating that OGT regulates HCF-1 cleavage via 
interaction with and O-GlcNAcylation of the HCF-1 PPD.  In contrast, although OGT also 
interacts with the basic domain in the HCF-1 amino-terminal subunit, neither the 
interaction nor the O-GlcNAcylation of this region are required for proteolysis. Moreover, 
we show that OGT-mediated modulation of HCF-1 impacts the expression of the herpes 
simplex virus immediate early genes, targets of HCF-1 during the initiation of viral 
infection. Together the data indicate that O-GlcNAcylation of HCF-1 is a signal for its 
proteolytic processing and reveal a novel crosstalk between these post-translational 
modifications. Additionally, interactions of OGT with multiple HCF-1 domains may 
indicate that OGT has several functions in association with HCF-1. 
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INTRODUCTION 
HCF-1 is a ubiquitously expressed chromatin-associated protein and a major 
transcriptional regulator controlling numerous cellular processes including cell cycle 
progression (reviewed in (Kristie et al. 2009)). 
HCF-1 undergoes a unique mode of limited proteolysis involving a series of 20 aa 
reiterations within the central proteolytic processing domain (PPD) (Kristie and Sharp 
1993; Wilson et al. 1995). Although the mechanism of cleavage remains to be fully 
defined, previous studies suggested that HCF-1 might possess an autoproteolytic activity 
(Vogel and Kristie 2000). HCF-1 cleavage occurs at one or more reiterated sites at the PPD, 
generating several N-terminal and C-terminal subunits that form stable heterodimers via 
two corresponding pairs of motifs, termed self association sequences (SAS) (Wilson et al. 
2000).    
Earlier studies indicated that proteolytic processing of HCF-1 is required to 
coordinate two major functions of HCF-1 in cell cycle progression (Julien and Herr 2003). 
The HCF-1 N subunit is necessary and sufficient to promote the G1 to S transition, while 
the C subunit is required for progression through mitosis (Julien and Herr 2003). However, 
the molecular properties that characterize the functions of the precursor versus the mature 
forms of HCF-1 remain unclear. It is likely that the gain or loss of specific protein 
interactions is one major consequence of HCF-1 processing. For instance, the 
coactivator/corepressor FHL2 interacts with the HCF-1 precursor via a motif located in the 
central region of the PPD. HCF-1 processing removes this motif, thus decreasing the 
activation of an HCF-1-dependent target gene (Vogel and Kristie 2006). 
OGT is a highly conserved enzyme that participates in critical nuclear and 
cytoplasmic signalling events (Butkinaree et al. 2010; Slawson et al. 2010). Similar to 
phosphorylation, OGT modifies S/T residues of target proteins with a single N-
acetylglucosamine (O-GlcNAc); regulating protein function by influencing protein 
interactions, enzymatic activity, and subcellular localization. Furthermore, O-GlcNAc 
modification is highly dynamic and ample evidence indicates the existence of extensive 
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crosstalk between O-GlcNAcylation and phosphorylation in controlling biological 
processes (Butkinaree et al. 2010; Slawson et al. 2010). The reversibility of O-
GlcNAcylation is ensured by a unique beta-N-acetylglucosaminidase (OGA) which is also 
highly conserved (Hu et al. 2010). OGT interacts with numerous cellular proteins, most 
notably transcription factors and regulators. Significantly OGT was previously shown to 
interact with and glycosylate the HCF-1 N subunit (Wang et al. 2010; Wysocka et al. 
2003). However, the biological significance and mechanism of this O-GlcNAcylation 
remain unknown. Here, we reveal a novel physical and functional link between O-
GlcNAcylation and limited proteolysis. 
 
RESULTS  
HCF-1 regulates the stability of nuclear OGT.    
HCF-1 possesses a unique modular structure consisting of an amino-terminal Kelch 
domain followed by: (i) a region rich in basic residues; (ii) the PPD containing the 20 aa 
reiterations that are the sites of specific proteolysis; (iii) an acidic activation domain; (iv) 
and a set of fibronectin repeats (Fig.1A). HCF-1 was previously shown to interact with 
OGT (Wysocka et al. 2003). However the abundance of nuclear OGT stably associated 
with HCF-1 relative to the entire nuclear pool was not known. To address this, we 
immunodepleted HCF-1 from HeLa nuclear extracts (Fig.1B). Quantification of OGT 
levels in the HCF-1 complexes fraction (IP) and the flow through (FT) revealed that nearly 
50% of the total nuclear OGT is stably associated with HCF-1. The association of a large 
proportion of OGT with HCF-1 suggests important roles of this complex. Strikingly, 
depletion of HCF-1 in HeLa cells by shRNA induced a corresponding dose-dependent 
decrease of OGT (Fig.1C). This result was confirmed by a pool of 4 siRNA 
oligonucleotides targeting HCF-1 (Fig.1C). Conversely, overexpression of HCF-1 induced 
an increase in OGT protein levels (Fig.1D). The reduction in OGT levels in the absence of 
HCF-1 were not due to a reduction in OGT mRNA levels (Fig.1E). Moreover, no detectable 
HCF-1 was found to be associated with the OGT promoter (Fig.1F). In contrast, HCF-1 was 
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readily detected on the promoter of p107 RB family member (Fig.1F), a known HCF-1 
target gene (Tyagi et al. 2007).  
The above results suggested that HCF-1 regulates OGT stability via a post-
transcriptional mechanism. Since OGT is distributed in both the cytoplasm and the nucleus 
while HCF-1 is primarily localized in the nucleus, we determined whether the nuclear pool 
of OGT was preferentially stabilized by HCF-1. Subcellular fractionation showed that the 
nuclear pool of OGT is significantly reduced relative to the corresponding cytoplasmic pool 
following depletion of HCF-1 (Fig.2A). These results were confirmed by immunostaining 
following knockdown of HCF-1 where a significant reduction of nuclear OGT could be 
observed in the HCF-1 depleted cells (Fig.2B). To determine whether OGT is regulated by 
proteasomal degradation, we transfected expression plasmids for OGT and ubiquitin, 
followed by treatment with the proteasome inhibitor MG132. After OGT 
immunoprecipitation, we observed a typical ubiquitination smear, which was increased by 
MG132 treatment (Fig.2C). We note that MG132 has a minor effect on OGT protein levels. 
This is due to the relatively long half-life of OGT (~ 12 hours) (Marshall et al. 2005). We 
also observed an increase in the ubiquitination of endogenous OGT following extended 
treatment with MG132 (Fig.S1). Next, we conducted a cycloheximide chase upon HCF-1 
knockdown and found that OGT was slightly reduced overtime while no change or even a 
small increase was observed for the shControl transfected cells (Fig.2D).  
 
OGT is required for HCF-1 proteolytic processing. 
It was previously reported that OGT interacts with and glycosylates HCF-1 
(Wysocka et al. 2003), suggesting an important reciprocal regulation. Strikingly, depletion 
of OGT induced an accumulation of the HCF-1 precursor with a corresponding decrease in 
the HCF-1 cleavage products (Fig.3A). Quantification indicated that  shRNA constructs, 
which depleted OGT to different extents, correlated in an inverse manner with the ratio of 
HCF-1 cleavage products (HCF-1 FL/HCF-1 cleaved forms). As expected, the extent of 
OGT knockdown also correlated with a proportional decrease of global O-GlcNAc 
modification. Transfection of siRNA oligonucleotide pools, which induced a substantial 
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knockdown of OGT, also resulted in a significant accumulation of HCF-1 FL (Fig.3A). 
OGT knockdown also inhibited HCF-1 cleavage in other cell types indicating that this 
inhibition is not cell-type specific (Fig.3A). Conversely overexpression of OGT along with 
HCF-1 FL resulted in: (i) an increase in global protein O-GlcNAcylation levels; (ii) a 
decrease in HCF-1 FL levels; and (iii) an increase in the levels of HCF-1 N and C 
polypeptides (Fig.3B). The effect on HCF-1 cleavage was dependent on OGT catalytic 
activity (Fig.S2).  
O-GlcNAc modification is dynamic and cycling is ensured by the concerted action 
of OGT and OGA (Hurtado-Guerrero et al. 2008; Love et al. 2010). We reasoned that 
overexpressed OGA would shift the equilibrium toward O-GlcNAc removal with a 
concomitant effect on HCF-1 cleavage. Although no significant changes were seen on the 
cleaved forms of HCF-1 following overexpression of OGA, a noticeable increase in the 
level of HCF-1 precursor was observed (Fig.3C). The decrease of global O-GlcNAc with 
overexpressed OGA was considerably less significant than with OGT RNAi (Fig.3C).  
Components of the nuclear pore complex are known to be heavily glycosylated by 
OGT suggesting that O-GlcNAc modification might be required for the nuclear import of 
proteins (Davis and Blobel 1987; Hanover et al. 1987; Jinek et al. 2004). Although not 
firmly established, HCF-1 appears to be cleaved in the nucleus (Wilson et al. 1995). We 
reasoned that depletion of OGT might induce cytoplasmic sequestration of HCF-1 FL from 
accessing factors required for its cleavage in the nucleus. However, in the absence of OGT, 
most of the HCF-1 FL is in the nucleus, indicating that the lack of HCF-1 cleavage was not 
due to a defect in nuclear import (Fig.3D). To further confirm these results, cells were 
stained for HCF-1 following shRNA knockdown of OGT. While substantial depletion of 
OGT was achieved, no noticeable cytoplasmic accumulation of HCF-1 was observed 
(Fig.S3). Interestingly, in contrast to HCF-1 cleavage, no effect of OGT knockdown was 
observed on the histone methyltransferase and transcription regulator MLL1, which is also 
subjected to specific proteolytic cleavage (Hsieh et al. 2003) (Fig.S4). We concluded 
therefore that OGT is required for HCF-1 cleavage. 
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OGT interacts with and glycosylates full length HCF-1.  
To investigate the mechanism of HCF-1 maturation, we sought to characterize the 
OGT interaction with HCF-1. First, we cotransfected HA-HCF-1 FL or HA-HCF-1 N (1-
1010aa) with Myc-OGT, and found that significantly more OGT is immunoprecipitated 
with HA-HCF-1 FL than HA-HCF-1 N (Fig.S5A), suggesting that the major determinants 
of OGT/HCF-1 interaction are contained within HCF-1 sequences that are not present in 
the HCF-1 N protein.  
Next we used the WT or an uncleavable form of HCF-1 mutant (NC) in which the 
critical glutamic acid of each repeat had been mutated to alanine (Vogel and Kristie 2006). 
Immunoprecipitation assays revealed that the uncleavable HCF-1 mutant was even more 
efficient in co-immunoprecipitation of OGT than the WT HCF-1 (Fig. S5B). These effects 
were also observed following co-expression of HCF-1 WT or the uncleavable mutant with 
OGT. In this case, OGT expression induced processing of the HCF-1 WT but not the HCF-
1 NC mutant (Fig.S5C). Of note, Myc-OGT was substantially stabilized in cells co-
transfected with HCF-1 NC accounting partly for the more efficient co-
immunoprecipitation. However, the ratio of the IP/Input supported the conclusion that OGT 
interacts more efficiently with the uncleaved HCF-1 than the HCF-1 WT (Fig.S5C). Next, 
in vitro GST-pull down assays using recombinant GST-OGT and various in vitro translated 
forms of HCF-1 (FL, N and C subunits) indicated that the GST-OGT interacts more 
efficiently (~10 fold) with the HCF-1 precursor than the HCF-1 N subunit (Fig.S6). No 
interaction was observed with the HCF-1 C (Fig.S6). To determine whether HCF-1 FL is 
O-glycosylated, we immunoprecipitated HCF-1 and found that the precursor reacts with the 
anti-O-GlcNAc antibody, suggesting that O-GlcNAcylation of HCF-1 precedes its 
processing (Fig.S7). We also note that large C-terminal fragments corresponding most 
likely to processing intermediates are O-glycosylated, however the most processed forms of 
HCF-1 C-terminal subunits appear to be very poorly O-glycosylated.  
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OGT interaction with and O-GlcNAcylation of the HCF-1 N-terminal subunit are not 
required for HCF-1 proteolytic cleavage. 
To determine the role of O-GlcNAc in the proteolytic processing of HCF-1, we 
utilized two approaches. We first conducted GST-pulldown assays with subdomains of the 
HCF-1 N subunit and observed that the HCF-1 basic region interacts with OGT (Fig.S8A). 
We further determined that a region between 500 and 550 aa of HCF-1 is sufficient for this 
interaction (Fig.S8A). Therefore, we generated a mutant of HCF-1 lacking this domain 
(Δ500-650 aa) (HA-HCF-1 ΔOBM) (Fig.S8B). Interestingly, this mutant was cleaved as 
efficiently as the WT HCF-1 (Fig.S8C, left panel). Moreover, the interaction of this HCF-1 
mutant with OGT was almost unchanged in comparison to the WT HCF-1 (Fig.S8C, left 
panel).  Next, we analysed the O-GlcNAcylation levels of this HCF-1 mutant and observed 
that while a significant decrease in the O-GlcNAcylation of the cleaved forms of HCF-1 
was evident, there was no substantial change in the overall O-GlcNAcylation of the 
uncleaved FL HCF-1 (Fig.S8C, right panel). The data indicate that neither the interaction of 
OGT with the N subunit nor its O-GlcNAcylation is responsible for the OGT mediated 
proteolysis of HCF-1. To confirm these results, we mutated all of the known O-
GlcNAcylation sites located in the HCF-1 N subunit (Wang et al. 2010) (HA-HCF-1 ΔO-
Glc) (Fig.S8B). Similar to the HCF-1 DOBM mutant, a substantial decrease in HCF-1 O-
GlcNAcylation was observed for the cleaved forms while no major changes in the O-
GlcNAcylation levels of the uncleaved HCF-1 were seen (Fig.S8C, right panel). 
Importantly the extent of HCF-1 cleavage remained essentially similar to the WT form 
suggesting that O-GlcNAc modification of the basic region within the HCF-1 N is not 
required for processing (Fig.S8C, left panel).  
 
OGT interacts with, O-glycosylates, and promotes the cleavage of the PPD. 
To provide further mechanistic insights into the role of OGT in HCF-1 processing, 
we investigated the role of the PPD in promoting the OGT/HCF-1 interaction. First we 
transfected cells with the uncleavable HCF-1 FL (HCF-1 NC) or HCF-1 lacking the PPD 
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(HCF-1 Δ PPD) and compared the interaction with OGT.  As shown in Fig.4A, the HCF-1 
lacking the PPD interacted less efficiently (~ 20-fold less) with OGT than the uncleavable 
form suggesting that the PPD is the major OGT-interacting domain. Previously it was 
demonstrated that the PPD was sufficient for cleavage in cells, although it is very poorly 
processed (Wilson et al. 1995). Therefore, we generated PPD expression constructs with 
and without a Nuclear Localization Signal (NLS) (Fig.S9A). In contrast to the PPD without 
the NLS (Myc-PPD), which was moderately cleaved, the PPD with the NLS (Myc-NLS-
PPD) was dramatically cleaved and only a faint band of residual uncleaved PPD could be 
detected (Fig.S9B). Of note, the Myc-NLS sequences (~3 kDa) enabled us to detect the 
smallest cleaved form of the Myc-NLS-PPD (PPD repeat 1-2).  
As detected by immunofluorescence, the Myc-PPD was distributed in the cytoplasm 
and nucleus (Fig.4B). In contrast, the Myc-NLS-PPD accumulated in the nucleus (Fig.4B). 
Interestingly, cells expressing Myc-NLS-PPD exhibited a typical pronounced nuclear OGT 
staining (Fig.4B), similar to mock transfected cells (Fig.2B). However, in cells expressing 
Myc-PPD, OGT was distributed evenly between cytoplasm and nucleus (Fig.4B), 
suggesting that this form of the PPD directly interacts with OGT and interferes with its 
nuclear localization. This result was confirmed by subcellular fractionation, i.e., cells 
expressing Myc-PPD exhibit significantly higher OGT levels in the cytoplasm (Fig. S10).  
Next, we found that the HCF-1 PPD (Myc-PPD) was sufficient to co-IP OGT (Fig.4C). In 
contrast, the smallest cleaved form of PPD does not interact with OGT indicating that this 
set of reiterations (R1-2) is not sufficient to mediate the association with OGT. Since the 
Myc-NLS-PPD appears to be dramatically cleaved, we reasoned that this domain might 
interact with OGT and be a target of OGT mediated O-GlcNAcylation  prior to its cleavage. 
In support of this, the Myc-PPD was modified by O-GlcNAc in an OGT-dependent manner 
(Fig.4D and Fig. S11). To further characterize the role of OGT in promoting HCF-1 
cleavage, we took advantage of the PPD without the NLS, which localizes in both 
cytoplasm and nucleus (Fig.4B), interacts with OGT, and is moderately cleaved (Fig.4C). 
Following over-expression of OGT, we observed a decrease in the levels of both the FL 
Myc-PPD and the cleavage products (Fig.4E). Conversely, knockdown of OGT induced an 
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accumulation of FL Myc-PPD (Fig S12). These results indicate that OGT directly promotes 
the cleavage of the HCF-1 PPD and intermediate processing forms. 
 
Depletion of OGT enhances HCF-1 target gene expression.  
Since we observed a significant accumulation of HCF-1 FL in the nucleus following 
depletion of OGT, we first determined whether it associates with chromatin. The 
chromatin/nuclear matrix fraction of HeLa cells was prepared from control and OGT-
depleted cells and treated with MNase (Sanders 1978). As shown in Fig.5A, HCF-1 was  
released into the soluble fraction following MNase treatment, indicating its association with 
chromatin.  
Finally, to determine the biological consequences of OGT mediated regulation of 
HCF-1 cleavage, we assessed the impact of OGT depletion on HCF-1 mediated gene 
expression using the well characterized model of HCF-1-dependent activation of the herpes 
simplex virus (HSV) IE genes (Kristie et al. 2009). HFF cells transfected with control or 
OGT siRNAs were infected with HSV and the levels of viral and control cellular mRNAs 
were determined by qRT-PCR. As shown in Fig.5B, depletion OGT (~80%) resulted in a 
substantial increase in the ratio of HCF-1 precursor to the HCF-1 cleavage products as 
compared to cells transfected with control siRNAs. Importantly, depletion of OGT also 
resulted in a consistent increase (~1.5 to 2.5-fold) in viral IE gene expression (Fig.5B).  In 
contrast, no impact was seen on expression of the control GAPDH or TBP mRNA levels. 
As factors such as the Sp1 transcription factor, a known component of the viral HSV IE 
gene expression regulatory circuit, as well as RNA polymerase II can be regulated by O-
GlcNAcylation (Kelly et al. 1993; Yang et al. 2001), we also analyzed the expression of a 
set of Sp1 target genes in cells depleted of OGT. In contrast to the impact on HSV IE gene 
expression, we did not detect any significant changes in the expression of these Sp1 target 
genes (Fig. S13). Thus, although we can not exclude possible effects resulting from O-
GlcNAcylation of other cellular factors, the loss of Sp1 or RNA polymerase II O-
GlcNAcylation does not likely account for the observed increase in HSV immediate-early 
gene expression. The results are consistent with previous data indicating that the full-
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length, non-processed form of HCF-1 was more efficient in induction of viral IE reporter 
genes (Vogel and Kristie 2006). 
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DISCUSSION 
Site-specific limited proteolytic cleavage is exploited as a signaling mechanism in 
nearly all living organisms. Moreover, the importance of this post-translational 
modification is emphasized by the fact that, in mammals, numerous physiopathological 
processes have evolved elaborate protein cleavage machineries. 
Mammalian HCF-1 is subjected to proteolytic cleavage via limited site-specific 
proteolysis within unique reiterations of the PPD. Interestingly, C elegans HCF does not 
have a domain homologous to PPD and is not cleaved (Liu et al. 1999). The Drosophila 
HCF, although also cleaved, does not contain cleavage sites homologous to the mammalian 
HCF-1 PPD (Mahajan et al. 2003). This suggests that a need developed for HCF-1 
proteolytic processing, although distinct mechanisms of cleavage have apparently evolved. 
Indeed, it has been shown that the Drosophila HCF is cleaved by the protease taspase 1, 
while human and mouse HCF-1 are cleaved in a taspase 1-independent manner (Capotosti 
et al. 2007).  
Here, we demonstrate that OGT is required for HCF-1 cleavage. Interestingly O-
GlcNAcylation is shown here to promote proteolytic cleavage, protein phosphorylation also 
impacts proteolytic cleavage by either stimulation or inhibition (Kurokawa and Kornbluth 
2009), thus highlighting the importance of post-translational modifications in tightly 
regulating limited proteolysis. In addition to the previously established role of OGT in 
inhibiting proteasomal degradation via O-GlcNAcylation of the proteasome or its substrates 
(Cheng and Hart 2001; Han and Kudlow 1997; Zhang et al. 2003), we have here uncovered 
an additional role for this enzyme in signalling limited proteolysis. Since both proteolytic 
cleavage and O-GlcNAcylation modulate the function of several transcription regulators, it 
would be interesting to determine whether this crosstalk represents a more global signaling 
event. 
The role of OGT in association with HCF-1 is likely to have several functions. With 
respect to the regulation of HCF-1 cleavage, it is possible that the PPD encodes a dormant 
protease that is stimulated by O-GlcNAcylation, following a significant conformational 
change. This model would provide a level of control that prevents promiscuous and 
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untimely autocleavage of HCF-1. Alternatively, O-GlcNAcylation of the PPD may provide 
a signal for recruitment of an, as yet unidentified, protease. Importantly, the PPD is not 
simply a domain containing proteolytic cleavage sites but is also a domain that interacts 
with HCF-1 binding partners. OGT mediated O-GlcNAcylation of the PPD or PPD 
interacting partners could result in an enhancement of cleavage via disruption of protective 
interactions. Thus, OGT-mediated cleavage of HCF-1 can provide a mechanism for 
controlling the dosage and functional competency of HCF-1 and its processed subunits. In 
support of this, depletion of OGT results in accumulation of the full-length HCF-1 and a 
stimulation of HCF-1 dependent transcriptional activation of the HSV IE genes.  Finally, an 
additional implication of the interaction of OGT with HCF-1 is the reciprocal impact of 
HCF-1 on OGT stability. Thus, as OGT interacts more efficiently with the HCF-1 
precursor, it may therefore modulate its own stability. 
In addition to modulating HCF-1 cleavage, OGT is also likely to have additional 
functional roles in association with HCF-1. In addition to its interaction with the HCF-1 
PPD, OGT also interacts with the basic domain of HCF-1 and remains associated with the 
cleaved HCF-1 subunits. Thus, OGT might modulate HCF-1 interactions with chromatin-
associated regulators. Notably, OGT is a metabolic sensing enzyme. It would be of 
continued interest to investigate whether changes in metabolic conditions impact HCF-1 
processing and/or function, which in turn would affect cell growth and cell cycle 
progression. Thus, as HCF-1 is a major regulator of cellular metabolism (Dejosez et al. 
2008; Vercauteren et al. 2008), O-GlcNAcylation of HCF-1 might provide a link between 
cellular metabolism and cell proliferation.  
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MATERIALS AND METHODS   
 
Plasmids and Antibodies  
shRNA constructs, expression plasmids, and antibodies used in this study are described in 
supplemental information.  
 
Cells and virus 
HeLa, U2OS, HFF (human foreskin fibroblast), and 293T cells were maintained according 
to standard protocols.  Infections of HFF cells with HSV-1, cell transfections, and western 
blotting were done as described in supplemental information. 
 
Immunodepletion and Immunoprecipitation  
Immunodepletion of HeLa nuclear extracts with anti-HCF-1 or control IgG were done as 
described in supplemental information. 
 
Biochemical fractionation of subcellular compartments  
Nuclear and cytoplasmic fractions were obtained using a hypotonic lysis buffer as 
described (Nakatani and Ogryzko 2003). Chromatin fractions and digestion with MNase 
were conducted as described (Groisman et al. 2003). 
 
In vitro GST-pulldown assays 
Recombinant GST-OGT fusion protein was purified using glutathione agarose beads and 
used for pull down assays as described in the text and supplemental information.  
 
Immunofluorescence 
Cells were fixed with paraformaldehyde and stained with the appropriate antibodies as 
detailed in the supplemental information. 
 
mRNA expression analysis and chromatin immunoprecipitations 
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mRNA was prepared according to standard procedures and cDNAs were used for real time 
qRT-PCR analysis of cellular and viral mRNA levels. Chromatin immunoprecipitation 
(ChIP) was done essentially as previously described (Bottardi et al. 2009) with minor 
modifications as described in supplemental information .  
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Figure 1 
HCF-1 is required for the maintenance of proper OGT levels.  
(A) Schematic representation of the domains of the human HCF-1. (B) Immunodepletion of 
HeLa nuclear extracts using anti-HCF-1. OGT and HCF-1 were detected in the HCF-1 
immunoprecipitate (IP) and flow through (FT) by western blot. The nuclear protein PARP1 
was used as a negative control. Quantification of OGT was done relative to PARP1. (C) 
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Depletion of HCF-1 using shRNA plasmids or siRNA olignucleotide pools induces OGT 
downregulation. Quantification of OGT or HCF-1 was done relative to β-actin. (D) 
Overexpression of HCF-1 increases OGT protein levels. HeLa cells were transfected with 
HCF-1 FL and 2 days post-transfection, cells were harvested for immunoblotting. (E) OGT 
mRNA is not affected by HCF-1 depletion. U2OS cells mRNAs were isolated and cDNAs 
were quantitated by qRT-PCR relative to GAPDH. shRNA for OGT was included as an 
internal control. All experiments were repeated at least 3 times and the data are presented as 
mean ± SD. (F) Promoter occupancy by HCF-1. ChIP assays were done using U2OS cell 
chromatin and anti-HCF-1 or IgG control. The enrichment of factors was calculated relative 
to the occupancy of the β-globin promoter. All experiments were repeated at least 3 times 
and data are presented as mean ± SD. 
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Figure 2  
HCF-1 regulates the stability of OGT. 
Nuclear OGT is preferentially downregulated following HCF-1 depletion (A-B). (A) 
Biochemical fractionation of nuclear and cytoplasmic compartments following HCF-1 
knockdown in U2OS. PARP1 and LDH, which are localized in the nucleus and cytoplasm, 
respectively, were used as controls for fractionation. Quantification of cytoplasmic versus 
nuclear OGT was done relative to LDH or PARP1, respectively. (B) Immunofluorescence 
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detection of OGT in U2OS cells following HCF-1 knockdown. (C) OGT is ubiquitinated 
and regulated by proteasomal degradation. 293T cells were transfected with Myc-OGT and 
HA-ubiquitin (HA-Ub). Two days post-transfection, cells were treated with 20 µM MG132 
for 4 hours prior to harvesting for immunoprecipitation and western blotting.  (D) OGT 
protein stability is decreased following HCF-1 depletion.  U2OS cells were transfected with 
HCF-1 shRNA plasmids. Three days later, cells were treated with CHX (100 µg/ml) and 
harvested for western blotting. 
 
 
 
 
 
 
 
 
 
 
  
  
 
78
 
 
 
Figure 3 
OGT is required for HCF-1 proteolytic cleavage.  
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(A) OGT depletion induces accumulation of the HCF-1 precursor with a decrease in the 
levels of the  cleaved forms. Cells were transfected with either OGT shRNA or OGT 
siRNA oligonucleotide pools and harvested for western blotting. Quantification of OGT is 
relative to β-actin. The HCF-1 cleavage ratio was estimated by dividing the signal value of 
the precursor by the sum of the signal values of the cleaved forms. (B) Overexpression of 
OGT promotes HCF-1 cleavage. 293T cells were transfected with either pcDNA3 control 
or Myc-OGT along with HA-HCF-1 FL. Two days post-transfection, cells were harvested 
for western blotting. (C) Overexpression of OGA inhibits HCF-1 cleavage. 293T cells were 
transfected with either pcDNA3 control or Myc-OGA along with HA-HCF-1 FL. Two days 
post-transfection, cells were harvested for western blotting. (D) Subcellular fractionation 
following knockdown of OGT. HeLa cells were transfected with OGT shRNA plasmids 
and harvested for fractionation and western blotting. YY1 and GAPDH were used as 
markers for nucleus and cytoplasm, respectively. 
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Figure 4 
OGT interacts with HCF-1 PPD and mediates its cleavage. 
(A) Interaction of OGT with HCF-1 lacking PPD or HCF-1 FL. 293T cells were transfected 
with either HCF-1 NC V5 or HCF-1 ΔPPD V5. Two days post-transfection, total cell 
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extracts were used for immunoprecipitation using an anti-V5. (B) Immunofluorescence 
localization of PPD with or without a nuclear localization signal. U2OS cells were 
transfected with  either Myc-PPD or Myc-NLS-PPD. Two days post-transfection, cells 
were used for immunostaining using an anti-Myc. (C) Interaction of PPD with OGT. 293T 
cells were transfected with either Myc-PPD or Myc-NLS-PPD. Two days post-transfection, 
total cell extracts were used for immunoprecipitation using an anti-Myc. (D) O-
GlcNAcylation of PPD with OGT. 293T cells were transfected with either Myc-PPD or 
Myc-NLS-PPD and Myc-OGT. Two days post-transfection, total cell extracts were used for 
immunoprecipitation under denaturing conditions using an anti-Myc. To ensure the 
specificity of signal, the O-GlcNAc antibody was pre-incubated for 1 H with 1 M of N-
acetylglucosamine before being applied to the membrane. (E) Overexpression of OGT 
promotes PPD proteolytic cleavage. 293T cells were transfected with Myc-PPD along with 
pCDNA3 or Myc-OGT. Two days post-transfection, total cell extracts were used for 
immunoblotting. 
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Figure 5 
Uncleaved HCF-1 associates with chromatin and enhances HCF-1-mediated viral gene 
expression. 
(A) HCF-1 precursor is associated with chromatin. HeLa were transfected with either non-
targeting control or OGT shRNA plasmids. Three days post-transfection, cells were 
harvested for cell fractionation. The chromatin/nuclear matrix fraction was treated with 
micrococcal nuclease (MNase) to release nucleosomes. Proteins were detected in the 
soluble and pellet fractions by immunoblotting or coomassie blue staining. (B)  HFF cells 
were transfected with control or OGT siRNAs.  Three days post transfection, cells were 
infected with 0.1 PFU HSV-1 and harvested for mRNA analysis (top panel) and 
immunoblotting (bottom panel). Levels of control cellular (GAPDH and TBP), OGT, and 
viral IE mRNAs in OGT depleted cells are shown relative to levels in control siRNA 
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transfected cells. All experiments were repeated at least 3 times and data are presented as 
mean ± SD. 
 
 
SUPPLEMENTAL INFORMATION 
 
 Supplemental Information contains additional methods; thirteen figures; the sequences of 
the OGT and HCF-1 shRNA constructs and additional references. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
84
SUPPLEMENTARY FIGURES 
 
Figure S1. 
Endogenous OGT is ubiquitinated and degraded by the proteasome.  
293T cells were treated with 20 µM MG132 for 10 hours. Denatured whole cell extracts 
were used to immunoprecipitate OGT which was subjected to immunoblotting with the 
indicated antibodies. 
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Figure S2. 
OGT regulates HCF-1 cleavage in catalytic activity-dependent manner. 
293T cells were transfected with HA-HCF-1 FL expression plasmid along with  pCDNA3, 
Myc-OGT or Myc-OGT D925A. Two days post-transfection, total cell extracts were used 
for immunoblotting with the indicated antibodies. 
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Figure S3. 
Depletion of OGT does not interfere with HCF-1 nuclear import. 
Immunofluorescence detection of HCF-1 following knockdown of OGT. U2OS cells were 
transfected with either non-targeting control or OGT shRNA plasmid for 3 days prior to 
fixation and immunostaining. Arrows indicate cells depleted for OGT. 
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Figure S4. 
OGT is not required for proteolytic cleavage of mixed lineage leukaemia MLL1. 
(A) HeLa cells were transfected with either non-targeting control or OGT shRNA plasmids. 
Three days post-transfection, cells were harvested for immunoblotting. (B) HeLa cells were 
transfected with either non-targeting control or OGT shRNA plasmids along with Flag-
MLL1 expression plasmid. Three days post-transfection, cells were harvested for western 
blotting. 
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Figure S5.  
OGT interacts more efficiently with the HCF-1 precursor. 
(A) Interaction of OGT with HCF-1 N subunit or HCF-1 FL. HeLa cells were transfected 
with either HA-HCF-1 FL or HA-HCF-1 N (1-1010 aa) along with Myc-OGT. Two days 
post-transfection, total cell extracts were used for immunoprecipitation using anti-HA and 
immunoblotting using the indicated antibodies. The efficiency of interaction was 
determined by densitometry quantification of OGT in the IP fraction versus OGT in the 
input cell extract for each condition. Note that transfected cells with both Myc-OGT and 
HCF-1 show a substantial increase in the levels of transfected OGT. In contrast, the signal 
of endogenous OGT is not significantly changed between control and HCF-1 conditions as 
the ratio of non-transfected cells versus transfected cells is high. (B) Interaction of OGT 
with uncleaved HCF-1 or HCF-1 FL. 293T cells were transfected with either HCF-1 FL V5 
or HCF-1 NC V5 and used for immunoprecipitation using anti-V5. The efficiency of 
interaction was determined as in panel A. (C) Interaction of overexpressed OGT with 
uncleaved HCF-1 or HCF-1 FL. 293T cells were transfected with either HCF-1 FL V5 or 
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HCF-1 NC V5 expression plasmids along with Myc-OGT. Two days post-transfection, 
total cell extracts were used for immunoprecipitation using an anti-V5. The 
immunocomplexes were subjected to western blotting. The efficiency of interaction was 
determined as in panel A. We note that: (i) large HCF-1 fragments containing portions of 
PPD interact more with OGT than HCF-1 N terminal subunit (ii) the uncleaved full length 
HCF-1 containing intact PPD interacts more efficiently with OGT than HCF-1 cleaved 
fragments. 
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Figure S6. 
Interaction in vitro between OGT and HCF-1 FL, HCF-1 N or HCF-1 C subunits.  
(A) Schematic representation of primers design for IVT of HCF-1 fragments. (B) HCF-1 
full length interacts more efficiently with OGT than HCF-1 cleaved fragments. GST-tagged 
OGT bound to GSH beads was incubated with various fragments of in vitro translated 35S 
labeled-HCF-1 for 8 hours. Following extensive washes, the bead-associated complexes 
were analyzed by coomassie blue staining for GST-OGT and autoradiography for HCF-1. 
The efficiency of interaction was determined by densitometry quantification of OGT in the 
pull down fraction versus OGT in the input fraction for each interaction. These in vitro 
studies indicate that OGT interacts with the N-terminus subunit of HCF-1. We note that the 
full-length HCF-1 (with intact PPD) interacts more strongly with OGT comparatively to 
HCF-1 N subunit. 
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Figure S7. 
The HCF-1 precursor is O-glycosylated.  
U2OS cell extracts were used for immunoprecipitation under denaturing conditions with an 
anti-HCF-1 C-terminal antibody. The immunocomplexes were used for western blotting 
with the indicated antibodies. 
 
  
 
92
 
Figure S8. 
HCF-1 N-terminal subunit interaction with OGT or its O-GlcNAcylation are not 
required for HCF-1 proteolytic cleavage. 
(A) Identification of OGT-binding domain in HCF-1 N. GST-tagged OGT bound to GSH 
beads was incubated with various fragments of in vitro translated 35S labeled-HCF-1. The 
bead-associated complexes were analyzed by coomassie blue staining for GST-OGT and 
HCF-1 was analyzed by autoradiography. (B) Schematic representation of the S/T O-
GlcNAcylation residues mutated in HCF-1 (HA-HCF-1 ΔO-Glc) and the deleted OGT-
binding motif OBM in HCF-1 (HA-HCF-1 ΔOBM). (C) O-GlcNAcylation status, 
proteolytic processing and interaction of HCF-1 mutants with OGT. 293T cells were 
transfected with HA-HCF-1 WT, HA-HCF-1 ΔOBM or HA-HCF-1 ΔO-Glc. Two days 
post-transfection, cells were harvested for immunoprecipitation using an anti-HA. We note 
that O-glycosylation of HCF-1 N subunit does not appear to play a role in HCF-1 cleavage 
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since (i) mutation of multiple glycosylation sites in the N-terminal subunit or (ii) deletion 
of the OGT-interacting motif in this subunit does not affect HCF-1 maturation. Thus the N-
terminal subunit, although it provides a distinct domain of interaction with OGT, is 
dispensable for HCF-1 cleavage. It remains possible that the interaction of the HCF-1 N-
terminal subunit with OGT is important for other HCF-1 functions that are distinct from the 
role of OGT in HCF-1 proteolytic processing. 
 
Figure S9. 
Expression of HCF-1 PPD with or without a nuclear localization signal.  
(A) Schematic representation of human HCF-1 showing the PPD with the designed 
constructs. 
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(B) 293T cells were transfected with either Myc-PPD or Myc-NLS-PPD expression 
plasmids. Two days post-transfection, total cell extracts were used for immunoblotting with 
anti-Myc antibody. NS, non specific band. 
 
 
Figure S10. 
HCF-1 PPD stabilizes OGT in the cytoplasm. 
 293T cells were transfected with Myc-PPD or Myc-NLS-PPD expression plasmids along 
with Myc-OGT expression plasmid. Forty-eight hours later, cells were homogenized using 
a dounce homogenizer to separate cytoplasm and nuclei. Homogenates was centrifuged at 
3500 g for 15 min, and the cytoplasmic fraction (supernatant) and nuclear fraction (pellet) 
were collected. Fractions were subjected to immunoblotting with the indicated antibodies. 
PARP1 and LDH, which are localized in the nucleus and cytoplasm, respectively, were 
used as controls for fractionation. 
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Figure S11. 
O-GlcNAcylation of HCF-1 PPD is dependent on OGT. 
293T cells were transfected with Myc-PPD or Myc-NLS-PPD expression plasmids along 
with OGT expression plasmid or pCDNA3. Forty-eight hours later, extracts of the cells 
were subjected to IP in denaturing conditions with anti-Myc antibody. Samples were 
analyzed by immunoblotting with the indicated antibodies. 
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Figure S12. 
RNAi of OGT inhibits cleavage of HCF-1 PPD. 
HeLa cells were transfected with the indicated shRNA constructs along with Myc-PPD 
plasmid and pBABE-puro. The next day, the cells were selected with 2 µg/ml of puromycin 
for 48 hours. Following selection, the cells were harvested and subjected to 
immunoblotting with the indicated antibodies. 
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Figure S13. 
Depletion of OGT does not affect Sp1 target gene expression. 
HFF cells were transfected with control or OGT siRNAs. Three days post transfection, cells 
were infected with 0.1 PFU HSV-1 and harvested for mRNA analysis. Levels of Sp1 target 
gene mRNAs in OGT-depleted cells are shown relative to levels in control siRNA 
transfected cells. All experiments were repeated at least 3 times and data are presented as 
mean ± SD. 
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MATERIALS AND METHODS  
 
Plasmids and Antibodies  
shRNA constructs for human OGT or HCF-1 were generated as described previously (Sui 
et al. 2002). The cDNAs of human OGT and OGA were cloned from HeLa cell RNA by 
RT-PCR. GST-OGT was generated by subcloning the OGT cDNA into pGEX-4T1 vector. 
Mammalian constructs to express N-terminal Myc-tagged OGT or OGA were generated by 
subcloning into the pDEST-N-Myc Gateway® plasmid (Invitrogen). The Myc-OGT 
D925A catalytic inactive mutant (Clarke et al. 2008) was generated by site-directed 
mutagenesis. The HCF-1 N (1-1010 aa) containing mutations in the O-glycosylation sites 
(S/T to A) was generated by direct gene synthesis (Biobasic Inc), and introduced into 
pCDNA3 (HA-HCF-1 FL ΔO-Glc). The HCF-1 lacking the OGT-binding motif (HA-HCF-
1 ΔOBM) was generated by PCR-based subcloning into pCDNA3. The plasmids pCGN-
HCF-1 FL and pCGN-HCF-1 N1011 were generously provided by Dr. Herr (Wilson et al. 
1993; Wilson et al. 2000). The Myc-PPD and Myc-NLS-PPD expression constructs were 
generated by PCR-based subcloning of HCF-1 sequence (3028-4305 bp) into pDEST-N-
Myc. The expression vectors V5-tagged wildype HCF-1 and the uncleavable HCF-1 have 
been described (Vogel and Kristie 2006). The HCF-1 D PPD V5 containing a deletion of 
the PPD (998-1456 aa) was derived from the WT HCF-1 (23). A plasmid containing the 
full length MLL1 was kindly provided by Dr. Hsieh (Hsieh et al. 2003). The anti-HCF-1 
PPD antibody has been described (Kristie et al. 1995; Kristie 1997). Additional antibodies 
were as follows: anti-HCF-1 (A301-400A) and anti-MLL1-N300 (A300-086A), Bethyl 
Laboratories; anti-βactin (MAB1501) and GAPDH (MAB374), Millipore; anti-OGT 
(H300, sc-32921), anti-OGT (A6, sc-74547), anti-ubiquitin (P4D1, sc-8017), anti-PARP-1 
(F2, sc-8007), anti-YY1 (H10, sc-7341) and rabbit IgG (sc-2027), Santa Cruz 
Biotechnology; anti-O-Linked N-Acetylglucosamine (RL2, GTX22739), GeneTex; anti-
HA (16B12, MMS-101P), anti-c-Myc (MMS-150P), Covance; anti-V5 (SV5, ab27671), 
Abcam. 
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Cell culture, RNAi and immunoblotting 
HeLa, U2OS and HEK293T (293T) cells were maintained according to standard culture 
protocols. Cells were transfected with either 5 µg of non-targeting control or RNA 
interference plasmids (shRNA) along with 0.2 µg pBABE puromycin resistance-encoding 
vector using Lipofectamine 2000 (Invitrogen). The transfected cells were selected after 1 
day by adding 2 µg/ml of puromycin for HeLa and 3 µg/ml for U2OS and 293T, for 2 
additional days as described (Affar et al. 2006). For siRNA, cells were transfected with 
either 200 pmol of non-targeting control, hOGT (L-019111-00) or hHCF-1 (L-019953-00) 
siRNAs ON-TARGETplus SMARTpool (Dharmacon). Three days post-transfection, cells 
were harvested for western blotting. HFF cells were transfected with control or OGT 
siRNAs. Three days post-transfection, cells were infected with 0.1 PFU HSV-1 and 
harvested for mRNA analysis and western blotting. Total cell extracts were prepared in 
lysis buffer (50 mM Tris-HCl, pH 7.3; 5 mM EDTA; 50 mM KCl; 0.1% NP-40; 1 mM 
phenylmethylsulfonyl fluoride (PMSF); 1 mM dithiothreitol and protease inhibitors cocktail 
(Sigma), and protein concentration was determined by Bradford assay. SDS-PAGE and 
Western blotting were done according to standard procedures. The band signals were 
acquired with a LAS-3000 LCD camera coupled to MultiGauge software (Fuji, Stamford, 
CT, USA). Densitometric analysis of protein bands and radioautographs were done using 
Gel-Pro Analyzer 3.1 (Media Cybernetics Inc). 
 
Immunodepletion and Immunoprecipitation  
Immunodepletion of nuclear extracts was conducted using HeLa nuclear extracts (~100 µg 
of proteins) incubated overnight at 4 ºC with 2 µg of anti-HCF-1 (A301-400A) or control 
IgG in IP buffer (50 mM Tris, pH 7.3; 150 mM NaCl; 5 mM EDTA; 10 mM NaF; 1% 
Triton X-100; 1 mM PMSF and protease inhibitors cocktail (Sigma)). The immuno-
complexes were collected on protein A agarose beads which were saturated with 1% BSA 
in IP buffer. Immuno-complexes were washed twice with the IP buffer supplemented with 
1% BSA. Bound proteins were eluted and subjected, along with the flow through fractions, 
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to western blotting. Co-immunoprecipitations to determine proteins interactions and O-
GlcNAc protein modification levels were conducted essentially as described above using 2 
mg of total cell lysates prepared in lysis buffer (50 mM Tris, pH 7.3; 150 mM NaCl; 5 mM 
EDTA; 10 mM NaF; 1% Triton X-100; 1 mM PMSF, protease inhibitors cocktail (Sigma) 
and 10 µM PUGNAc (Toronto Research Chemicals). Denaturing immunoprecipitations 
were done using the same lysis buffer containing 300 mM NaCl and 1% SDS. After boiling 
for 3 mins, the samples were diluted 10 fold with the same buffer used above without SDS 
prior to immunoprecipitation. 
 
In vitro interaction assays 
Recombinant GST-OGT fusion protein was purified using glutathione agarose beads 
(Sigma) and 2 to 3 µg of beads containing bound proteins were incubated with 10 µl of in 
vitro translated methionine-35S labelled HCF-1 (TNT® T7 Quick Coupled 
Transcription/Translation System, Promega) for 6 to 8 hours at 4 ºC in 50 mM Tris, pH 7.5; 
50 mM NaCl; 0.02% Tween 20; 1 mM PMSF and 500 µM dithiothreitol). The beads were 
extensively washed with the same buffer, and bound proteins eluted in Laemmli buffer and 
subjected to autoradiography or western blotting. The primers used for the amplification of 
HCF-1 fragments used IVT assays are provided below. 
 
Immunofluorescence 
Cells were fixed for 20 min using 3 % paraformaldehyde in phosphate-buffered saline 
(PBS), permeabilized in PBS containing 0.5 % NP-40 for 20 min. Following incubation in 
blocking solution (PBS containing 0.1% NP-40 and 10% FBS), cells were stained with the 
polyclonal anti-HCF-1 (A301-400A), the monoclonal anti-OGT (A6) or the monoclonal 
anti-c-Myc (MMS-150P). Anti-mouse Alexa Fluor® 594 or Alexa Fluor® 488, and Anti-
rabbit Alexa Fluor® 488 or Alexa Fluor® 594  (Invitrogen) were used as secondary 
antibodies. Nuclei were stained with 4', 6-diamidino-2-phenylindole (DAPI). Images were 
acquired using Leica DMRE microscope, HCX PL APO 63X/ 1.32-0.6 OIL CS objective 
and Retiga Ex (Qimaging) camera. 
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mRNA expression analysis 
RNA was prepared using Trizol reagent (Invitrogen) and the RNeasy kit (QIAGEN). Total 
mRNA was used for reverse transcription using the Superscript III reverse transcriptase and 
oligo(dT)12-18 primers (Invitrogen). The obtained cDNAs were subjected to Real time PCR 
using SYBR Green detection kit (Invitrogen) to determine levels of individual mRNAs. 
PCR was conducted on an iCycler iQ apparatus (Bio-Rad). The primers used are listed 
below. 
 
Chromatin immunoprecipitation analysis 
Chromatin immunoprecipitation (ChIP) experiments were done essentially as previously 
described (Bottardi et al. 2009) with the following modifications. U2OS cells (5 X 106) 
were incubated with EGS (ethylene glycolbis [succnimidyl succinate], Sigma-Aldrich) as 
described (Nowak et al. 2005; Zeng et al. 2006) and were cross-linked with 1% 
formaldehyde in PBS for 10 min. Following quenching with glycine, cells were scraped in 
cold PBS, washed with buffer A (50 mM Tris-HCl, pH 8.0; 0.1% NP40; 2 mM EDTA; 
10% glycerol; 1 mM PMSF and protease inhibitors cocktail, Sigma) and then sonicated in 
Buffer B (50 mM Tris-HCl, pH 8.0; 1% SDS; 10 mM EDTA; 1 mM PMSF and protease 
inhibitors cocktail). After centrifugation and pre-clearing, the suspension was incubated 
with anti-HCF-1 (A301-400A) or an IgG control. DNA was purified from 
immunocomplexes and quantitated by qPCR using the 2– CT method, where CT is 
calculated as follows: (ChIP CT– input CT of the control antibody) – (ChIP CT – input CT 
of the target antibody). The results are shown as a ratio of target gene promoter to a 
reference gene promoter. The primers are listed below. 
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SUMMARY  
The tumor suppressor BAP1 interacts with chromatin-associated proteins and 
regulates cell proliferation, but its mechanism of action and regulation remain poorly 
defined. We show that the ubiquitin conjugating enzyme UBE2O multi-mono-ubiquitinates 
the nuclear localization signal of BAP1, thereby inducing its cytoplasmic sequestration. 
This activity is counteracted by BAP1 auto-deubiquitination through intramolecular 
interactions. Significantly, we identified cancer-derived BAP1 mutations that abrogate 
auto-deubiquitination and promote its cytoplasmic retention, indicating that BAP1 auto-
deubiquitination ensures tumor suppression. The antagonistic relationship between UBE2O 
and BAP1 is also observed during adipogenesis, whereby UBE2O promotes differentiation 
and cytoplasmic localization of BAP1. Finally, we established a putative targeting 
consensus sequence of UBE2O and identified numerous chromatin remodeling factors as 
potential targets, several of which tested positive for UBE2O-mediated ubiquitination. 
Thus, UBE2O defines an atypical ubiquitin-signaling pathway that coordinates the function 
of BAP1 and establishes a paradigm for regulation of nuclear trafficking of chromatin-
associated proteins.  
 
 
 
HIGHLIGHTS 
• UBE2O ubiquitinates BAP1 on its NLS, and regulates its subcellular localization 
• The mechanism of BAP1 auto-deubiquitination is disrupted in cancer 
• UBE2O and BAP1 have antagonistic roles in cell cycle regulation and 
differentiation 
• UBE2O targets itself and a subset of chromatin regulators 
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INTRODUCTION 
 
The covalent attachment of ubiquitin to target proteins, i.e., ubiquitination, regulates 
both protein stability and function, and is fundamental to diverse biological processes 
(Hammond-Martel et al., 2012; Jackson and Durocher, 2013). The deubiquitinase (DUB) 
BAP1 is a transcriptional regulator required for mammalian development (Dey et al., 2012; 
Yu et al., 2010). BAP1 is also a tumor suppressor inactivated in various cancers, and 
reconstitution studies in cancer cells harboring BAP1 mutations indicated that both BAP1 
catalytic activity and nuclear localization are required for its growth suppressive properties 
(Carbone et al., 2013; Ventii et al., 2008). Moreover, RNAi-mediated depletion of BAP1 
also induces defects in cell cycle progression indicating that this protein is a key regulator of 
cell proliferation (Machida et al., 2009). At the molecular level, BAP1 assembles a large 
multi-protein complex consisting of numerous transcription factors and chromatin-
associated proteins including the Host Cell Factor-1 (HCF-1), the Polycomb Group (PcG) 
proteins Additional Sex Combs Like 1 and 2 (ASXL1/2), the histone demethylase KDM1B, 
the O-linked N-acetylglucosamine transferase (OGT), the forkhead transcription factors 
FOXK1/FOXK2, and the zinc finger transcription factor Yin Yang1 (YY1) (Machida et al., 
2009; Misaghi et al., 2009; Sowa et al., 2009; Yu et al., 2010). 
The Drosophila BAP1, Calypso, is a PcG protein that interacts with Additional Sex 
Combs (ASX), localizes at PcG-target gene regulatory regions, and represses HOX gene 
expression. Calypso/ASX heterodimer, termed PR-DUB (Polycomb repressive DUB), 
deubiquitinates histone H2A (Scheuermann et al., 2010), a chromatin modification 
involved in chromatin remodeling and gene silencing (Lanzuolo and Orlando, 2012). 
We and others previously identified the ubiquitin conjugating enzyme UBE2O as a 
substoichiometric factor that co-purifies with the human BAP1 (Machida et al., 2009; Sowa 
et al., 2009; Yu et al., 2010), suggesting that it might be involved in the coordination of 
BAP1 function. UBE2O belongs to the E2 family of ubiquitin-conjugating enzymes, 
although, unlike most members of this family, it is unusually large (140 kDa) (van Wijk 
and Timmers, 2010). Pioneering studies from Pickart’s group suggested that UBE2O might 
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function as an E2/E3 hybrid (Berleth and Pickart, 1996; Klemperer et al., 1989). This was 
essentially based on the observation that UBE2O can ubiquitinate free histones in vitro, in 
the presence of E1 enzyme only. It has been proposed that ubiquitination by UBE2O 
involves an intramolecular thioester relay mechanism since this enzyme is inhibited by 
phenylarsine oxide (PAO) which can crosslink adjacent cysteines (Klemperer et al., 1989). 
Otherwise, the physiological substrates of UBE2O are largely unknown.  Nonetheless, it 
was recently shown that UBE2O regulates TRAF6-dependent NF-κB in a catalytic activity-
independent manner (Zhang et al., 2013b), monoubiquitinates SMAD6 during bone 
morphogenetic protein signaling (Zhang et al., 2013a), and coordinates endosomal protein 
trafficking (Hao et al., 2013) thus implicating UBE2O in numerous cellular processes. In 
this study, we uncover a novel ubiquitin-signaling pathway, mediated by UBE2O, that has 
important implications for chromatin-associated processes. 
 
 
RESULTS 
 
The ubiquitin conjugating enzyme UBE2O interacts with and ubiquitinates BAP1  
We previously described the purification of complexes formed by wild type and 
catalytic dead BAP1 (C91S)  (Yu et al., 2010). The complexes were essentially identical, 
although when probed with an anti-ubiquitin antibody, the C91S complex exhibited a 
dramatic increase in signal (Figure 1A). We also routinely observed mono-ubiquitination of 
BAP1 in transfected cells, independently of its DUB activity (Figure 1A and Figure S1A-
E). This suggests that BAP1 might be functionally regulated by distinct ubiquitination 
events in DUB activity-dependent and -independent manner. To identify E3 ligases 
responsible for the ubiquitination of BAP1, we initially considered UBE2O which was 
more abundant in the C91S versus the wild type BAP1 complex (Figure 1A). The UBE2O 
association with BAP1 was not affected by mutation of the HCF-1 Binding Motif (HBM) 
which eliminates HCF-1, a major component of the complex (Figure 1A). Glycerol density 
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gradient fractionation of nuclear extracts indicated that UBE2O co-sediments with the 
BAP1 complex (Figure 1B). Next, we co-transfected BAP1 or C91S with UBE2O or its 
catalytic dead mutant C1040S (hereafter UBE2O CD) and ubiquitin into 293T cells. 
Strikingly, UBE2O ubiquitinates BAP1, and modified forms were more abundant in the 
C91S mutant (Figure 1C). Incubation of UBE2O-modified BAP1 C91S with an excess of 
USP2 DUB catalytic domain resulted in its complete deubiquitination further 
demonstrating ubiquitin conjugation (Figure S1F). Of note, deletion of the UCH catalytic 
domain results in the abolishment of the constitutive mono-ubiquitination (Figure S1G). On 
the other hand, a similar UBE2O-dependent ubiquitination pattern could be observed for 
BAP1 C91S or BAP1 ∆UCH indicating that UBE2O-mediated ubiquitination is distinct 
from its constitutive mono-ubiquitination.  
To control for the specificity of UBE2O-mediated BAP1 ubiquitination, we 
evaluated other E2s and none was able to ubiquitinate BAP1 (Figure S1H,I). We also tested 
two known H2A DUBs, i.e., USP16 and MYSM1, as well as the SUMO protease SENP2, 
and no UBE2O-mediated ubiquitination could be observed (Figure S1J). Using multiple 
sequence alignment, we identified three main conserved regions in UBE2O namely CR1 
(conserved region 1), CR2 (conserved region 2) and UBC (Ubiquitin conjugating) (Figure 
1D, Figure S1K). Secondary structure prediction analysis revealed all-β domains within 
CR1 and CR2 and the typical α/β UBC fold. Deletion of either N- (ΔCR1-CR2) or C-
terminal (ΔC) regions of UBE2O completely disrupted BAP1 ubiquitination (Figure 1D, 
E). Moreover, deletion of only the N-terminal CR1 region (ΔCR1-A) was sufficient to 
abolish UBE2O catalytic activity. Hence, the integrity of multiple domains of UBE2O is 
required for ubiquitination of BAP1.  
 
UBE2O catalyzes the multi-mono-ubiquitination of BAP1  
To determine the mechanism of UBE2O action on BAP1, we established an in vitro 
assay for BAP1 ubiquitination using wild type and C91S complexes immobilized on the 
beads (Figure S2A). UBE2O-mediated ubiquitination appears to be highly specific for the 
C91S mutant as no modified forms were observed for other BAP1 partners (Figure 2A). 
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Moreover, ubiquitination of the C91S mutant did not disrupt complex integrity, since none 
of the complex components was released into the soluble fraction in a UBE2O-dependent 
manner (Figure 2A). Notably, we did not detect ubiquitination of wild type BAP1 as 
opposed to C91S, and this ubiquitination was completely abolished by the UBE2O inhibitor 
PAO (Figure 2A, Figure S2B). We note that UBE2O, purified from HeLa cells under high 
or low salt conditions or from bacteria, ubiquitinates C91S to similar extents (Figure 
S2C,D). Importantly, although less efficient, ubiquitination was also observed using 
bacteria-purified BAP1 and UBE2O (Figure S2E). Therefore UBE2O is an atypical E2/E3 
enzyme with substrate binding and ubiquitin conjugating functions. 
To further confirm that auto-deubiquitination prevents accumulation of ubiquitin on 
BAP1, the beads-bound wild type complex was pretreated with N-ethylmaleimide (NEM), 
which resulted in a significant ubiquitination of BAP1 by UBE2O (Figure S2A, Figure 2B). 
Next, we used methylated ubiquitin, which is unable to form poly-ubiquitin or linear chains 
in the in vitro reaction (Figure 2C). The reaction with methylated ubiquitin was as efficient 
as with the unmodified ubiquitin and resulted in a similar ubiquitination pattern, indicating 
that UBE2O multi-mono-ubiquitinates BAP1. The same observation was made in vivo 
when a K0 ubiquitin mutant, incapable of chain formation, was used for co-transfection of 
293T cells with the C91S mutant and UBE2O (Figure 2D). Next, 293T cells were co-
transfected with wild type BAP1 or C91S mutant and UBE2O, and then treated with the 
proteasome inhibitor MG132 (Figure 2E). The typical multi-mono-ubiquitination pattern of 
BAP1 was unchanged after proteasome inhibition, indicating that UBE2O is unable to 
directly catalyze poly-ubiquitin chain elongation with subsequent degradation of BAP1. 
Immunodetection of endogenous CDC25A was conducted as a control for proteasome 
inhibition. Next, we tested several E3s that interact with either UBE2O or BAP1 and no 
further chain elongation was observed (Figure S2F-I). To further confirm that the stability 
of BAP1 is not directly regulated by UBE2O, we performed siRNA knockdown of UBE2O 
in MCF7 cells, which express high protein levels of this enzyme, followed by treatment 
with cycloheximide (CHX) (Figure 2F). Endogenous BAP1 appears to be highly stable and 
UBE2O knockdown did not significantly change BAP1 protein levels. We concluded that 
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UBE2O catalyzes BAP1 multi-mono-ubiquitination without directly promoting its 
proteasomal degradation under normal growth conditions. Of note, UBE2O depletion also 
did not affect the constitutive mono-ubiquitination of BAP1 observed in cells transfected 
with this DUB (Figure S2J).  
 
The NLS of BAP1 is required for UBE2O-mediated ubiquitination 
Using a GST pull down assay, we found that the BAP1 C-terminal region (598-729 
aa), which includes the C-terminal domain (CTD) and NLS, is necessary and sufficient for 
UBE2O binding (Figure 3A). Surprisingly, co-expression of UBE2O with CTD-NLS 
promoted the latter’s degradation by the proteasome, since it could be reversed by MG132 
(Figure 3B, left panel and Figure S3A, B). Immunoprecipitation of the CTD-NLS revealed 
an ubiquitination pattern similar to that of the full length BAP1 (4-5 sites of multi-mono-
ubiquitination), although some high molecular weight smears were also detected (Figure 
3B, right panel). Next, we found that both wild type and K0 ubiquitin mutants promoted 
UBE2O-mediated multi-mono-ubiquitination and degradation of the CTD-NLS (Figure 
S3C). Moreover, knockdown of endogenous UBE2O rescued the degradation of CTD-NLS 
(Figure 3C). These results confirm that the CTD-NLS represents both the interaction and 
ubiquitination region for UBE2O. The degradation of CTD-NLS can be explained by the 
small size of this region (only 101aa), in line with a recent discovery by Ciechanover’s 
group indicating that monoubiquitinated substrates of less than 150 aa can be degraded 
without further ubiquitin chain formation (Shabek et al., 2012). Next, we purified the 
complex of the BAP1∆CTD mutant that possesses a large deletion of aa 631-693 leaving 
only the NLS region intact (aa 699-729) (Figure 3D). The abundance of UBE2O was nearly 
unchanged between the wild type and the mutant indicating that UBE2O binds the NLS 
region. BAP1 possesses a complex NLS region (Figure S3D,E). We designed a set of 
BAP1 NLS mutants in the C91S background to render the ubiquitination analysis more 
sensitive. We found that both C91S∆688-716 and C91S∆711-729 mutants were unable to 
bind and to be ubiquitinated by UBE2O (Figure 3E). Therefore, the NLS region that 
includes the RRR (aa 699-701) site, the hydrophobic GVSIGRL patch (aa 703-709) as well 
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as the basic amino acid stretch RRKRSRPYKAKRQ (aa 717-729) is required for binding 
and ubiquitination by UBE2O. The region of basic amino acids RRKRSR (aa 717-722) is 
strictly required for binding and ubiquitination by UBE2O (Figures 3E, Figure S3F-G). 
Thus, multiple determinants of this composite and highly conserved NLS are required for 
UBE2O-mediated ubiquitination of BAP1 (Figure S3H). 
 
UBE2O ubiquitinates the NLS of BAP1 and regulates its subcellular localization 
To identify the UBE2O ubiquitination sites on BAP1, we performed an anti-Flag 
affinity purification of C91S co-transfected with ubiquitin and UBE2O (Figure 4A). MS 
peptide analysis revealed 14 unique ubiquitination sites in BAP1, 9 of which were detected 
more than once (Figure 4B). Analysis of all ubiquitination events revealed that 50 % are 
located in the area of NLS, which represents only 4 % of the protein. Next, we introduced a 
series of lysine to arginine mutations in the CTD-NLS region (12 K/R) or in the NLS alone 
(5 K/R) of C91S (Figure 4C). Mutation of all lysine sites in the CTD-NLS (12 K/R) 
strongly reduced C91S ubiquitination; moreover, mutation of lysines in the NLS (5 K/R) 
region had an identical effect on C91S ubiquitination compared with the 12 K/R mutant. 
Interestingly, the binding of UBE2O to either mutants of C91S was unchanged indicating 
that K/R mutations do not significantly affect UBE2O binding affinity. Taken together, 
these results indicate that UBE2O ubiquitinates primarily the NLS of BAP1.  
Ubiquitination was reported to promote nuclear export of proteins (Groulx and Lee, 
2002; Li et al., 2003). Therefore, we evaluated whether the ubiquitination of BAP1 affects 
its subcellular localization. BAP1 is prominently nuclear, but displayed strong cytoplasmic 
staining when co-expressed with UBE2O. This effect depends on the catalytic activity of 
UBE2O. Notably, the effect of UBE2O on the C91S mutant was more pronounced with 
almost all cells showing cytoplasmic or nucleo-cytoplasmic localization (Figure 4D). In 
addition, the C91S mutant usually displayed a more pronounced cytoplasmic localization 
compared to the wild type BAP1. Of note, overexpression of UBE2O, but not its catalytic 
dead form, also promoted cytoplasmic localization of endogenous BAP1 (Figure S4). To 
probe whether this effect is due to its inability to deubiquitinate its NLS, we compared the 
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nuclear localization of BAP1 and C91S (5 K/R) mutants (Figure 4E). Remarkably, the K/R 
mutation rescued the C91S mutant from the cytoplasmic sequestration, thus supporting the 
notion that NLS auto-deubiquitination is involved in the regulation of BAP1 nuclear 
import/export.  
  
Intramolecular interaction in BAP1 is required for efficient NLS auto-
deubiquitination 
UCH37 is highly similar to BAP1 and its crystal structure suggests that an 
intramolecular interaction occurs between the UCH and the CTD (Figure S5A) (Burgie et 
al., 2011). Since catalytically dead UCH37 C88A is also strongly ubiquitinated by an 
unknown E3 ligase (Figure S5B), we reasoned that both BAP1 and UCH37 might use their 
respective CTD regions for interaction with the UCH domain (Figure S5C). Examination of 
CTD and UCH flanking sequences of BAP1 revealed putative coiled coil motifs that can 
engage in intramolecular interactions (Figure S4D). Next, we used the crystal structure of 
UCH37 to generate a superimposed model of BAP1 (Figure 5A). This model suggests that 
the CTD region (containing the CC2) forms an interaction interface with the CC1 and the 
UCH domain. We note that this model cannot predict the structure of the NLS and NORS 
regions, which are not present in UCH37. To validate our computational prediction, we 
designed a series of deletion mutants in the N- terminus of BAP1 including the UCH 
domain alone and a larger fragment that includes CC1 (UCH-CC1) (Figure 5B). Co-IP 
between the fragments revealed that both UCH and UCH-CC1 interact with CTD-NLS 
(Figure 5C). To test whether this interaction can promote deubiquitination of CTD-NLS, 
we took advantage of the earlier observation that CTD-NLS can be degraded as a result of 
ubiquitination by UBE2O. We designed a complementation/rescue system in which the 
degradation of CTD-NLS would be counteracted by the N-terminus of BAP1. Indeed, the 
degradation of CTD-NLS was efficiently rescued only by UCH-CC1 but not by UCH 
alone, and this was dependent on the catalytic activity of BAP1 (Figure 5D). This suggests 
that despite direct CC2/UCH interaction, the CC1/CC2 interface plays an important role in 
NLS deubiquitination. To further test the requirement of the CC1/CC2 in the context of the 
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full-length protein, CC1 and CTD deletion mutants were used (Figure 5B). Deletion of the 
CTD (∆CTD) or CC2 (∆CC2) almost completely blocked the auto-deubiquitination activity 
of BAP1 despite the presence of a catalytically proficient UCH domain (Figure 5E). The 
CC1 deletion mutant had a less pronounced auto-deubiquitination defect consistent with the 
fact that CC2 interacts with both CC1 and UCH. To test whether the deficiency in the 
ability of BAP1 to auto-deubiquitinate the NLS affects its localization, cell lines stably 
expressing the wild type or mutants BAP1 were generated. IF analysis revealed that the 
wild type BAP1 displayed a typical nuclear localization, whereas the ∆CTD and ∆CC2 
mutants had a stronger cytoplasmic localization similar to the C91S mutant (Figure 5J). 
Notably the ∆HBM mutant displayed normal localization similar to wild type BAP1. Thus 
BAP1 auto-deubiquitination depends on an intramolecular binding between CC2 and UCH-
CC1 and is important to counteract the E3 ligase activity of UBE2O towards the NLS. 
 
BAP1 NLS auto-deubiquitination is disrupted by cancer-associated mutations of CTD 
Our results suggest that disruption of auto-deubiquitination leads to improper BAP1 
localization. We thus searched for cancer mutations in BAP1 that may target the UCH-CC1 
interaction interface with CC2. We first tested G13V and F660A mutations and none had a 
noticeable effect on BAP1 auto-deubiquitination (Figure S5E,F). Next, we considered two 
small in frame deletions of CC2 (∆E631-A634 and ΔK637-C638InsN) (Harbour et al., 
2010) (Figure 5B). We conducted complex purification of BAP1, ∆E631-A634 and 
ΔK637-C638InsN, and strikingly observed in both mutants an intense band around 230 
kDa that corresponds to UBE2O (Figure 5F). Other major components of the complex such 
as OGT and HCF-1 showed no apparent differences (Figure 5F). The CC2 directly interacts 
with UCH, so mutations in this region may interfere with the catalytic activity of BAP1. To 
test this, we used an in vitro deubiquitination assay using a BAP1 natural substrate, i.e., the 
nucleosomal histone H2A ubiquitinated at position K119 (Figure S5G, H, I). The activities 
of both cancer mutants were very similar to BAP1, whereas the control C91S failed to 
deubiquitinate H2A (Figure 5G). Next, to evaluate whether these cancer mutations affect 
the auto-deubiquitination activity of BAP1, we exploited the UCH/CTD rescue system and 
  
 
114
the ability of UBE2O to promote degradation of the BAP1 CTD-NLS. We cloned the CTD-
NLS region of ΔK637-C638InsN mutant, and a mutant with a large internal deletion in 
CC2 (Δ636-655) as a control (Figure 5B). Remarkably, complementation with UCH-CC1 
rescued the wild type CTD-NLS, but not the ΔK637-C638InsN and Δ635-655 (Figure 5H). 
Next, we sought to investigate these mutations in the context of the full-length protein. The 
effect of UBE2O on the cancer mutants was almost as dramatic as on the C91S despite their 
catalytic proficiency (Figure 5I). Finally, ∆E631-A634 and ΔK637-C638InsN mutants 
displayed increased cytoplasmic localization similar to the C91S mutant (Figure 5J).  
 
UBE2O is regulated by active nucleo-cytoplasmic transport mechanisms and 
promotes BAP1 cytoplasmic localization during adipocyte differentiation 
UBE2O possesses two functional NLS motifs, but the full-length enzyme displayed 
predominant cytoplasmic localization (Figure S6A-E). Next, purification of UBE2O-
associated proteins followed by MS analysis revealed numerous components of the nuclear 
import/export machinery as well as several kinases that might coordinate its nuclear 
trafficking (Figure S6F). Taking into account that UBE2O is a heavily phosphorylated 
enzyme (Figure S6G), we sought to determine the impact of kinase inhibition on UBE2O 
localization. We treated cells with a panel of kinase inhibitors of various specificities and 
observed a nuclear translocation of UBE2O with the CDK-inhibitors Purvalanol A and RO-
3306 (Figure 6A,B). Interestingly, UBE2O catalytic dead form was strongly retained in the 
nucleus indicating the importance of catalytic activity in coordinating its nucleo-
cytoplasmic transport. Consistent with its potential role in negatively regulating BAP1 
function, siRNA-depletion of UBE2O increased cell proliferation whereas siRNA-depletion 
of BAP1 resulted in decreased cell proliferation (Figure 6C). Of note, no noticeable 
changes in UBE2O or BAP1 localization were observed in unperturbed cycling cells (Data 
not shown), suggesting that only very limited pools of UBE2O or BAP1 might be imported 
or exported respectively. Taking into account that BAP1 tightly coordinate cell 
proliferation, we reasoned that a substantial change in BAP1 localization might be observed 
during permanent cell cycle exit. Since UBE2O was implicated in promoting adipocyte 
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differentiation in the mouse embryo cell line C3H10T1/2, we recapitulated this effect using 
the 3T3-L1 cellular model of adipocyte differentiation as determined by immunoblotting 
for aP2 and Perilipin (PLIN) adipogenic markers and Oil Red O staining (Figure 6D,E). 
Significantly, a fraction of BAP1 become excluded from the nucleus as 3T3-L1 cells 
differentiate into adipocytes (Figure 6F). In addition, mutation of the UBE2O-
ubiquitination sites in BAP1 resulted in a substantial retention of this DUB in the nucleus. 
Since BAP1 5K/R mutant still interact with UBE2O and is ubiquitinated on other sites, we 
also replaced the NLS region of BAP1, containing the UBE2O-interacting motif, with T-
large antigen NLS which prominently prevented the cytoplasmic localization of this DUB 
during differentiation.    
 
UBE2O targets a subset of bipartite NLS-containing transcription regulators 
UBE2O displays prominent UBC-dependent auto-catalytic activity in vitro and in 
vivo (Figure 7A and Figure 1C), which is inhibited by PAO (Figure S2B, Figure 7A).  In 
addition, a nuclear retention of UBE2O, more pronounced for the catalytic dead form was 
observed following treatment with CDK inhibitors (Figure 6A,B). Thus, we sought to 
determine if NLS sequences within UBE2O may constitute auto-ubiquitination sites. 
Strikingly the NLS1/A mutant was completely auto-ubiquitination-deficient similar to 
UBE2O CD, whereas mutation of NLS2 had no significant effect on UBE2O auto-
ubiquitination (Figure S6A, Figure 7B). In addition, the bipartite NLS regions of UBE2O 
and BAP1 contain a highly conserved patch of aliphatic hydrophobic amino acids (VLI 
patch) between the minor and major NLS sites (linker region) (Figure 7C). Mutation of the 
VLI patch disrupted auto-ubiquitination (Figure S7A).  Of note, the NLS1 architecture is 
highly conserved between most UBE2O orthologs (Figure S6E). These results prompted us 
to search whether this subtype of bipartite NLS may serve as a specific signal for UBE2O 
recognition and ubiquitination in other proteins. Several candidates were identified, notably 
chromatin-associated proteins, suggesting that UBE2O might exert extensive control over 
nuclear signaling pathways (Figure S7F). We selected four proteins, i.e., p400, CDT1, 
INO80 and CXXC1, predicted as potential UBE2O substrates. INO80 and p400 are 
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members of SWI/SNF family of chromatin-remodeling ATPases (Jin et al., 2005; Vassilev 
et al., 1998) containing the predicted NLS sequences (Figure 7C). CXXC1 is the CpG 
island binding protein and component of the SET1 complex (Lee and Skalnik, 2005) that 
contains two predicted NLS sequences with NLS2 containing the putative UBE2O binding 
motif. The DNA replication factor CDT1 also harbors a potential binding and 
ubiquitination site for UBE2O (Nishitani et al., 2000). INO80, p400 and CDT1 were 
degraded following co-expression with UBE2O in a catalytic-activity dependent manner, 
ostensibly as a result of ubiquitin chain extension by unknown E3 ligases (Figure 7D, 
Figure S7B). CXXC1 showed several slow migrating bands suggesting its ubiquitination 
without degradation (Figure 7D, right panel). Next, we selected INO80 and CXXC1 as two 
contrasting examples of UBE2O action for further characterization of their ubiquitination 
by UBE2O (Figure 7D). When the immunoprecipitated INO80 was loaded in equal 
amounts, the ubiquitin blot showed a typical polyubiquitin smear in the stacking gel (Figure 
7D, left panel). The ubiquitination profile of CXXC1 was similar to that of BAP1 and 
UBE2O with several distinct multi-mono-ubiquitin bands (Figure 7D, right panel). 
Ubiquitination of INO80 and CXXC1 by UBE2O had a pronounced effect on their 
subcellular localization, as both proteins displayed stronger cytoplasmic localization 
following co-expression of wild type but not UBE2O CD mutant (Figure 7E). We also 
found a potential UBE2O binding consensus in ALC1, another nuclear SWI/SNF family 
chromatin-remodeling enzyme (Ahel et al., 2009), but UBE2O had no effect on ALC1 
ubiquitination and localization (Figure S7C,D,E). This can be explained by the absence of 
the major NLS stretch in the vicinity of the consensus and/or the location of the consensus 
in the masked fold of its Macro domain. Therefore, UBE2O targets a subset of chromatin 
remodeling and modifying factors containing a bipartite NLS with a specific VLI patch in 
the linker region with the exception of CDT1, which contains the major NLS stretch 
upstream of the UBE2O consensus. Thus, substrate ubiquitination by UBE2O can induce 
cytoplasmic localization, which might be accompanied by further proteasomal degradation 
as a consequence of ubiquitin chain extension by other E3 ligases. 
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DISCUSSION 
Regulation of BAP1 by UBE2O-mediated ubiquitination  
Here, we define a regulatory mechanism involving the E2/E3 hybrid UBE2O which 
multi-mono-ubiquitinates BAP1 in the NLS region. Under normal growth conditions, 
BAP1 is predominantly nuclear whereas UBE2O is mainly cytoplasmic suggesting that 
BAP1 ubiquitination is highly regulated. In particular, this compartmentalization raises the 
question regarding the cellular compartment where the ubiquitination actually occurs. 
UBE2O could be  imported into the nucleus to ubiquitinate BAP1 and promote its 
ubiquitin-mediated nuclear export as observed for other proteins (Groulx and Lee, 2002; Li 
et al., 2003). Since we did not observe a noticeable accumulation of endogenous UBE2O in 
the nucleus, it is possible that only a small fraction of UBE2O is imported into this 
compartiment at any given time. Controling UBE2O import itself would provide another 
level of regulation for the fine-tuning of BAP1 ubiquitination. Indeed, (i) BAP1 and 
UBE2O exert antagonistic functions during cell proliferation, (ii) CDK inhibitors promoted 
UBE2O nuclear localization with a stronger effect towards its catalytic dead form, (iii) 
UBE2O exhibits an auto-ubiquitination activity towards its own NLS, and (iv) two recent 
studies revealed that the K521 residue (K516 in mouse), part of UBE2O NLS1, is 
ubiquitinated in vivo (Figure S6G). Our data do not exclude the possibility that, under 
specific conditions, BAP1 might be exported to the cytoplasm prior to its ubiquitination, 
although we did not identify any export signal in BAP1. Further studies are needed to 
dissect the possible mechanisms of UBE2O nucleocytoplasmic transport including its 
regulation.  
On the other hand, since ubiquitination of BAP1 is counteracted by auto-
deubiquitination, one can predict that a yet to be identified signal is needed to inactivate 
BAP1 catalytic activity. This initiating event would render this DUB susceptible to 
ubiquitination by UBE2O. BAP1 could be modified by other post-translational 
modifications that inhibit its auto-deubiquitination. In fact, several phosphorylation and 
ubiquitination sites of BAP1 were identified in proteomics studies (Figure S6H), and in this 
study we identified several ubiquitination sites on UCH, some of which might result from 
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the action of other E3 ligases. Under normal cell growth conditions, UBE2O-mediated 
ubiquitination of BAP1 might not necessarily lead to a net accumulation of BAP1 in the 
cytoplasm, since this could be a protracted process that is concomitant with both de novo 
synthesis of BAP1 and further degradation or re-import of this DUB. We speculate that this 
could be an editing mechanism that might coordinate the transcriptional competency of 
BAP1. In contrast, during adipocyte differentiation, we observed a net cytoplasmic 
redistribution BAP1 that would drastically impact its transcriptional activity. It is also 
possible that BAP1 might exert cytoplasmic functions in terminally differentiated 
adipocytes. We note that, since our conclusion is based on ectopically expressed BAP1, 
further work is needed to establish this regulation for the endogenous enzyme and to 
provide insights into the possible concerted action of post-translational modifications in 
regulating the trafficking and function of this DUB. 
 
Auto-deubiquitination of BAP1 and its disruption in cancer 
 Auto-deubiquitination of DUBs was previously observed for UCH-L1, which was 
able to counteract its own ubiquitination by an unknown E3 ligase (Meray and Lansbury, 
2007). Interestingly, in our study, we noticed a similar mechanism regulating UCH37. We 
also note that UCH37 and BAP1 share a common ancestry. Although vertebrate BAP1 
acquired the long NORS region, which contains the HCF-1 interaction motif, the 
intramolecular interaction between the amino and carboxy termini seems to be evolutionary 
conserved. It is possible that DUB auto-deubiquitination might constitute a regulatory 
mechanism, which is more widely used than currently appreciated.  
 Cancer-associated mutations in BAP1 disrupt its function by multiple means. Large 
deletions in the BAP1 gene result in dysfunctional proteins. Point mutations in the UCH 
domain of BAP1 often target the catalytic site or its immediate environment resulting in 
disruption of catalytic activity. The cancer-derived mutations of BAP1 in the catalytic site 
are predicted to impact both auto-deubiquitination as well as DUB activity towards other 
substrates. Histone H2A is a substrate of BAP1 (Scheuermann et al., 2010; Yu et al., 2014), 
and other substrates such as HCF-1 and OGT were previously also described (Machida et 
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al., 2009; Misaghi et al., 2009; Ruan et al., 2012). In this study, we identified two cancer-
mutations in the coiled-coil motif of the C-terminal region that remarkably did not 
compromise BAP1 complex assembly, but instead promoted UBE2O association with this 
DUB. It would be interesting to further determine whether this is a result of structural 
changes in BAP1 that facilitate UBE2O binding, or rather is a consequence of increased 
cytoplasmic sequestration of BAP1. Importantly, the two cancer-derived mutations 
selectively compromised the auto-deubiquitination activity of BAP1 without affecting its 
H2A DUB activity. These cancer-derived mutations also revealed that auto-
deubiquitination function of the enzyme is important for its proper nuclear localization. 
Thus, by separating the two activities of BAP1, we provide a biochemical paradigm for 
testing the involvement of other ubiquitin signaling cascades in regulating BAP1 function.  
 
UBE2O acts as an atypical E2/E3 that ubiquitinates a subset of NLS-containing 
proteins 
The evolution of protein conjugation pathways can be traced back to prokaryotic 
and archea cells. In eukaryotes, this system diversified resulting in establishment of the 
classical E1/E2/E3/substrate ubiquitin transfer cascade (Burroughs et al., 2012; 
Hochstrasser, 2009). UBE2O is highly conserved in plants and animals suggesting that it 
evolved from a common ancestor at least 1.6 billion years ago, when the prototypic animal 
and plant cell types were evolving (Meyerowitz, 2002). UBE2O seems to employ the 
properties of both E2 and E3 enzymes suggesting that it might recognize a limited number 
of substrates. In our study, we discovered that UBE2O specifically binds and ubiquitinates 
a subset of bipartite NLS that contain a VLI patch in their linker. Based on the consensus 
between two identified UBE2O substrates, i.e. BAP1 and UBE2O itself, we were able to 
predict the substrate specificity of the enzyme in turn allowing us to identify more putative 
UBE2O substrates including proteins involved in RNA processing, transcription, DNA 
replication, and chromatin remodelling. Thus, UBE2O might be involved in coordinating 
major signaling pathways in the cytoplasm, organelles, and nucleus that orchestrate cell 
function during proliferation and differentiation or in response to extracellular stimuli. 
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Although we were able to detect UBE2O expression in multiple cultured cell lines, its 
expression seems to be highly regulated. UBE2O levels were previously reported to 
increase during erythroid differentiation (Wefes et al., 1995). Chromatin of differentiating 
cells is subjected to multiple epigenetic and structural changes, requiring specific ubiquitin 
signaling pathways to promote the displacement of chromatin-associated regulators to 
activate or repress gene expression (Geng et al., 2012). Indeed, UBE2O promotes adipocyte 
differentiation and is also highly expressed in brain, heart, and skeletal muscle (Nagase et 
al., 2000; Yokota et al., 2001; Zhang et al., 2013a), all of which comprise post-mitotic cells 
that must finely coordinate gene expression programs to fulfill metabolically demanding 
requirements.  
 
 
MATERIALS AND METHODS 
 
Cell culture, transfections and western blot 
 
 Cells were cultured according to standard protocols. siRNA and plasmids were 
transfected using Lipofectamine or PEI. Total cell lysates were used for western 
blotting. Differentiation of 3T3L1 and additional details are provided in the 
supplemental text. 
 
Imunoprecipitation of BAP1 and UBE2O 
Cell lines stably expressing BAP1, ∆E631-A634, ΔK637-C638InsN, ∆CTD, ∆CC1 
or UBE2O were generated following retroviral transduction and used for 
immunoprecipitation under native or denaturing conditions as indicated in the supplemental 
text. 
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Glycerol gradient fractionation 
Molecular mass fractionation of nuclear extract was conduced using a 10-40 % 
glycerol gradient as indicated in the supplemental text. 
  
In vitro interaction assays 
Recombinant GST-BAP1 fusion proteins were purified using glutathione agarose 
beads and incubated with His-UBE2O. The beads were extensively washed and bound 
proteins eluted in Laemmli buffer and subjected to western blotting. Additional details are 
described in the supplemental text.  
 
In vitro and in vivo ubiquitination assay 
In vitro ubiquitination reactions were conducted using, human recombinant UBE1, 
BAP1 and UBE2O complexes or bacteria-purified enzymes. Additional details and Mass 
spectrometry analysis of ubiquitination sites was done as described in the supplemental 
text. 
In vitro nucleosome deubiquitination assays 
Preparation of chromatin fractions from Flag-H2A transfected 293T cells and 
digestion with Micrococcal nuclease (MNase) were conducted with modification of the 
original protocol (Groisman et al., 2003). The procedure is described in the supplemental 
text.  
 
Immunofluorescence 
The procedure was carried out as previously described (Daou et al., 2011) with 
additional details provided in the supplemental text.  
 
Protein sequence analysis, and structure modeling 
Protein sequences were analyzed using Geneious 6.1.2 created by Biomatters, 
available from http://www.geneious.com. Other bioinformatics tools are described in the 
supplemental text.  
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Figure 1. UBE2O interacts with and ubiquitinates BAP1 and this effect is actively 
counteracted by BAP1 auto-deubiquitination. (See also Figure S1). 
A) Purified BAP1 complexes were used for western blot. B) HeLa nuclear extract was 
resolved by glycerol gradient, and used for western blot. C) 293T cells were co-transfected 
with 2 µg of HA-Ub, 2 µg of Myc-UBE2O (wild type or CD), and 1 µg of Flag-BAP1 
(wild type or C91S) expression vectors, and cell extracts were used for 
immunoprecipitation. D) Top, schema representing the human UBE2O with secondary 
structure prediction (alpha helixes are in red and beta strands are in yellow). The main 
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predicted domains are indicated as CR1 (conserved region 1), CR2 (conserved region 2), 
UBC (ubiquitin conjugating) and CTR (C-terminal region). Bottom, schema representing 
UBE2O deletion mutants used for the ubiquitination assay. E) 293T cells were co-
transfected with 2 µg of HA-Ub, 2 µg of Myc-UBE2O fragments, and 1 µg of C91S 
expression vectors, and cell extracts were used for western blot. 
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Figure 2. Characterization of UBE2O mediated ubiquitination of BAP1. (See also 
Figure S2). 
A) In vitro ubiquitination reaction with beads-immobilized BAP1 or C91S complexes 
incubated with immunopurified UBE2O. Fractions were used for western blot detection of 
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components of the BAP1 complex. B) In vitro ubiquitination reaction using the BAP1 
complex inhibited with NEM. C) The C91S complex was used for in vitro reaction with 
UBE2O and either unmodified or methylated ubiquitin. D) 293T cells were co-transfected 
with 2 µg of wild type ubiquitin or K0 mutant ubiquitin, 1 µg of BAP1 or C91S and 2 µg of 
empty vector or His-UBE2O expression vectors, and cell lysates were used for 
immunoprecipitation. E) 293T cells were co-transfected with 1 µg of HA-Ub, 2 µg of 
BAP1 or C91S and 1 µg of His-UBE2O expression vectors. Cells were treated with DMSO 
or 20 µM MG132 for 8 hours before immunoprecipitation. F) MCF7 cells were transfected 
with non-targeting or UBE2O siRNA for 96 hours, treated with 20 µg/ml of cycloheximide 
and analyzed by western blot. *indicates non-specific bands. 
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Figure 3. BAP1 NLS is required for its ubiquitination by UBE2O. (See also Figure S3). 
A) Schematic representation of GST-BAP1 fragments used for pull-down assay with His-
UBE2O. B) 293T cells were co-transfected with 2 µg of HA-Ub, 2 µg of His-UBE2O, and 
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1 µg of Myc-CTD-NLS expression vectors, and cell extracts were used for 
immunoprecipitation. C) U2OS cells were co-transfected with 2 µg of shControl, 
shUBE2O#1 or shUBE2O#2 and 1 µg of HA-Ub and 0,5 µg of Myc-CTD-NLS expression 
vectors, and cell extracts were used for western blot. D) Purified complexes of BAP1 or 
BAP1 ∆CTD were used for western blot detection of components of BAP1 complex. E) 
293T cells were co-transfected with 2 µg of HA-Ub, 2 µg of His-UBE2O, and 1 µg of 
Myc-BAP1 mutants expression vectors, and cell extracts were used for 
immunoprecipitation. * indicates non-specific bands. 
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Figure 4. Ubiquitination of BAP1 NLS by UBE2O promotes its cytoplasmic 
sequestration. (See also Figure S4). 
A) 293T cells were co-transfected with 2 µg of HA-Ub, 2 µg of Myc-UBE2O, and 1 µg of 
Flag-C91S, and cell extracts were used for Flag immunoprecipitation. The indicated bands 
were excised for MS analysis. B) Table of ubiquitination events detected by MS. C) Cells 
were co-transfected with 2 µg of HA-Ub, 2 µg of His-UBE2O, and 1 µg of Myc-tagged 
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BAP1 mutants expression vectors, and cell extracts were used for immunoprecipitation. D) 
U2OS cells were co-transfected with either 2 µg of empty vector, Myc-UBE2O or Myc-
UBE2O CD and 3 µg of either Flag-HA-BAP1 or Flag-HA-C91S expression vectors and 
were used for immunofluorescence analysis. Representative cell counts for BAP1 
subcellular localization are shown. C, cytoplasmic; N, Nuclear. E) U2OS cells were 
transfected with Flag-HA-BAP1 mutants expression vectors and used for 
immunofluorescence analysis as in panel D. 
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Figure 5. BAP1 intramolecular interaction promotes auto-deubiquitination, a 
mechanism disrupted by cancer mutations. (See also Figure S5). 
A) Predicted model of BAP1 UCH/CTD interface based on UCH37 crystal structure (PDB: 
3IHR). Note that NLS and NORS are not present in UCH37, and thus not included in the 
model. B) Schematic representation of the mutants used for the complementation assay and 
the deletion mutants used in the context of full length BAP1. C) 293T cells were co-
transfected with 2 µg of the indicated GFP fusion constructs and 2 µg of Myc-CTD-NLS 
expression vectors, and cell extracts were used for immunoprecipitation. D) 293T cells 
were co-transfected with 2 µg of HA-Ub and either 2 µg of empty vector or His-UBE2O, 1 
µg of the indicated GFP fusion constructs and 1 µg of Myc-CTD-NLS expression vectors. 
E) 293T cells were co-transfected with 2 µg of HA-Ub, 2 µg of His-UBE2O, and 1 µg of 
Myc-BAP1 mutants expression vectors. F) Purified BAP1 complexes were analyzed by 
silver stain and western blotting. Densitometric ratios between UBE2O and BAP1 indicate 
its relative abundance in the complexes. The histogram shows two independent 
experiments. G) In vitro nucleosome deubiquitination reaction with purified BAP1 
complexes. Samples were incubated at 37°C for the indicated times. H) 293T cells were co-
transfected with 2 µg of HA-Ub, 2 µg of His-UBE2O expression vectors, 1 µg of indicated 
GFP fusion constructs and 1 µg of Myc-tagged constructs. I) 293T cells were co-
transfected with 2 µg of HA-Ub, 2 µg of His-UBE2O, and 1 µg of Myc-tagged BAP1 
mutants expression vectors. J) U2OS cell lines stably expressing Flag-HA-BAP1 and its 
mutant forms were used for immunofluorescence analysis. 
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Figure 6. UBE2O shuttles between the nucleus and cytoplasm and promotes BAP1 
cytoplasmic localization during adipocyte differentiation. (See also Figure S6). 
A) Effect of kinase inhibition on nuclear localization of UBE2O. U2OS cells were 
transfected with 4 µg Myc-UBE2O or Myc-UBE2O CD expression vectors and then treated 
with a panel of kinase inhibitors for 24 hours prior harvesting for IF. + and - Indicate the 
relative intensity in the nuclear staining of UBE2O. B) Representative images of UBE2O 
localization in U2OS cells treated with CDK inhibitors. C) Effects of siRNA-depletion of 
UBE2O, BAP1 on cell proliferation, determined by MTT assay. siRNA for OGT is used as 
a control of decreased proliferation. Note that the values are relative to the non-target 
control siRNA for each time point. D,E) Effects of overexpression of UBE2O wild type or 
catalytic dead form on the differentiation of 3T3L1. Immunodetection of differentiation 
markers (E) and Oil-Red O staining (F). YY1 is used as a loading control.  F) Localization 
of BAP1 and mutants during adipocyte differentiation. The BAP1 NLST1 corresponds to a 
mutant in which the NLS region of BAP1 which includes the UBE2O-binding motif is 
replaced with the T large antigen NLS. The BAP1 K/R mutant is mutated in the UBE2O-
ubiquitination sites of the NLS. 
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Figure 7. UBE2O targets a subset of chromatin-associated proteins. (See also Figure 
S7). A) In vitro ubiquitination reaction with the purified UBE2O. Samples were incubated 
for the indicated times. B) 293T cells were co-transfected with 2 µg of HA-Ub and 2 µg of 
indicated Myc-UBE2O mutants, and cell extracts were used for immunoprecipitation. C) 
Sequence alignment between the UBE2O/BAP1 NLS and a subset of identified UBE2O 
substrates. Hydrophobic amino acids are in red and polar amino acids are in blue. A large 
N-terminal extension containing the NLS of CDT1 is not shown. D) 293T cells were co-
transfected with 2 µg of HA-Ub and 1 µg of Flag-CXXC1 or 2 µg of Flag-INO80, and 
either 2 µg of empty vector, Myc-UBE2O or Myc-UBE2O CD expression vectors, and cell 
extracts were used for immunoprecipitation. E) U2OS cells were co-transfected with 0,5 µg 
of HA-Ub and either 1 µg of empty vector, Myc-UBE2O, Myc-UBE2O CD and 1 µg of 
either Flag-INO80 or Flag-CXXC1 expression vectors and used for immunofluorescence 
analysis. Representative cell counts are shown. 
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SUPPLEMENTAL INFORMATION INVENTORY 
 
Figure S1. Related to Figure 1. 
Contains the initial characterization of the UBE2O-independent BAP1 monoubiquitination, 
the comparison of UBE2O with other E2s, the in vivo ubiquitination controls for UBE2O 
specificity and UBE2O sequence conservation. 
 
Figure S2. Related to Figure 2. 
Contains schema of the protein purifications, the in vitro ubiquitination reactions and 
characterization of the effects of other E3 ligases on UBE2O-mediated ubiquitination of 
BAP1.  
 
Figure S3. Related to Figure 3. 
Contains the information about the degradation of CTD-NLS, the characterization of BAP1 
NLS, the alanine mutagenesis screen in BAP1 NLS and the alignment of NLS regions of 
BAP1 orthologs. 
 
Figure S4. Related to Figure 4. 
Contains immunostaining of UBE2O overexpression and its effects on the localization of 
endogenous BAP1, YY1 and HCF-1. 
 
Figure S5. Related to Figure 5. 
Contains the characterization of UCH37 in respect to its auto-deubiquitination activity, the 
alignment of UCH37 and BAP1 C-terminal regions, crystal structure of UCH37, the 
characterization of the effect of the G13V mutation on BAP1 auto-deubiquitination activity 
and the establishment of the in vitro H2A DUB assay on nucleosomes. 
 
Figure S6. Related to Figure 6. 
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Contains the mapping and characterization of UBE2O NLS regions, purification of 
UBE2O-associated proteins and schema of UBE2O and BAP1 post-translational 
modifications. 
 
Figure S7. Related to Figure 7. 
Contains the effects of the mutation in the VLI patch which disrupts UBE2O auto-catalytic 
activity, the effects of UBE2O on the degradation of p400 and CDT1 following expression 
of UBE2O, the characterization of the predicted UBE2O substrate ALC1 which tested 
negative for UBE2O-mediated ubiquitination and the list of the predicted UBE2O nuclear 
substrates based on the [KR][KR][KR]-X(1,3)-[VLI]-X-[VLI]-X-X-[VLI] consensus. 
 
EXTENDED EXPERIMENTAL PROCEDURES 
 
SUPPLEMENTAL REFERENCES 
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Figure S1 (Related to Figure 1).  
Characterization of the UBE2O-independent mono-ubiquitination of BAP1. 
A) Detection of the modified form of BAP1 in U2OS cells stably expressing Flag-HA-
BAP1. U2OS cells were transduced with empty pOZ-N vector or pOZ-N-BAP1, selected 
with anti-IL2 receptor-coupled magnetic beads (4 rounds of selection), as previously 
described (Yu et al., 2010), and cell lysates were subjected to western blotting with the 
indicated antibodies. B) 293T cells were transfected with 3 µg of Flag-BAP1 C91S and 
harvested three days-post-transfection for immunoprecipitation. Anti-Flag column-purified 
C91S was incubated with 200 nM of recombinant USP2 catalytic domain and collected for 
western blotting at the indicated time points. Note the decrease of the constitutive ubiquitin 
modification. C) Schema of the double column purification strategy of ubiquitin-depleted 
and -enriched fractions of BAP1. D) Analysis of the anti-HA beads-bound and the flow 
through fractions revealed that the slower migrating band was enriched in the HA-bound 
fraction and depleted in the flow through fraction proving the monoubiquitination nature of 
the modification. Monoubiquitination of BAP1 does not influence its ability to incorporate 
the ubiquitin vinylmethylester (Ub-VME) suicide substrate. HA-Ub-Flag-BAP1 and 
unmodified Flag-BAP1 fractions where incubated with 1 µM of Ub-VME probe and 
analyzed by western blot as recently described (Yu et al., 2014). Note the similar 
efficiency of Ub-VME incorporation that corresponds to the slower migrating form of 
BAP1. E) Fluorometric analysis of the BAP1 activity towards the Ub-AMC DUB 
substrate. Adjusted amounts of the HA-Ub-Flag-BAP1 and unmodified Flag-BAP1 
fractions where incubated with 100 nM of the Ub-AMC and fluorescence was analyzed in 
real time. Data are represented as mean +/- SD. Note that the modified form of BAP1 
displays a similar DUB activity as the modified form towards this model substrate. F) The 
ubiquitinated forms of C91S can be efficiently deubiquitinated by USP2. The procedure 
was carried out essentially as in panel B except that UBE2O was included in the co-
transfection. G) Similar UBE2O-mediated multi-mono-ubiquitination of BAP1 C91S or 
ΔUCH. 293T cells were co-transfected with 1 µg of Myc-C91S or Myc-BAP1 ∆UCH, 2 
µg of HA-Ub and 2 µg of either empty vector or UBE2O. Three days later, cell lysates 
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were used for western blotting and probed with the indicated antibodies. Note the decrease 
of the constitutive BAP1 mono-ubiquitination upon the deletion of the UCH domain 
indicating that distinct activities modify BAP1.  
Characterization of UBE2O specificity towards BAP1. 
H) Comparison of several members of class I and IV ubiquitin carrier enzymes. I) To 
control for specificity, we evaluated other E2s (van Wijk and Timmers, 2010) including 
BRUCE, the closest evolutionary relative of UBE2O which was previously shown to act as 
an E2/E3 hybrid on other substrates (Bartke et al., 2004; Hao et al., 2004).  
293T cells were co-transfected with 1 µg of Myc-C91S, 2 µg of HA-Ub and either 2 µg of 
empty vector, Myc-UBC7, Flag-UBCH8, 5 µg of Flag-BRUCE or 5 µg Flag-BRUCE CD 
(C4654S) expression vectors. Three days later, cell lysates were used for western blotting. 
J) We also tested two known H2A DUBs, i.e., USP16 and MYSM1 (Joo et al., 2007; Zhu 
et al., 2007), as well as the SUMO protease SENP2 (Kim et al., 2000). 293T cells were co-
transfected with 2 µg of HA-Ub and either 2 µg of empty vector or 2 µg of His-UBE2O 
and either 1 µg of GFP-BAP1, GFP-MYSM1, GFP-USP16 or Myc-SENP2 expression 
vectors. Three days later, cell lysates were used for western blotting. K) Multiple sequence 
alignment of UBE2O orthologs, conserved regions are highlighted.  
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Figure S2 (Related to Figure 2).  
Set up of the in vitro ubiquitination reaction.  
A) Schema of protein purification and in vitro ubiquitination reactions for figure 2A, 2B, 
S2B, S2D and S2E. B) Purified BAP1 or C91S complexes were incubated with 
immunopurified UBE2O in an in vitro ubiquitination reaction. Samples were treated with 
100 µM PAO as indicated. C) Mammalian Flag/HA or bacterial His/Flag purified UBE2O 
was loaded on a 4-12% gel and used for silver staining. D) Purified C91S complexes were 
incubated with UBE2O, purified from human cells or bacteria, in an in vitro ubiquitination 
reaction. Note that UBE2O maintains similar activity towards C91S independently of its 
origin and method of purification. HS and LS represent high salt and low salt washes, 
respectively. E) Ubiquitination with recombinant enzymes. His-C91S was purified from 
bacteria and used for in vitro reaction with bacteria purified Flag-UBE2O-His.  
UBE2O- and BAP1-interacting ubiquitin ligases do not influence UBE2O 
ubiquitination activity towards BAP1.  
F) Summary of potential UBE2O- and BAP1-interacting ubiquitin ligases. Our purification 
and mass spectrometry analysis of UBE2O- or BAP1-interacting proteins revealed 
additional substoichiometric E3 ligases that might participate in UBE2O-dependent or –
independent ubiquitination of BAP1. Other E3 ligases previously reported as potential 
UBE2O- or BAP1-interacting enzymes are also included. G) 293T cells were transfected 
with 2 µg of HA-Ub, 1 µg of HA-BRCA1 and/or 0,5 µg of HA-BARD1, 1 µg of BAP1 
and either 2 µg of empty vector or Myc-UBE2O expression vectors. Three days later, cell 
lysates were used for western blotting with the indicated antibodies. We note that BAP1 
was described as a partner of the tumor suppressor and RING E3 ligase complex 
BRCA1/BARD1 that may perform ubiquitin chain elongation (Jensen et al., 1998; Wu-
Baer et al., 2003). Nonetheless co-transfection with BRCA1/BARD1 did not significantly 
affect the pattern of BAP1 ubiquitination by UBE2O. H) Cells were transfected with 2 µg 
of HA-Ub, 1 µg of His-RING1B, 1 µg of BAP1 or C91S and either 2 µg of empty vector 
or Myc-UBE2O expression vectors. Three days later, cell lysates were used for western 
blotting with the indicated antibodies. BAP1 acts in concert with the RING1B E3 ligase to 
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regulate H2A ubiquitination (Carbone et al., 2013; Scheuermann et al., 2010). However, no 
direct ubiquitination of BAP1 or cooperation between RING1B and UBE2O were 
observed. I) Cells were transfected with 2 µg of HA-Ub, 0.5 µg of C91S, 2 µg of empty 
vector or His-UBE2O and 3 µg of GFP-TRIM28, Myc-TRIM27, Flag-RNF219 or Flag-
RNF10 expression vectors. Three days later, cell lysates were used for western blotting 
with the indicated antibodies. Note the similar pattern of the C91S ubiquitination 
independently of the ubiquitin ligase co-expression. We were unable to express significant 
levels of HUWE1 (~500 kDa). Thus, we did not conclude about its potential effect alone or 
on UBE2O-mediated ubiquitination of BAP1. J) U2OS cell line stably expressing Flag-
HA-BAP1 was transfected with control siRNA or siUBE2O. Three days later, cell lysates 
were used for western blotting with the indicated antibodies. Note that the knockdown of 
UBE2O has no effect on the constitutive monoubiquitination of BAP1 (described in Figure 
S1A-E, G). 
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Figure S3 (Related to Figure 3).  
UBE2O promotes degradation of BAP1 CTD-NLS.  
A) 293T cells were co-transfected with 2 µg of HA-Ub, 2 µg of His-UBE2O, and 1 µg of 
Myc-CTD-NLS expression vectors. Three days later, cells were treated with 20 µM of 
MG132 for the indicated time points and harvested for western blotting. B) U2OS cells 
were co-transfected with 0,5 µg of HA-Ub, 1 µg of His-UBE2O and 1 µg of Myc-CTD-
NLS expression vectors and plated on coverslips. Three days later, cells were fixed and 
used for immunofluorescence. C) 293T cells were co-transfected with increasing amounts 
of HA-Ub or HA-Ub K0 (0.5 µg, 1.5 µg or  4 µg), 2 µg of His-UBE2O, and 1 µg of Myc-
CTD-NLS expression vectors. Three days later, cells extracts were analyzed by western 
blotting. Note that UBE2O promotes the Myc-CTD-NLS degradation in ubiquitin-
dependent manner, and a similar degradation profile is obtained with either wild type or 
K0 ubiquitin mutant. 
Characterization of the BAP1 NLS region.  
D) Representation of the predicted BAP1 NLS. The basic regions are in blue and 
hydrophobic regions are in red. BAP1 possesses a complex NLS region that shares 
similarities with classical monopartite (Conti et al., 1998), bipartite (Robbins et al., 1991) 
and the atypical hydrophobic/basic PY NLS (Lee et al., 2006). E) U2OS cells were 
transfected with 0,5 µg of the indicated GFP fusion NLS. Three days later, cells were fixed 
and used for fluorescence microscope imaging. The region spanning a short stretch of basic 
amino acids RRKRSR (aa 717-722) is necessary for proper nuclear localization of BAP1 
(Ventii et al., 2008). However, when fused to GFP, this motif was not sufficient to promote 
nuclear localization, i.e., additional sequences are required for NLS function. Therefore, 
we considered the entire aa 699-729 region as BAP1 NLS for further characterization. 
Requirement of the major NLS site of BAP1 for UBE2O-mediated ubiquitination.  
F) Schematic representation of the alanine screen mutants, mutations are indicated in red. 
G) 293T cells were co-transfected with 2 µg of HA-Ub, 2 µg of His-UBE2O, and 1 µg of 
Myc-C91S mutants expression vectors. Three days later, cell extracts were used for 
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western blotting and probed with the indicated antibodies. Single point mutations in the 
region did not cause significant reduction of C91S ubiquitination, but cumulative alanine 
mutations were able to gradually decrease the efficiency of ubiquitination. The substitution 
of RRKRSR to a similarly positively charged histidine stretch also strongly reduced the 
ubiquitination by UBE2O indicating that the arginine/lysine residues are critical 
Sequence comparison of the NLS region from different BAP1 orthologs.  
H) Multiple sequence alignment of the NLS regions of BAP1 from metazoan species using 
the Geneious tool, polar amino acids are in blue, hydrophobic amino acids are in red.  
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Figure S4 (Related to Figure 4). 
Overexpression of UBE2O promotes cytoplasmic localization of endogenous BAP1. 
U2OS cells were transfected with 4 µg of the Myc-UBE2O or Myc-UBE2O CD. Three 
days later, cells were fixed and used for Immunofluorescence for BAP1 (A) or HCF-1 and 
YY1 (B). UBE2O promoted cytoplasmic localization of BAP1 but had no visible effect on 
YY1 and HCF-1. 
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Figure S5 (Related to Figure 5). 
BAP1 and UCH37 may employ a similar auto-deubiquitination mechanism.  
A) Crystal structure of UCH37 (3IHR) (Burgie et al., 2011). B) UCH37 (UCHL5) is highly 
similar to BAP1 with respect to domain architecture (Sanchez-Pulido et al., 2012). Crystal 
structure of UCH37 suggests that an intramolecular interaction occurs between the UCH 
and the CTD. Therefore, we evaluated the possibility that UCH37 might also be regulated 
by UBE2O. 293T cells were co-transfected with 1 µg of Myc-Ub, 1 µg of HA-UCH37 
wild type or HA-UCH37 C88A and either 2 µg of empty vector or Myc-UBE2O 
expression vectors. Three days later, cells lysates were used for IP with HA antibodies 
under native or denaturing conditions. Western blots were probed with the indicated 
antibodies. We detected ubiquitination of UCH37, which was more pronounced for its 
catalytic dead mutant (C88A), but this effect was independent of UBE2O. UCH37 also 
failed to interact with UBE2O in co-IP. Nonetheless, this result suggests that UCH37 may 
employ the same auto-deubiquitination mechanism as BAP1 to counteract the action of 
another, yet to be identified E3 ligase. Note that UCH37 co-immunoprecipitates 
endogenous YY1 providing an indication of IP validity (Yao et al., 2008). C) Alignment of 
human BAP1 and human UCH37 C-terminal regions, polar amino acids are in blue, 
hydrophobic amino acids are in red. Note the difference in the C-terminal region of both 
proteins, NLS in BAP1 and ADRM1-interacting region (KEKE) in UCH37 (Hamazaki et 
al., 2006; Yao et al., 2006). D) Prediction of coiled-coil domains in BAP1 using COILS 
program (Lupas et al., 1991). The amino acid sequences of CC1 and CC2 are presented. 
The hydrophobic amino acids are indicated in red.  
G13V cancer mutant of BAP1 does not impair auto-deubiquitination of NLS. 
We initially tested the G13V mutation recently described in renal carcinoma (Pena-Llopis 
et al., 2012).  E) Prediction for the G13/F660 intra-molecular interaction (left) based on the 
crystal structure of UCH37 (3IHR)(right). F) 293T Cells were co-transfected with 2 µg of 
HA-Ub, 2 µg of His-UBE2O, and 1 µg of Myc-BAP1 expression vectors. Three days later, 
samples were used for western blotting and probed with the indicated antibodies. The G13 
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residue in UCH is predicted to interact with the F660 residue of the CC2; nonetheless 
G13V and F660A mutations did not have a noticeable effect on the auto-deubiquitination 
activity of BAP1. 
Establishment of the in vitro nucleosome deubiquitination assay.  
G) Schema representing the steps for the preparation of nucleosomes containing H2A 
mono-ubiquitinated on lysine 119 and the in vitro DUB assays. H) DNA from nucleosomal 
Flag elution was purified using phenol/chloroform separation and loaded on EtBr agarose 
gel (left). The Ponceau S staining of the nucleosomal Flag elution indicates the presence of 
all four histone types (right panel).  I) In vitro nucleosome deubiquitination reaction with 
purified BAP1 complexes and bacteria purified BAP1. Samples were incubated at 37°C for 
4 hours, reactions were stopped with 2X Laemmli buffer, and used for western blot with 
the indicated antibodies. Note that recombinant BAP1 (not assembled into its complex) 
does not deubiquitinate H2A . 
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Figure S6 (Related to Figure 6).  
Subcellular localization of UBE2O deletion mutants reveals nuclear and cytoplasmic 
targeting regions. 
A) Schema of UBE2O mutants used to study its subcellular localization. B) U2OS cells 
were transfected with 1 µg of GFP fusion expression vectors of UBE2O NLS regions or 
empty vector and plated on coverslips. Two day later, cells were fixed and used for 
fluorescence microscopy analysis. C) U2OS cells were transfected with 3 µg of Flag-HA 
tagged expression vectors of UBE2O mutants and plated on coverslips. Two days later, 
cells were fixed and used for the immunofluorescence analysis with HA antibody. D) 
Representative cell counts for UBE2O subcellular localization are shown.  
Multiple sequence alignment of NLS1 region from different UBE2O orthologs. 
E) Multiple sequence alignment of NLS regions in UBE2O orthologs, polar amino acids 
are in blue, hydrophobic amino acids are in red. 
F) Tandem affinity purification of UBE2O-associated proteins from HeLa cells followed 
by MS analysis. The regulators of nuclear traffic and protein kinases are presented 
Post-translational modifications of UBE2O and BAP1. 
G) Schema of known UBE2O phosphorylation and ubiquitination sites (modified from 
http://www.phosphosite.org/) 
H) Schema of known BAP1 phosphorylation and ubiquitination sites (modified from 
http://www.phosphosite.org/) 
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Figure S7 (Related to Figure 7).  
NLS1 hydrophobic VLI patch is required for auto-catalytic UBE2O targeting. 
A) 293T cells were co-transfected with 2 µg of HA-Ub and 2 µg of indicated Myc-tagged 
UBE2O mutants, and cell extracts were used for immunoprecipitation. 
UBE2O promotes degradation of p400 and CDT1. 
B) 293T cells were co-transfected with 2 µg of HA-Ub and 2 µg of empty vector, Myc-
UBE2O or Myc-UBE2O CD and either 1 µg of Flag-CDT1 or 5 µg Flag-p400 expression 
vectors. Three days later, samples were used for western blotting and probed with the 
indicated antibodies.  
UBE2O does not ubiquitinate or promote localization change of ALC1, protein with 
unrelated NLS and the predicted consensus within Macro domain. 
C) Sequence alignment between the UBE2O/BAP1 in comparison to ALC1 NLS. VLI 
patch is in red, and basic amino acids are in blue. Note that the K/R NLS region is absent 
downstream of the UBE2O consensus found in ALC1. The previously defined NLS 
sequence of ALC1 does not show similarities with the UBE2O consensus (Cheng et al., 
2013). D) U2OS cells were co-transfected with 0,5 µg of HA-Ub and either 1 µg of empty 
vector, Myc-UBE2O or Myc-UBE2O CD and 1 µg of Flag-ALC1 expression vectors and 
plated on coverslips. Three days later, cells were fixed and used for immunofluorescence 
analysis with the indicated antibodies. E) 293T cells were co-transfected with 2 µg of HA-
Ub and 2 µg of empty vector, Myc-UBE2O or Myc-UBE2O CD and 1µg of Flag-ALC1 
expression vectors. Three days later, samples were used for western blotting and probed 
with the indicated antibodies. 
Identification of potential UBE2O substrates 
F) Prediction of UBE2O substrates based on BAP1/UBE2O NLS consensus 
aUniProt accession number.  
bprotein name. 
cprotein positions of the [KR][KR][KR]-X(1,3)-[VLI]-X-[VLI]-X-X-[VLI] UBE2O binding 
consensus. 
dconsensus sequence (consensus-defined amino acids are capital).  
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eexperimental evidence for the predicted UBE2O-mediated substrate ubiquitination (see 
Figures 7 and figure S7). 
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EXTENDED EXPERIMENTAL PROCEDURES 
 
 
Plasmids and Antibodies  
 
UBE2O and RING1B were cloned from HeLa total RNA by reverse transcription 
and inserted into pENTR D-Topo plasmid (Life Technologies). MYSM1 and USP16 were 
cloned from HeLa total RNA by reverse transcription and inserted into pEGFP-C1 
plasmid. Human RNF10 and RNF219 were cloned from U2OS total RNA by reverse 
transcription and inserted into p3XFLAG-CMV™-7 expression vector (Sigma-Aldrich). 
UBE2O expression constructs were generated using LR clonase kit (Life Technologies) in 
pDEST-Myc, pDEST-His or retroviral pMSCV-Flag/HA-IRES-Puro (Sowa et al., 2009).  
For bacterial expression, the UBE2O cDNA was cloned into pET-30a+ vector 
(Novagen), to generate N-terminal Flag- and the C- terminal His-tags for the double 
column purification. 
The catalytically inactive UBE2O was generated by site-directed mutagenesis. Non-
tagged pCDNA3-BAP1 and C91S were generated by subcloning the cDNA from pOZ-N 
BAP1 and pOZ-N C91S respectively. BAP1 cancer mutants ∆E631-A634, ΔK637-
C638InsN, ΔCC2 and ΔCTD and UBE2O NLS mutants were generated using gene 
synthesis (BioBasic) and then subcloned into modified pENTR D-Topo plasmid.  
BAP1 NLS mutants were generated by subcloning of annealed short adapters 
containing corresponding mutations in pENTR D-Topo BAP1 and/or C91S. NLS-GFP 
were generated by subcloning of annealed short adapters containing corresponding BAP1 
or UBE2O NLS sequences in pOD35 plasmid provided by Dr. Paul Maddox (Institute for 
Research in Immunology and Cancer, Canada). All constructs were sequenced. 
shRNAs for human UBE2O were from Sigma (#1 NM022066x814s1c1 and #2 
NM022066x4103s1c1). The constructs used to produce recombinant full length GST-
BAP1 and various deletion fragments, and BAP1 mutant deleted in the NHNY sequence 
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corresponding to the HCF-1 binding domain (ΔHBM) and BAP1 catalytic dead C91S were 
described (Yu et al., 2010).  
Flag-INO80 expression vector was provided by Dr. Yang Shi (Harvard Medical 
School, USA) (Wu et al., 2007). Flag-p400 was provided by Dr. David M. Livingston 
(Harvard Medical School, USA) (Chan et al., 2005). Flag-CXXC1 expression vector was 
provided by Dr. David Skalnik (Indiana University-Purdue University Indianapolis, USA) 
(Tate et al., 2009). Flag-CDT1 expression vector was provided by Dr. Kevin Struhl 
(Harvard Medical School, USA) (Miotto and Struhl, 2011). Flag-ALC1 expression vector 
was provided by Dr. Simon Boulton (London Research Institute, UK) (Ahel et al., 2009). 
Flag-BRUCE and Flag-BRUCE CD expression vectors were from Dr. Stefan Jentsch (Max 
Planck Institute of Biochemistry, Germany) (Bartke et al., 2004). HA-UCH37 and HA-
UCH37 C88A expression vectors were from Dr. Joan Conaway (Stowers Institute for 
Medical Research, USA) (Yao et al., 2008). Myc-UBC7 expression vector was provided 
by Dr. Allan M. Weissman (Center for Cancer Research National Cancer Institute, USA) 
(Tiwari and Weissman, 2001). Flag-UBCH8 expression vector was provided by Dr. Dong-
Er Zhang (UC San Diego, USA) (Kim et al., 2004). GFP-TRIM28 expression vector was 
provided by Dr. Fanxiu Zhu (Florida State University USA) (Liang et al., 2011). Myc-
TRIM27 expression vector was provided by Dr. Patrick R. Potts (UT Southwestern Dallas, 
USA) (Hao et al., 2013). HA-BRCA1 was generated by subcloning from the GFP-BRCA1 
plasmid previously described (Hammond-Martel et al., 2010) into pCDNA3 plasmid. 
BARD1 expression vector was from Origene (SC119847). HA-wild type and K0 Ub 
expression vectors were from Dr. Ted Dawson (John Hopkins University, USA) (Lim et 
al., 2005). 
The siRNA ON-TARGETplus® smart pool for human UBE2O and a non-target 
control were from Dharmacon (Thermo Scientific). 
Rabbit polyclonal anti-UBE2O was from Novus Biologicals (NBP-03336). Mouse 
monoclonal anti-BAP1 (C4), rabbit polyclonal anti-BAP1 (H300), rabbit polyclonal anti-
YY1 (H414), rabbit polyclonal anti-OGT (H300), mouse monoclonal anti-GFP (B2), rabbit 
polyclonal anti-GFP (FL), mouse monoclonal anti-RING1B (N-32), mouse monoclonal 
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anti-BRCA1 (D-9), mouse monoclonal anti-BARD1 (2059c4a), mouse monoclonal anti-
CDC25A (F6), mouse monoclonal anti-Ubiquitin (P4D1) were from Santa Cruz. Rabbit 
polyclonal anti-HCF-1 (A301-400A) and rabbit polyclonal anti-ASXL2 (A302-037A) were 
from Bethyl Laboratories. Mouse monoclonal anti-Flag (M2) was from Sigma. Mouse 
monoclonal anti-Myc (9E10) and mouse monoclonal anti-HA (HA11) were from Covance. 
Rabbit polyclonal anti-HA (ab9110) was from Abcam. Rabbit monoclonal anti-Perilipin 
(PLIN) was from New England BioLabs (D1D8) XP®).  Rabbit polyclonal anti-aP2 
(FABP4) was from Cayman Chemicals. Mouse polyclonal anti-FOXK1 was provided by 
Dr. Xiao-Hua Li from Southwestern University of Texas. A rabbit polyclonal anti-FOXK2 
was generated using a recombinant fragment of human FOXK2 by Pacific Immunology. 
 
 
Chemicals and reagents 
 
UBE1, USP2 CD, Ub-VME, Ub-AMC, recombinant Myc-Ub and Ub were from 
Boston Biochem. Cycloheximide (CHX), N-methylmaleimide (NEM), Phenylarsine oxide 
(PAO), MG132, Micrococcal nuclease (MNase) where from Sigma. Casein kinase II 
(CKII) inhibitor TBB (100 µM), Casein kinase I (CKI) inhibitor IC261 (10 µM), protein 
kinase G inhibitor KT5823 (10 µM), CDK1 inhibitor RO-3306 (10 µM) where purchased 
from Millipore. The CDK1, CDK2 and CDK5 inhibitor Roscovitine (10 µM), MEK1/2 
inhibitor UO126 (20 µM) and the protein kinase A (PKA) inhibitor H-89 (20 µM) were 
purchased from Cell Signaling. The CDK2 inhibitor Purvalanol A (50 µM) was purchased 
from  Abcam. Protein kinase C inhibitor PKC412 (20 µM) and STK inhibitor GSK 650394 
(20 µM) were from Santa Cruz. The PI3-Kinase inhibitor caffeine (10 mM), CDK inhibitor 
CDKi (100 µM), CDK2 inhibitor GW8510 (20 µM) and JNK inhibitor SP600125 (30 µM) 
were from Sigma. SU 9516 (5 µM), Chk1 inhibitor SB 218078 (1 µM). Broad spectrum 
kinase inhibitor Staurosporine (100 nM), tyrosine kinase inhibitor Genistein (20 µM), CDK 
inhibitor Olomoucine (30 µM), CKII inhibitor Apigenin (20 µM), CKII and CDK inhibitor 
DRB (50 µM), PI3-Kinase inhibitor LY294002 (20 µM), CKII inhibitor NSC 210902 (15 
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µM), CKI inhibitor D 4476 (25 µM) and CKII inhibitor CAY10578 (15 µM) where from 
Cayman chemical. 
 
 
Cell culture, transfections and western blot 
 
HeLa S3 cervical cancer, MCF7 breast cancer, U2OS osteosarcoma, human 
embryonic kidney 293T, 293GPG virus-producing cells and 3T3-L1 mouse preadipocytes 
and human primary lung fibroblasts LF-1 were cultured in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% fetal bovine serum and penicillin/streptomycin.  
siRNA and plasmid DNA were transfected in MCF7 and U2OS cells, respectively, 
using Lipofectamine 2000 (Life Technologies). HEK293T (293T) cells were transfected 
using PEI (Sigma). 
Total cell lysates were prepared in buffer containing 25 mM Tris-HCl  pH 7.5 and 
1% SDS, samples were immediately boiled at 95°C for 10 min and sonicated to break 
down DNA. Samples were diluted using 2X or 4X Laemmli buffer (Laemmli, 1970). SDS-
PAGE and western blotting were conducted according to standard procedures. Images 
were acquired using ImageQuant™ LAS 4000 biomolecular imager (GE Healthcare, 
USA). Densitometry quantification of western blot bands was performed using Gel-Pro 
Analyzer 3.1 (Media Cybernetics). 
 
 
 
 
 
Stable cell lines 
 
HeLa S3 cell lines stably expressing Flag-HA-BAP1, Flag-HA-C91S, Flag-HA-
∆E631-A634, Flag-HA-ΔK637-C638InsN, Flag-HA-∆CTD, Flag-HA-∆CC1 were 
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generated following retroviral transduction using pOZ-N-based retroviral constructs and 
selected using anti-IL2 magnetic beads (Life Technologies) as previously described (Yu et 
al., 2010).  
U2OS cell lines stably expressing Flag-HA-BAP1, Flag-HA-C91S, Flag-HA-∆E631-
A634, Flag-HA-ΔK637-C638InsN, Flag-HA-∆CTD, Flag-HA-∆CC1 were generated 
following retroviral transduction of pMSCV-Flag/HA-IRES-Puro based constructs and 
selected with 3 µg/ml of puromycin.  
3T3-L1 cell lines stably expressing Flag-HA-BAP1, Flag-HA-BAP1 5 K/R, Flag-
HA-BAP1 NLS T1, Flag-HA-UBE2O and Flag-HA-UBE2O CD were generated following 
retroviral transduction of pMSCV-Flag/HA-IRES-Puro based constructs and selected with 
3 µg/ml of puromycin.  
Stable HeLa S3 Flag-HA-UBE2O cell line was generated following retroviral 
transduction of pMSCV-Flag/HA UBE2O-IRES-Puro and selected with 2 µg/ml of 
puromycin. 
 
 
Purification of BAP1 complexes and UBE2O-interacting proteins  
 
HeLa S3 (~12 X 109) cells stably expressing Flag-HA-BAP1, Flag-HA-C91S, Flag-
HA-∆E631-A634, Flag-HA-ΔK637-C638InsN, Flag-HA-∆CTD and Flag-HA-UBE2O 
were grown in spinner flasks. The cytosolic fraction was used for the purification of 
UBE2O with Flag and HA immunoaffinity columns essentially as previously described 
(Groisman et al., 2003) the Flag and HA columns were washed with either low salt buffer 
containing 100 mM KCl (Flag-HA-UBE2O LS) or 300 mM NaCl (Flag-HA-UBE2O HS) 
(Figure S2A, C, D)). The BAP1 protein complexes were purified from total soluble protein 
extracts in EBcom (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0,5% NP-40, 50 mM NaF, 10 
mM β-glycerophosphat, 1 mM Na3VO4 1 mM DTT, 1 mM EDTA, 1 mM PMSF and 
protease inhibitors cocktail (Sigma)). The extracts were clarified by centrifugation at 
30,000g for 1 hour, with subsequent filtration of supernatants through a 0,45 µm pore 
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filter. The extracts were incubated with the anti-Flag M2 resin overnight and extensively 
washed with EBcom. The resin was eluted three times with EBcom containing 200 ng/ml 
of Flag peptide. The eluted fractions were incubated with anti-HA resin overnight, and the 
procedure was repeated as for the previous column. The HA eluted fractions were used for 
silver stain, western blot and in vitro DUB assay. Mass spectrometric identification of 
UBE2O-interacting proteins was done at the Taplin Mass Spectrometry facility (Harvard, 
USA). Identification of additional BAP1-interacting proteins was done at the Proteomics 
Platform of the Quebec Genomics Center (CHUQ, Laval University, Canada). 
 
 
Immunoprecipitation 
 
Cells were lysed in buffer EB150 (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-
40, 10 mM β-mercaptoethanol, 1 mM PMSF and protease inhibitors cocktail (Sigma)) and 
the lysates were clarified by centrifugation at 21,000 g for 30 min. The supernatants were 
incubated with indicated antibodies for 3 hours and then protein-G beads were added and 
incubated for an additional hour. The samples were extensively washed with EB150 and 
re-suspended in 2X Laemmli buffer. For an IP under denaturing conditions, the cells were 
harvested as described for western blot, and diluted in EB300 (50 mM Tris-HCl pH 7.5, 
300 mM NaCl, 1% NP-40, 10 mM β-mercaptoethanol). The lysates were incubated 
overnight with antibody and protein-G beads. The beads were washed several times with 
EB300 and resuspended in 2X Laemmli buffer. 
 
 
Mass spectrometric identification of ubiquitination sites 
 
293T (~1 X 109) cells were transfected with HA-Ub, Flag-C91S, and His-UBE2O 
expression vectors. 96 hours later, the cells were lysed in EB300 containing 20 mM NEM 
and protease inhibitor cocktail. The extracts were clarified by centrifugation at 30,000g for 
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1 hour. The extracts were incubated with the anti-Flag M2 resin overnight and extensively 
washed with EB300. The resin was eluted three times with EB300 containing 200 ng/ml of 
Flag peptide. The eluted fractions were combined and concentrated using TCA 
(trichloroacetic acid) precipitation and loaded on the NuPAGE® Bis-Tris Precast Gel (Life 
Technologies). The gel was stained with Coomassie G-250 and the modified C91S bands 
were excised and sent for MS analysis at Taplin Mass Spectrometry facility (Harvard, 
USA).  
 
 
Glycerol gradient  
 
Molecular mass fractionation of nuclear extract was conduced using a 10-40 % 
glycerol gradient prepared in 20 mM Tris-HCl, pH 7.9; 100 mM KCl; 5 mM MgCl2; 1 mM 
PMSF; 0.1% NP40 and 10 mM β-mercaptoethanol. The samples were centrifuged for 12 
hours at 50,000 RPM (SW55Ti rotor, Beckman,) at 4 ºC. Individual fractions were then 
collected from top to bottom and analyzed by western blotting. The BAP1 complex is 
estimated to have a molecular mass of 1.6 MDa. 
 
 
In vitro interaction assays 
 
Recombinant GST-BAP1 fusion proteins were purified from bacteria using 
glutathione agarose beads (Sigma) and 2 to 3 µg of bound proteins were incubated with 
His-UBE2O for 6 to 8 hours at 4 ºC in pull down buffer (50 mM Tris-HCl, pH 7.5; 50 mM 
NaCl; 0.02% Tween 20; 1 mM PMSF and 500 µM dithiothreitol). The beads were 
extensively washed with the same buffer, and bound proteins eluted in 2X Laemmli buffer 
and subjected to western blotting.  
 
 
  
 
170
In vitro ubiquitination assay 
 
Ubiquitination reactions were conducted in a total volume of 30 µl containing 25 
mM Tris-HCl pH 7.5, 10 mM MgCl2, 5 mM ATP, 50 ng/µl Ub, 250 ng of human 
recombinant UBE1 and 1 mM β-mercaptoethanol. Purified Flag-HA-BAP1, Flag-HA-
C91S, His-C91S (bacterial recombinant), Flag-UBE2O-His (bacterial recombinant) and 
Flag-HA-UBE2O were added as indicated.  
Reaction on the beads-immobilized complexes was performed when indicated. 
Briefly, the anti-Flag M2 beads were incubated with high salt nuclear extracts from HeLa 
S3 Flag-HA-BAP1 or Flag-HA-C91S for 5 hour and washed 8 times with buffer 
containing 20 mM Tris-HCl pH 7.5, 100 mM KCl, 1 mM MgCl2, 5 mM EDTA, 0.1% 
Triton X-100 and 1 mM PMSF. The last wash was performed using buffer containing 25 
mM Tris-HCl pH 7.5 and 10 mM MgCl2. The beads-bound complexes (25 µl) were used 
for the reaction essentially in the same conditions as for the reaction in solution. Reactions 
were incubated at 37ºC with constant shaking overnight. Met-Ub was previously described 
(Kirisako et al., 2006) 
 
 
Purification of the nucleosomes and In vitro nucleosome DUB assay 
 
Preparation of chromatin fractions and digestion with Micrococcal nuclease (MNase 
Sigma) were conducted as previously described (Groisman et al., 2003), with some 
modifications. The 293T cellular pellet was resuspended in EB420 (50 mM Tris-HCl pH 
7.5, 420 mM NaCl, 1% NP-40, 10 mM β-mercaptoethanol, 20 mM NEM and protease 
inhibitor cocktail). The soluble fraction was discarded and the pellet was extensively 
washed with MNase buffer (20 mM Tris-HCl pH 7.5, 100 mM KCl, 2 mM MgCl2, 1 mM 
CaCl2, 0.3 M sucrose, 0.1% NP-40, and protease inhibitor cocktail). Following MNase 
treatment (3 U/ml for 10 min at room temperature), the reaction was quenched with 5 mM 
of EGTA and 5 mM of EDTA. The samples were then centrifuged at 20,000g for 10 
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minutes at 4°C to obtain the soluble chromatin fraction.  The extract was incubated with 
anti-Flag M2 resin overnight and washed with EB300 buffer. The beads then were eluted 
with EB300 containing 200 ng/ml of Flag peptide.  
The eluted soluble chromatin fraction was incubated with the indicated Flag/HA 
purified BAP1 complexes and used for western blotting. 
 
 
Immunofluorescence 
 
The procedure was carried over essentially as previously described (Daou et al., 
2011). Briefly cells were fixed in 3% PFA-PBS and permeabilized using PBS 0.1% NP-40. 
Anti-mouse Alexa Fluor® 594 and Anti-mouse Alexa Fluor® 488  (Life Technologies) 
were used as secondary antibodies. Nuclei were stained with 4',6-diamidino-2-
phenylindole (DAPI).  
Images were acquired using Zeiss. Z2 microscope and Plan Apochrmat 40X/0.95 
Korr, Plan Apochrmat 63X/1.4 Oil DIC and Plan Apochrmat 100X/1.4 Oil DIC objectives 
and AxioCam MRm camera. Images were processed using WCIF-ImageJ program (NIH).  
 
 
 
 
 
Adipogenic differentiation of 3T3-L1 preadipocytes. 
 
3T3-L1 cell lines stably expressing BAP1 or UBE2O were plated at the same 
density, upon reaching of confluency the growth media was changed to induction media 
containing 10% fetal bovine serum, penicillin/streptomycin, 1 µM dexamethasone, 1 µg/ml 
insulin and 500 µM IBMX (Sigma). Two days post-induction, the media was changed to 
maintenance media containing 10 % fetal bovine serum, penicillin/streptomycin, 1 µg/ml 
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insulin. The cells were fixed with PFA or harvested for western blotting  two to three days 
post-induction. Lipid droplet content was evaluated using Oil-Red O lipid stain (Sigma). 
 
Protein sequence analysis, and structure modeling 
 
Protein sequences were analyzed and aligned using Geneious 6.1.2 created by 
Biomatters, available from http://www.geneious.com. NLS consensus were analyzed using 
ProSite (Sigrist et al., 2013) and NLStradamus (Nguyen Ba et al., 2009). Coiled-coil 
regions were predicted using COILS (Lupas et al., 1991). BAP1 3D structure modeling 
was performed using SWISS-MODEL (Arnold et al., 2006) and crystal structure of 
UCH37 (Burgie et al., 2011) (PDB code: 3IHR). 
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Discussion 
Regulation of the OGT/HCF-1 complex by O-GlcNAcylation 
and limited proteolysis. 
 
Although the OGT/HCF-1 are found in several chromatin regulatory complexes, our 
initial interest in these factors was driven by their presence as components of the BAP1 
complex. OGT/HCF-1 appears to be important for the functions of the BAP1 complex in 
chromatin function, tumor suppression as well as maintenance of the metabolic balance 
(Pena-Llopis et al., 2012; Ruan et al., 2012). Therefore the information about their cross-
regulation is crucial to our understanding of the function and significance of the OGT/HCF-
1/BAP1 complex. We initially contributed to the understanding of how OGT/HCF-1 
regulate each other through a complex crosstalk (Daou et al., 2011).  
 
Regulation of OGT protein levels by HCF-1 
We found that OGT and HCF-1 constitute a tight complex, and that their normal 
function is dependent on each other. We found that almost half of the cellular pool of OGT 
is complexed with HCF-1 (Daou et al., 2011). We showed that about half of OGT protein 
interacts within HCF-1 in the nucleus. Indeed, depletion of HCF-1 by shRNA-mediated 
knockdown decreased the total levels of OGT by around 50%. Notably, 
immunofluorescence microscopy confirmed that the levels of nuclear OGT were affected 
the most following depletion of HCF-1. This observation strongly suggests that the function 
of OGT as an epigenetic regulator is coordinated by HCF-1. 
Co-stabilization of the subunits of the same complex by each other is shared among 
multiple transcription regulators; including, for instance, the previously discussed 
BAP1/ASXL1/2 complex (Daou et al., submitted) (Scheuermann et al., 2010) and 
SUZ12/EZH2 components of the PRC2 complex (Cao and Zhang, 2004). 
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The mechanism by which HCF-1 stabilizes OGT remains unknown. Since HCF-1 is 
a highly abundant transcriptional regulator and often implicated in transcription activation, 
it may regulate the expression level of OGT. However, the knockdown of HCF-1 did not 
affect the mRNA levels of OGT and moreover HCF-1 seems to be poorly enriched at the 
OGT promoter. These results indicate that transcription of the OGT gene is not regulated 
by HCF-1. Furthermore, overexpression of HCF-1 stabilized endogenous OGT. These data 
indicate that OGT is stabilized by HCF-1 via direct physical interaction.   
Several mechanisms might explain the role of HCF-1 in stabilizing OGT. The first 
possibility is that the interaction of HCF-1 with OGT competes with the recruitment of 
ubiquitin E3 ligase or its adapter protein. Indeed we were able to detect the ubiquitination 
of OGT, represented by several monoubiquitination bands as well as polyubiquitin chain 
conjugates (see the results section). However, cycloheximide chase experiments did not 
reveal a drastic change in OGT protein levels, which can be explained by the long half-life 
of the protein.  
Another possibility, which was not addressed in our study, is that the depletion of 
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Figure 6. Regulation of HCF-1 proteolytic processing by OGT (Daou et al., 2011) 
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HCF-1 exposes the aggregation/misfolding prone surfaces of the OGT, which might result 
in the loss of its native structure or/and solubility inducing OGT aggregation. We were 
unable to detect visible OGT inclusions in the HCF-1 depleted cells, although the 
intracellular chaperone/heat shock and aggregate degrading systems may clear out damaged 
and misfolded OGT by recruiting the ubiquitin ligase CHIP (McDonough and Patterson, 
2003). The other possibility is that the cellular autophagy machinery might degrade the 
misfolded OGT. In this case the ubiquitinated aggregates would recruit several well 
described ubiquitination/autophagy mediators such as the ubiquitin receptor p62 and the 
AAA+ type ATPase/unfoldase p97/VCP. At the later steps of this process the 
ubiquitin/substrate aggregates would be recruited to the autophagosome and degraded 
(Meyer et al., 2012). The latter process may have far reaching implications for energy 
balance sensing and metabolic regulation as OGT has been implicated as an intracellular 
energy sensor. Perturbation of the intracellular energy level could promote the micro- and 
macro-autophagy pathways with the subsequent decrease of OGT levels, thus reducing O-
GlcNAcylation of transcription regulators and signaling proteins and promoting adequate 
cellular response. 
 
 
OGT is required for HCF-1 proteolytic processing. 
 
Previous studies identified OGT as a component of the HCF-1 complex (Wysocka 
et al., 2003). These studies used the N-terminal region of the HCF-1 as a bait for affinity 
capture studies and were able to recover a significant amount of OGT. We found that HCF-
1 possesses at least two major OGT interaction regions. One of these, as previously 
described, is localized to N-terminal basic region of HCF-1. We further mapped the region 
to the short fragment of the basic region (termed OBM). Notably, although this region was 
able to bind OGT, its deletion had no impact on the level of OGT in the context of the full 
length HCF-1. This can be explained by the identification of the second site for OGT 
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binding in the HCF-1 central region termed PPD. The affinity of OGT to this domain seems 
to be at least 10 fold higher when compared to the OBM region in the N-terminus. We 
showed that the PPD region was required to stabilize OGT, which in turn promoted the 
proteolytic processing of the HCF-1 at the PPD. Although the OGT itself does not possess 
any known protease domain its catalytic activity and O-GlcNAcylation are required for the 
proteolytic cleavage of HCF-1.  
Limited proteolysis is usually performed by endoproteases, although attempts to 
purify the HCF-1 specific protease activity failed to reveal the occurrence of such an 
enzyme. This can be explained by the requirement of O-GlcNAcylation for this process, 
which involves several factors including the UDP-GlcNAc, OGT itself and the protease. A 
study by W. Herr group proposed that OGT itself possesses the proteolytic activity towards 
the PPD (Capotosti et al., 2011; Lazarus et al., 2013). Indeed some evidence suggests that 
this mechanism may indeed be executed by OGT. The bacteria-purified OGT was able to 
promote, to some extent, the processing of the bacteria-purified PPD. However, this does 
not exclude the possible contamination of the purified reagents by a bacterial protease, 
which might promote, to some extent, the proteolysis of O-GlcNAcylated PPD. In support 
of the direct role of OGT in mediating proteolysis, Walker and Herr groups recently 
published a study of the crystal structure of the OGT catalytic domain and the PPD and 
proposed a biochemical mechanism for the reaction (Lazarus et al., 2013). 
It is worth mentioning that previous studies on the bacteria-expressed HCF-1 
showed that it might possess an intrinsic proteolytic activity (Vogel and Kristie, 2000a; 
Wilson et al., 1995).  The bacterially expressed HCF-1 PPD was able to be auto-processed 
without the involvement of OGT (Vogel and Kristie, 2000a; Wilson et al., 1995). In these 
assays, the use of a series of conventional protease inhibitors resulted in an unusual 
inhibitor sensitivity profile with most of the compounds having weak or no effect on the 
PPD processing, with the exception of the AEBSF serine protease inhibitor that completely 
blocked the processing. This result suggests that PPD might possess protease activity, 
which can be enhanced by O-GlcNAcylation, although the contribution of bacteria 
proteases cannot be firmly excluded. Nonetheless, the O-GlcNAcylation of the PPD by the 
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OGT might promote conformational changes within the proteolytic repeat that would 
facilitate the autocatalytic processing.  
Interestingly, we noticed that the PPD domain itself cannot be efficiently processed 
when co-expressed with OGT even though the PPD had a strong stabilizing effect on OGT 
and was able to promote the sequestration of OGT to the cytoplasm, indicating stable 
interaction (Daou et al., 2011). In contrast, a dramatic enhancement of the proteolytic 
process was achieved when the PPD was forced to enter the nucleus, by fusing it with the 
strong NLS sequence of the SV40 T-large antigen. This result indicates that the nuclear 
import and/or nuclear localization of both components were required for the PPD 
processing. Therefore, an additional nuclear factor or possibly a protease might be required 
for the process, and that OGT is required but not sufficient to promote the efficient 
proteolytic processing of HCF-1 in vivo. Unfortunately so far we do not have any 
information on the missing proteolytic processing factor. The studies of the PPD-associated 
proteome may shed light on the intriguing mechanism of HCF-1 maturation.  
Another important question is the significance of HCF-1 cleavage. The limited 
proteolysis in the cell usually occurs for a number of reasons. The regulatory proteolysis of 
proteins promotes their activation, or inactivation. A number of proteins are kept inactive 
until specific signals induce their cleavage. The limited proteolysis in the Notch signaling 
pathway promotes the cleavage of the Notch receptor cytoplasmic NICD tail (Notch 
intracellular domain) upon ligand-mediated receptor activation. The NICD acts as a signal 
mediator, that is transported to the nucleus and promotes the assembly of the transcription 
regulatory complex to promote gene expression (Guruharsha et al., 2012). Several proteases 
are proteolytically processed from their inactive proenzymes (zymogens). This mechanism 
prevents their uncontrolled catalytic activity towards the cellular proteins. The activation of 
caspases upon the induction of apoptosis results in their autocatalytic processing that 
promotes their dimerisation and activation (Raina et al., 2005; Renatus et al., 2001). On the 
other hand the caspase mediated proteolysis of the substrates often remove their regulatory 
regions/domains and result in their inactivation or constitutive activation (Affar et al., 
2001).  
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The proteolytic processing of HCF-1 is required for the proper execution of the cell 
cycle. Previous studies indicated that the N-terminal region is sufficient to promote the 
G1/S transition, while the C terminal domain is necessary for normal cytokinesis (Julien 
and Herr, 2003, 2004). HCF-1 mutant with a deletion of the PPD failed to rescue the 
cytokinesis defects induced by RNAi-mediated depletion of HCF-1, suggesting that 
proteolytic processing is necessary to activate the C-terminal region (Julien and Herr, 
2003). It remains unknown, why the N- and C-terminal parts of HCF-1 have to be separated 
and further structural studies are needed to address these questions. A recent study solved 
the structure of the HCF-1 SAS (Self association sequence) domain along with the C-
terminal FN3 (Fibronectin type domain 3) domains (Park et al., 2012; Wilson et al., 2000). 
The SAS is a part of the FN3-1 of the C-terminus. It is thus possible that the unprocessed 
HCF-1 is unable to properly assemble the SAS/FN3-1 structure, and that the PPD 
processing ensures this association. On the other hand the HCF-1 C-terminus was sufficient 
to rescue the mitotic aberration phenotype caused by HCF-1 depletion, suggesting that the 
SAS/FN3-1 is not required. Therefore the inhibitory function might be contained within the 
N-terminus and this inhibitory effect is abrogated upon HCF-1 maturation. 
 
Future work regarding HCF-1/OGT complex  
 
The study of the HCF-1/OGT complex has far reaching implications for the basic 
understanding of chromatin function and transcription regulation in physiological as well as 
human pathological processes such as metabolic, neurological and neoplastic disorders.  
The HCF-1/OGT complex may serve as a link between the energy balance, 
epigenetic modifications and cell cycle regulation. The HCF-1 is one of the most heavily 
O-GlcNAcylated proteins in the nucleus, containing at least 20-40 O-GlcNAcylation sites. 
We showed the O-GlcNAcylation of the PPD resulted in its cleavage. But most of the O-
GlcNAcylation occurs in the HCF-1 N-terminal basic region. The function of these 
modifications remains unclear, as mutation of the multiple O-GlcNAcylation sites in the N-
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terminal basic region did not affect HCF-1 maturation. Nonetheless, the basic region acts as 
an interaction platform for multiple HCF-1 partners (i.e. SIN3A, OGT, GABP, Miz-1 also 
see the introduction section), and it is possible that the O-GlcNAcylation of this region 
might enhance or disrupt the binding of these co-factors. The O-GlcNAcylation might also 
play the role as competitive post-translational modification towards phosphorylation of 
serine and threonine. Indeed, numerous proteomic studies revealed that HCF-1 is also 
extensively phosphorylated, often on overlapping sites with O-GlcNAcylation in the N-
terminal basic region (Huttlin et al., 2010; Myers et al., 2013; Olsen et al., 2010).  
Since O-GlcNAcylation is highly dependent on the availability of energy, one can 
speculate that changes in the energy balance would have proportional effects on the O-
GlcNAcylation of HCF-1 basic region. A gradual modification of the HCF-1 N-terminus 
may act as a rheostat that converts the energy status input information into gene 
expression/epigenetic output. The participation of HCF-1/OGT in the multiple chromatin 
modifying complexes (BAP1 complex, TET 2/3 complexes, MLL and BAP1 complexes, 
CLOCK/BMAL1 complex (Cai et al., 2010; Chen et al., 2013; Deplus et al., 2013; Ito et 
al., 2014; Li et al., 2013; Yu et al., 2010) would link the energy balance sensing to gene 
expression regulation during ES cell maintenance and differentiation cell cycle progression, 
DNA demethylation, tumor suppression and the circadian rhythm regulation. 
The metabolic alterations during cellular transformation are recognized as one of 
the major hallmarks of cancer (Hanahan and Weinberg, 2011). Indeed, convoluted and 
often counterintuitive reorganization of the cell metabolism is required for tumorigenesis in 
multiple types of cancer. Tumor cells switch their metabolic pathways to promote the 
generation of metabolites/catabolites that ensure the survival and proliferation of cancer 
cells. OGT expression and protein O-GlcNAcylation profile are disrupted in multiple types 
of cancers such as pancreatic, breast and prostate cancer (Caldwell et al., 2010; Huang et 
al., 2013). Indeed, abnormally high levels of O-GlcNAcylation were implicated in the 
cancer cell proliferation, tumor angiogenesis and metastasis as well as maintenance of 
constant pro-inflammatory signaling. (Hart et al., 2011; Ma and Vosseller, 2013; Wang et 
al., 2012). The suggested role of the OGT in the PI3K signaling also predicts its possible 
  
 
185
role in receptor tyrosine kinases (RTK) signaling, one of the most prominent oncogenic 
pathways. OGT functions as a negative regulator of Akt signaling at the level of insulin 
receptor activation, and also acts as an insulin desensitizer. It would be interesting to 
determine if OGT also acts as an agonist/antagonist of the well-established oncogenic 
RTKs pathways, i.e., EGFR, HER, Met and VEGFR, although the function of the OGT in 
these pathways may be independent of HCF-1. The immediate effects of the receptor 
protein signaling on the chromatin landscape are much less studied, and the HCF-1/OGT 
complex might provide the link between the RTK signaling and chromatin modifications. 
The OGT/HCF-1 is associated with multiple tumor suppressors such as BAP1 and 
TET 2/3 and proto-oncogenes such as MLL1 and MLL5. Mutations of the OGT and HCF-1 
have been detected in human malignancies, but their role in tumor development is 
unknown. The importance of the OGT/HCF-1 complex for cell cycle progression suggests 
that any loss of function mutations would not be beneficial for the cancer cell, therefore the 
gain of function mutation would be more likely to play a role in this process. Further 
studies are needed to understand the role of such mutations in cancer development. The 
study of the role of the HCF-1/OGT in the oncogenic process may shed light on the 
mechanisms of tumor suppression/oncogenesis and provide a platform for the development 
of targeted anticancer therapeutic strategies.  
 
Regulation of the tumor suppressor BAP1 by the atypical 
ubiquitin ligase UBE2O 
 
The last decade of research in the field of DUBs uncovered numerous functions for 
this family of enzymes. DUBs were shown to play important roles in almost every aspect of 
ubiquitin signaling, from ubiquitin processing, to protein degradation and ubiquitin 
recycling. Despite all the progress in the field, the mechanisms of DUB regulation remain 
much less understood.  
The recent rise of interest in BAP1 resulted from the discovery of its role as a tumor 
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suppressor in a plethora of human malignancies. Although the exact mechanism of BAP1 
action still remains elusive, it is clear that it is involved in transcription regulation and DSB 
repair through its DUB activity towards the histone repressive mark, the ubiquitinated H2A 
(K119) (Scheuermann et al., 2010; Yu et al., 2010; Yu et al., 2014). The multiple BAP1 
partners (LSD2, HAT1, OGT) may act in the concert with its core subunit (BAP1) and 
promote coordinated demethylation, acetylation and O-GlcNAcylation in order to ensure 
specific chromatin associated events (Carbone et al., 2013; Fang et al., 2010; Hart et al., 
2011; Parthun, 2007). 
 Our work describes a novel regulatory circuit between the DUB BAP1 and the 
unusual ubiquitin-conjugating enzyme UBE2O. We found that UBE2O dynamically and 
reversibly ubiquitinates BAP1 on its NLS. Notably, this process promotes the sequestration 
of BAP1 to the cytoplasm. The BAP1 auto-deubiquitination mechanism counteracts the 
action of UBE2O and ensures its proper localization. We found that the auto-
deubiquitination ability of BAP1 is targeted by mutations in the CTD region that disable 
this activity and promote its cytoplasmic localization. Together our data indicate that 
ubiquitination/deubiquitination play a dynamic role of in the regulation of BAP1 function. 
In addition to histone H2A and itself, BAP1 also appears to act on other substrates. 
This includes the abundant BAP1 partners HCF-1 and OGT (Dey et al., 2012; Machida et 
al., 2009; Misaghi et al., 2009). The two independent studies showed that the HCF-1 is 
deubiquitinated by BAP1, although the sites and even the regions of the protein were 
different. The first study showed that BAP1 deubiquitinates HCF-1 on their interaction 
interface that contained the ubiquitination sites within the HCF-1 Kelch domain (Misaghi et 
al., 2009). The parallel study showed that the HCF-1 is deubiquitinated by BAP1 on its 
ubiquitination sites localized within the C-terminal region (Machida et al., 2009). In both 
studies BAP1 had a marginal effect on HCF-1 stability suggesting possible regulatory role 
for HCF-1 ubiquitination, rather than its degradation. Two independent studies also 
revealed that BAP1 deubiquitinate and stabilize OGT (Dey et al., 2012). Notably the study 
by Dixit group found that the conditional knockout of BAP1 displayed dramatic drop in 
OGT as well as HCF-1 protein levels, supporting the idea of BAP1 as a DUB for OGT and 
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HCF-1 that may regulate their stability. 
 
 
UBE2O as an atypical ubiquitin E2/E3 hybrid 
 
The fact that UBE2O can act as an ubiquitin ligase was already suggested by earlier 
studies (Berleth and Pickart, 1996; Klemperer et al., 1989; Zhang et al., 2013a). The Class 
IV ubiquitin carriers emerged as E3 independent enzymes (Bartke et al., 2004; Berleth and 
Pickart, 1996). The very limited number of enzymes of this group (only three in human 
genome) suggests a unique mechanism of ubiquitin transfer. From the chemical point of 
view, the ubiquitination reaction does not require any other enzymes apart an E1, which 
activate the ubiquitin by forming the thioester ubiquitin adduct. The subsequent reactions of 
the ubiquitin transfer funnel the ubiquitin cascade to specific subsets of substrates and 
specify the particular type of ubiquitin chain. The fact that UBE2O directly engages and 
ubiquitinates the NLS of BAP1 is unusual but quite plausible from the biochemical point of 
view. The mechanism of this atypical UBE2O mediated E2/E3 ubiquitination reaction is 
unknown. The sensitivity of the enzyme to PAO indicates an internal ubiquitin thioester 
relay mechanism (Berleth and Pickart, 1996).  
UBE2O can be viewed as a hypothetical fusion between the E2 carrier enzyme and 
the HECT domain ubiquitin ligase. According to this model, upon the E2-Ub thioester 
formation, the ubiquitin is being further transferred to the catalytic cysteine of the HECT 
domain and then to the target lysine of the substrate. UBE2O shares no similarity with any 
HECT domain ligase, but it may employ a similar strategy for the ubiquitination of 
substrates. Moreover, UBE2O sequence analysis revealed at least three putative protein 
domains (including the UBC), reinforcing the possibility that these regions may act 
similarly to the lobes of the HECT domain in complex with the E2. According to the crystal 
structure of the HECT/E2 complex (i.e. E6AP/UbcH7 (Huang et al., 1999)), the N-lobe of 
the HECT domain acts as a bridge between the UBC catalytic domain (UbcH7) and the C- 
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catalytic lobe of the ligase.  The C-lobe and UBC oppose each other through a relatively 
large gap of around 40 Å. The charged UBC stimulates conformational changes that allow 
the closure of the gap and transfer of the ubiquitin to the C-lobe catalytic cysteine, and than 
to the substrate. 
If we extrapolate this data, the CR1 domain of UBE2O would act as a HECT C-
lobe, the CR2 domain of UBE2O as the N-lobe and the UBC domain of t UBE2O would 
correspond to the HECT recruited E2 (UbcH7). According to our data the CR1 region is 
absolutely required for substrate ubiquitination, which, to some extend, support this model.  
The sensitivity of UBE2O to the PAO suggests the existence of at least two 
catalytically active cysteine sites. In an effort do decipher the mechanism of UBE2O 
mediated catalysis we analyzed the conservation of the UBE2O sequence across its 
orthologs in metazoans and plants. As expected, the catalytic cysteine of the enzyme 
(C1040 in humans) is the most conserved residue across the UBE2O orthologs. The 
analysis of the other 23 cysteine residues of human UBE2O did not reveal a consistent 
pattern of conservation that ranged from nonconserved (for example found only in 
mammals) to more conserved (found in most metazoans). The C230, which resides within 
the CR1 domain and is conserved across metazoans (apart the Drosophila) and plant 
species, was selected for mutagenesis. Unfortunately the C230S mutation did not affect the 
catalytic activity of UBE2O (Nazar Mashtalir and El Bachir Affar unpublished data). This 
result can be explained by the possible redundancy of the cysteine residues within a specific 
domain of UBE2O that may promote further ubiquitin transfer. Otherwise the C230S may 
simply not be the required site for ubiquitin transfer and other less conserved cysteine 
residues may play a role. A more systematic mutagenesis approach would provide insights 
into the mechanism of UBE2O-mediated ubiquitin transfer.  
The mechanism of substrate binding by UBE2O is unknown. Our attempts to 
identify the substrate-binding domain failed to pinpoint the exact UBE2O region, meaning 
that substrate binding might involve the combination of multiple domains (Nazar Mashtalir 
and El Bachir Affar unpublished data). 
On the other hand the other member of the class IV ubiquitin conjugating enzymes 
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BRUCE (BIRC6) also ubiquitinates a subset of substrates in an E3-independent manner 
(Bartke et al., 2004; Hao et al., 2004). UBE2O and BRUCE share similarities only in their 
UBC domain. BRUCE and UBE2O are likely to use their non-catalytic protein sequences 
to engage the substrate and promote ubiquitination by UBC. Indeed, the crystal structure of 
the UBC domain of BRUCE revealed the classical core fold with the addition of a subset of 
atypical structures with unknown functions (PDB code 3CEG). The typical ubiquitin 
charged E2 cannot easily transfer the ubiquitin moiety to the target lysine. The ligation 
reaction requires the recruitment of the E3 enzyme, for example the RING domain ligase, 
which stimulates the conformational shift within the Ub-UBC to promote ubiquitin 
discharge. The structures found in BRUCE (and in UBE2O by similarity) can be involved 
in the E3-independent ubiquitin discharge upon substrate binding. According to this model, 
the UBC of and the rest of the domains might be involved in substrate binding and proper 
orientation towards the catalytic site. 
 
 
Auto-deubiquitination as an anti-E3 self defense mechanism 
 
The principle of autocatalytic regulation is widely spread among the enzymes, i.e. 
kinases, ubiquitin ligases and proteases (Bakkenist and Kastan, 2003; Chen et al., 2002; 
Chen and Hochstrasser, 1996; Raina et al., 2005). This ability of autocatalysis usually 
results in the positive regulation of the enzyme by either exposing the catalytic site, 
removal of the negative regulatory sequence or the stimulation of protein/protein 
interaction. The auto-deubiquitination activity of DUBs stands aside of other autocatalytic 
reactions since it is being imposed by E3 ligases. The DUBs are often regarded as 
antagonists of E3 ligases since they reverse the substrate ubiquitination. The notion that the 
ligases also can directly and negatively regulate DUBs is much less studied, with only few 
papers published. 
One of the studies on another UCH family DUB member UCH-L1 described its 
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potential regulatory mechanism by ubiquitination/autodeubiquitination (Meray and 
Lansbury, 2007). The UCH-L1 is a DUB highly expressed in the neural tissues (up to 10% 
of all the protein biomass in the brain) and is used as one of these tissues histological 
markers. The exact function of the enzyme is not well understood; nonetheless some studies 
showed that it might be implicated in the development of Parkinson disease (Lowe et al., 
1990). 
UCH-L1 is monoubiquitinated and displays an autodeubiquitination activity. 
Indeed, the catalytic dead mutant of UCH-L1 (C90S) had more pronounced ubiquitin signal 
than the wild type protein. The ubiquitination sites of the UCH-L1 are scattered through all 
the lysine residues of the enzyme including the N-terminus, but are frequently located in 
the vicinity of the catalytic site (Meray and Lansbury, 2007). The exact function of UCH-
L1 deubiquitination remains unclear, but the monoubiquitinated UCH-L1 displayed lower 
ubiquitin binding affinity, indicating that ubiquitination of UCH-L1 may regulate its 
catalytic activity or/and substrate binding. 
Since UCH-L1 consists of just one single UCH catalytic domain, the auto-
deubiquitination mechanism is probably different from the one we described for 
UBE2O/BAP1, which involves intramolecular binding followed by autodeubiquitination of 
the NLS. Nonetheless, we found some ubiquitination sites in the UCH domain of BAP1 
indicating possible additional mechanism similar to UCH-L1 (see the results section). 
The other DUBs that display the auto-deubiquitinase activity are the muscle specific 
DUB USP25m (Denuc et al., 2009) and the histone H2A DUB MYSM1 (Nazar Mashtalir 
and El Bachir Affar unpublished data). The exact function of this E3 counteractions are 
unknown and may act as a protective mechanism against degradation or might act as 
enzymatic activity regulatory mechanisms. 
In our study, we found that the BAP1 and its close relative UCH37 display the auto-
deubiquitination activity. We found that the atypical class IV E2 UBE2O acts as an 
ubiquitin E3 ligase for the BAP1 NLS region. Notably, UBE2O was highly specific to 
BAP1, and displayed no activity towards UCH37, which is ubiquitinated by other unknown 
ubiquitin E3 ligase.  
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BAP1 auto-deubiquitination mechanism and its disruption in cancer 
 
UCH37 and BAP1 share common ancestry and are highly similar in their N- and C- 
terminal regions (Figure 4). The UCH37 crystal structure revealed that the CTD domain is 
engaged in an intramolecular interaction between the UCH domain and the H8/H9 helices 
in its C-terminus. This coiled-coil fold positions the C-terminal region of UCH37 in 
proximity of the UCH domain of the protein. The very last 30 aa (ADRM1 interaction 
region or the KEKE motif) of the protein are not defined by the crystal structure as a result 
of the unstructured nature of the region (Burgie et al., 2011; Yao et al., 2008; Yao et al., 
2006). Nonetheless, it is highly likely that the intramolecular interaction might facilitate the 
targeting of the KEKE motif on UCH37. The experimental evidence of the ubiquitination 
of the C88A UCH37 catalytic dead mutant also supports this notion (se the result section).  
The main structural differences between BAP1 and UCH37 proteins are represented 
by the presence of the NLS region at the C-terminus of BAP1, as well as the acquisition of 
the large (400 aa) NORS region between the CC1 (corresponds to H8 in UCH37) and the 
CC2 (corresponds to H9 in UCH37). Despite such a drastic protein sequence acquisitions, 
the intramolecular interaction between the CC1 and the CC2 regions remained conserved 
(see result section). 
The importance of the BAP1 auto-deubiquitination mechanism is further confirmed 
by the identification of cancer mutations in the CC2 that abrogate this ability of BAP1. 
Mutations of BAP1 target the catalytic domain, the HBM and the NLS regions. In addition, 
our studies revealed that additional cancer-associated mutations that promote the loss of 
ASXL1/2 inducing a loss of DUB activity toward H2A or induce a disruption of 
autocatalytic activity (Salima Daou, et al., submitted).  
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The mechanism of the BAP1 and UBE2O nuclear import and export 
 
We described the effect of UBE2O-mediated ubiquitination of BAP1, which 
promoted the accumulation of this DUB in the cytoplasm. Although the mechanism of this 
process remains to be defined, several molecular signaling scenarios may take place.  
The simple explanation of the BAP1 cytoplasmic retention by UBE2O may be the 
result of the interference with the NLS binding by the nuclear import machinery imposed 
by the ubiquitin moiety. The structural studies of the NLS recognition indicate that the NLS 
sequence has to remain accessible to the HEAT repeats of karyopherins, moreover the 
charges of lysine and arginine residues is crucial for the interaction (Conti et al., 1998; Lee 
et al., 2006). Therefore, the bulky nature of ubiquitin may physically interfere with the 
proper binding with karyopherin. This effect may be further increased by targeting multiple 
lysine residues of the NLS (we found at lest 4 sites in BAP1 NLS region). This mechanism 
predicts that BAP1 would be engaged by UBE2O in the cytoplasm and would remain 
retained in this compartment unable to be imported into the nucleus. The mono-
ubiquitinated BAP1 might be subsequently targeted by the ubiquitin chain extending E3 
ligases and degraded in a proteasome-dependent manner. 
The other possibility would require the UBE2O import into the nucleus and 
subsequent BAP1 ubiquitination. Being predominantly cytoplasmic, the UBE2O possesses 
two functional NLS regions. The reason for such unexpected localization remains unclear, 
though it is possible that UBE2O in its inactive form remains in a “locked” conformation 
with masked NLS region. On the other hand, the MS analysis of the TAP purified UBE2O 
interacting proteins revealed numerous components on the protein import and export 
machinery, such as several types of the NLS receptors and nuclear import factors (i.e. 
TNPO1, IPO7, IPO9) as well as the components of nuclear protein and RNA export factors 
(i.e. XPOT, XPO1 (CRM1), XPO7, XPO5) (se the results section). This data suggest that a 
dynamic equilibrium may exist between the export and import of UBE2O, with export 
mechanism being more efficient than import, resulting in the cytoplasmic localization of 
the protein. The MS analysis also identified a subset of protein kinases that may be 
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involved in the regulation of UBE2O. One might predict that 
phosphorylation/dephosphorylation would stimulate the shift of the equilibrium towards the 
import of UBE2O. This would provide UBE2O access to BAP1 and other substrates 
inducing their subsequent nuclear export.  
In an effort to identify the condition we performed a focused screen that included 
several kinase/phosphatase inhibitors and stress inducers. The subset of CDK inhibitors 
(Purvalanol A and RO3306) promoted the nuclear localization of UBE2O in catalytic 
activity-dependent manner, with the catalytic dead mutant being more responsive to the 
treatment. This result indicates that the nucleocytoplasmic transport of UBE2O is regulated 
at multiple levels involving protein kinases and ubiquitin conjugation mechanisms. The 
involvement of ubiquitination in regulating UBE2O localization is further supported by the 
observation of autocatalytic activity towards its own NLS (NLS1). The ubiquitination 
targeting of NLS1 is predicted to inactivate it and promote UBE2O export or block its 
import. Therefore, the higher sensitivity of UBE2O CD towards CDK inhibitors may occur 
as a result of combination of both factors. Taken together this data indicate the multilayer 
regulatory mechanism behind the UBE2O activity and nucleocytoplasmic transport. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Regulation of BAP1 nucleocytoplasmic transport by UBE2O 
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We identified the region of UBE2O responsible for the dominant cytoplasmic 
localization of this enzyme. This region included the UBC domain along with the upstream 
region of 300 amino acid residues.  
The classical CRM1 inhibitor Leptomycin-B, which promotes the accumulation of 
dynamically exported proteins in the nucleus, had no effect on the subcellular localization 
of UBE2O. The sequence analysis of UBE2O for the CRM1 mediated protein export signal 
(nuclear export signal NES) identified two degenerate LXXLXL motifs that proved to be 
non-functional (as GFP fusions) (la Cour et al., 2004). This explains the insensitivity of 
UBE2O localization to CRM1 inhibition confirming that CRM1 is not directly involved in 
the cytoplasmic retention of UBE2O (Nazar Mashtalir and El Bachir Affar unpublished 
data) 
The UBC catalytic activity and Ub charging were shown to be required for proper 
nuclear import of one of the class III E2 enzymes UbcM2. UbcM2 was able to interact with 
importin-11 only when charged with ubiquitin.  Therefore, the catalytic dead mutant of the 
UbcM2 was retained in the cytoplasm (Plafker et al., 2004). In respect to the UBE2O, the 
charging does not seem to be involved in the import process, since the UBE2O WT as well 
as CD were both predominantly cytoplasmic. Nevertheless, the auto-ubiquitination of the 
UBE2O NLS1 seems to play an important role in its cytoplasmic retention (see the result 
section).  
There are two main possibilities that describe the mechanism of action of 
cytoplasmic retention region. First, the region may represent, or incorporate the atypical 
export sequence, that promotes UBE2O nuclear export in concert with exportin factors. 
Second, the region might mask the NLS motif via intramolecular or intermolecular 
interactions. To date our results suggest that the main pool of UBE2O under normal growth 
conditions remains mostly cytoplasmic, with the possibility of a small fraction being 
imported to the nucleus with very short residence time as a result of its efficient export 
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mechanism. Otherwise, an unidentified signal might promote the unmasking of the NLS 
sequence, with its subsequent nuclear import, and quick export back to the cytoplasm. 
There is no information about the fate of BAP1 in the cytoplasm. The most likely 
scenario is that it is being targeted by ubiquitin chain extending E3 ligase with its 
subsequent proteasomal degradation. Such a mechanism was described for several 
transcription factors such as HIF-1a and p53 as well as ubiquitin ligase factor DCN1 (Boyd 
et al., 2000; Groulx and Lee, 2002; Li et al., 2003; Wu et al., 2011). The plausible 
explanation of the mechanism would predict the nuclear ubiquitin receptor recognizes the 
monoubiquitinated NLS and promotes its export to the cytoplasm.  
The alignment of BAP1 and UBE2O NLS regions allowed us to identify the 
UBE2O recognition consensus that led to the identification of multiple UBE2O substrates, 
notably three of them INO80, p400 and CDT1 where degraded in UBE2O co-expression 
experiments. No monoubiquitinated products where detected for either of proteins 
suggesting that the polyubiquitinated protein products where rapidly degraded possibly as a 
result of ubiquitin chain extension by another E3. Therefore the fate of the UBE2O 
ubiquitinated protein probably depends on additional factors and specific signaling 
pathways.   
 Under normal conditions, BAP1 is highly stable and there is no evidence for its 
regulation by ubiquitin mediated degradation. Since BAP1 is involved in the regulation of 
normal cell proliferation and differentiation, we decided to test whether UBE2O may play a 
role in its regulation during cell cycle exit. Indeed, UBE2O was shown to be involved in the 
regulation of cell differentiation, and down regulation of this enzyme in primary cells 
promoted their increased proliferation. In contrast BAP1 knockdown induced a delay in cell 
cycle progression. This prompted us to study the role of UBE2O and BAP1 during cell 
cycle exit (see the result section). 
Indeed, we observed the increased cytoplasmic localization of BAP1 during 
terminal cell cycle exit in differentiating 3T3-L1 preadipocytes, and this effect was 
dependent on the ubiquitination of BAP1 NLS. Moreover, the overexpression of UBE2O 
but not its CD form promoted 3T3-L1 differentiation. Taken together, these results suggest 
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that UBE2O may play a major role in the regulation of cell cycle and cell differentiation. 
UBE2O was indeed shown to be upregulated in several models of cellular differentiation 
including neuronal, erythroid and muscle (Berleth and Pickart, 1996; Yokota et al., 2001). 
The data from Arabidopsis thaliana have shown that UBE2O ortholog UBP23 was 
promptly and highly upregulated during the induction of abscisic acid and ethylene 
signaling, major plant signaling pathways of abscission, senescence and fruit ripening (De 
Paepe et al., 2004; Hoth et al., 2002), Taken together this data defines a conserved role of 
UBE2O in the regulation of cell proliferation and differentiation.  
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